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SUMMARY 
 
 
Neuropathic pain (NP) embraces a broad range of conditions linked with a disease or lesion of 
the peripheral or central somatosensory system and its prevalence in the general population 
may be as high as 7-10%. Up to the present, the larger part of our understanding of pain 
mechanisms come from basic sciences studies which has resulted in a vast increase in our 
knowledge. The obvious issues in translational pain research reveal the limitations of certain 
experimental models, and on that account result of limitations in clinical research. In spite of 
such difficulties, the scientific community wish for a better understanding of pain mechanisms 
helped by the new insights of basic research. For that reason, the first of the three parts of this 
work aim to recognise additional changes in the somatosensory system through a series of 
experiments done in an experimental model of NP. 
NP following peripheral nerve injury is associated with hyperexcitability in damaged myelinated 
sensory axons, which begins to normalise over time. We investigated the composition and 
distribution of shaker-type-potassium channels (Kv1 channels) within the nodal complex of 
myelinated axons following injury. At the neuroma that forms after damage, expression of Kv1.1 
and 1.2 was markedly decreased. In contrast Kv1.4 and 1.6, which were hardly detectable in 
the naıve state, showed increased expression following injury. Within the dorsal root we noted a 
redistribution of Kv1-channels towards the paranode. Blockade of Kv1 channels with a-DTX 
after injury reinstated hyperexcitability of A-fibre axons and enhanced mechanosensitivity. 
Changes in the molecular composition and distribution of axonal Kv1 channels, therefore 
represents a protective mechanism to suppress the hyperexcitability of myelinated sensory 
axons that follows nerve injury.  
To date, both basic and human data suggest that a lesion of afferent pathways is required for 
development of NP. In addition, numerous studies demonstrate that not one but various 
mechanisms can induce to NP. This not only evidence the complexity of NP, but also underline 
the clinical significance of identifying underlying pain mechanisms in every single patient. 
Because different management plans are required for different pain mechanisms, a mechanism-
based treatment approach can guide clinicians to better outcomes. With these concepts in mind 
the second chapter of this study aim to clarify some links between one of the most novel 
techniques used in the diagnosis of NP, the Quantitative Sensory Testing (QST), which has 
been used to determine the pathological mechanisms functioning and the phenotype 
expressed. With the painDETECT Questionnaire as screening tool for NP, we analyse whether 
the overall PDQ score or its items reflect phenotypes of sensory loss in NP as determined by 
QST. The results of our study conclude that patients with loss of thermal sensation significantly 
more often reported pain evoked by light touch, and patients with loss of mechanical sensation 
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significantly more often reported numbness and significantly less often burning sensations and 
pain evoked by light touch. Although the PDQ was not designed to assess sensory loss, single 
items reflect thermal and/or mechanical sensory loss at group level, but because of substantial 
variability, the PDQ does not allow for individual allocation of patients into sensory profiles.  
Finally, the last part of this thesis focuses its attention in the management of NP, more precisely 
in Complex Regional Pain Syndrome (CRPS) in children.  This chapter review the evidence for 
invasive pain procedures along with presenting a management algorithm for paediatric CRPS, 
including invasive procedures for patients who do not respond to the conventional first-line 
treatment. We also report on the course and management of a series of children diagnosed with 
CRPS, applying the multidisciplinary management approach described above. We conclude 
that because of the severity and rapid progression of the symptoms in CRPS an early diagnosis 
of the condition together with comprehensive, and individualized multidisciplinary treatment 
offers children with CRPS the best opportunity for a complete recovery. Within this approach we 
encourage clinicians to consider invasive procedures as a reliable option of treatment. 
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RESUMEN 
 
El Dolor Neuropático (DN) abarca, o acompaña, a una amplia variedad de patologías ligadas 
con enfermedad o lesión del sistema somatosensorial a nivel central o periférico, oscilando su 
prevalecía en la población general en torno al 7-10%.  En la actualidad la mayor parte del 
conocimiento que tenemos de los mecanismos subyacentes al origen y desarrollo del DN han 
sido obtenidos de estudios en ciencias básicas. Los obvios problemas que surgen de la 
traslación en investigación médica revelan las importantes limitaciones de ciertos modelos 
experimentales, y desde esa línea se originan esenciales limitaciones para la investigación 
clínica. A pesar de estas dificultades, la comunidad científica escruta sin cesar nuevas y 
mejores ideas que nos ayuden a entender mejor la patofisiología del dolor basándose 
fundamentalmente en nuevos descubrimientos en el campo de las ciencias básicas. Por esta 
razón, la primera de las tres partes de las que se compone este trabajo tiene como objetivo el 
reconocimiento de cambios o hallazgos no descritos en el sistema somatosensorial en un 
modelo experimental de DN. 
El DN tras un daño nervioso periférico esta asociado con la hiperexcitabilidad de los axones 
sensoriales mielinizados afectos, la cual comienza a normalizarse con el tiempo. Este trabajo 
investiga la composición y distribución de los canales de potasio voltaje dependientes de la 
familia Shaker (Kv1) en el complejo nodal de los axones mielinizados tras la lesión nerviosa. En 
el neuroma que se forma tras el daño, la expresión de Kv1.1 y Kv1.2 estaba considerablemente 
reducida. Por el contrario Kv1.4 y Kv1.6, que eran casi imperceptibles en el estado naive, 
mostraron un importante aumento en su expresión tras el daño. En la raíz dorsal se pudo 
demostrar una redistribución de los canales Kv1 hacia el paranodo. El bloqueo de los canales 
Kv1 con a-DTX tras la inducción de la lesión reinstauró la hipersensibilidad de las fibras A y 
aumentó la sensibilidad mecánica. Los cambios observados en la composición molecular y 
distribución axonal de los canales Kv1, representan por tanto un mecanismo protector que 
disminuye la hiperexcitabilidad de los axones sensoriales mielinizados tras un daño nervioso.  
Actualmente, tanto la evidencia animal como la humana coinciden en que para el desarrollo del 
DN una lesión de las vías aferentes somatosensoriales es necesaria. Además, numerosos 
estudios demuestran que son varios los mecanismos que pueden inducir el desarrollo del DN. 
Esto no solo pone de manifiesto la complejidad del DN, sino que también destaca la 
importancia clínica de identificación de los mecanismos subyacentes del dolor en cada uno los 
individuos que lo sufren. Ya que diferentes planes de tratamiento son necesarios para el 
manejo de los diferentes mecanismos, un abordaje terapéutico basado mecanismos podrá 
guiar a los profesionales de la salud hacia mejores resultados. Con estos conceptos en mente 
el segundo apartado de esta tesis tiene como objetivo descubrir posibles asociaciones entre 
una de las mas novedosas técnicas utilizadas para el diagnostico del DN, el Test de 
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Cuantificación Sensorial (QST), el cual se puede aplicar para determinar los posibles 
mecanismos subyacentes activos, y el fenotipo sensorial expresado. Con el cuestionario 
painDETECT (PDQ) como herramienta de screening para DN, nosotros analizamos si el 
resultado obtenido para el PDQ o sus ítems reflejan fenotipos de perdida sensorial en DN 
demostrados con QST. Los resultados de nuestro estudio concluyen que los pacientes con 
perdida significativa de sensación térmica reportaban mas frecuentemente dolor evocado por 
tacto fino, y los pacientes con perdida significativa de sensibilidad mecánica reportaban mas 
frecuentemente adormecimiento, así como una menos frecuente sensación de quemazón y 
dolor evocado por tacto fino. A pesar de que el PDQ no fue diseñado para evaluar la perdida de 
sensibilidad, sus ítems individuales pueden reflejar la perdida de sensibilidad térmica y/o 
mecánica, pero debido a la importante variabilidad  existente, el PDQ no nos permite la 
asignación de pacientes en perfiles sensoriales.  
Finalmente, la ultima parte de este trabajo enfoca su atención en el tratamiento del DN, mas 
específicamente en el tratamiento del Síndrome de Dolor Regional Complejo (CRPS) en niños. 
Este capitulo revisa la evidencia científica actual para el tratamiento de este síndrome con 
procedimientos invasivos, además de presentar un algoritmo terapéutico para el manejo del 
CRPS pediátrico. Destacar que en este algoritmo se incluyen los procedimiento invasivos para 
aquellos sujetos no respondedores a los tratamientos convencionales de primera línea.  
Conjuntamente,  este capitulo detalla el curso y manejo de una serie de casos de pacientes 
pediátricos con CRPS refractarios al tratamiento convencional y a los que se les aplicó de 
manera satisfactoria el algoritmo terapéutico descrito en este trabajo. La conclusión de este 
capitulo nos hace ver que debido a la rápida progresión y severidad de los síntomas en el 
CRPS solo con un diagnostico precoz acompañado de un manejo metódico, multidisciplinar e 
individualizado pueden ofrecer a estos pacientes la mejor oportunidad para una recuperación 
satisfactoria.  Cabe destacar la inclusión de los procedimientos invasivos en el momento 
adecuado como una opción eficaz de tratamiento. 
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1. Chronic & Neuropathic Pain. An introduction to the problem 
 
Chronic pain (ChP) is one of the most burdensome health issues facing the society today; its cost to 
Western countries is nearly the same of to the cost of cancer and diabetes mellitus combined (Vos et al. 
2012). Reliable epidemiological research on ChP provides key information on prevalence and factors 
linked to its genesis and perpetuation. Enhancing our understanding of the details surrounding the disease 
will improve the clinical management, boundarying severity, and minimizing disability. There are well 
founded hypothesis that the recent estimations of global burden of disease have underestimated the 
contribution of ChP (Smith et al. 2007, Shmagel et al. 2016). The World Health Organisation (WHO) and 
other researchers forecast that for the 2030 the four leading responsible of global burden of disease will be 
coronary heart disease, road traffic accidents, depression and cerebrovascular disease (Vos et al. 2015). 
Unsurprisingly, ChP is a major co-morbidity linked to all of these; however, ChP is much more than a 
simple a co-morbidity of other injury or disease. ChP is to date acknowledged as a condition in its own 
right (Merskey 1994, Tracey and Bushnell 2009, Treede et al. 2015). Roughly one fifth of the adult 
European population suffer ChP (Breivik et al. 2006) and, in addition to the physical and emotional burden 
it brings, the monetary cost to society is vast, currently estimated greater than €200 billion per annum in 
Europe and $150 billion per annum in the USA (Tracey and Bushnell 2009). 
Our understanding of the pathophysiology of ChP has increased substantially over the past 20 years, 
including from the periphery to the brain (Dubin and Patapoutian 2010, Apkarian et al. 2011, Baron et al. 
2012). Nonetheless, we still do not understand why ChP develops in some people and not in others, yet 
we know that the magnitude or type of injury, psychosocial features, religious beliefs, occupation, 
education level, race or the postcode are not reliable predictors (Chou 2010). Extensive research into the 
genetics of ChP has also failed to predict the onset of the disease, possibly because the great number of 
genes involved and the contradictory research outcomes(Diatchenko et al. 2007, Møller and Jensen 
2010). ChP treatment is usually a tedious and complex task, where the pain specialist and the patient 
should create a strong and genuine relation. It seems that despite great progress in multiple fields, little 
ground has been made (White et al. 2011, Rajapakse et al. 2014, Moulin et al. 2015). 
Within the evolutionary picture the activation of any type of specialised nociceptor as the high threshold 
mechanoreceptors have a protective role, behaving as a warning system for threatening signals. However 
whereas inflammatory pain is adaptive, evolution has not succeeded to account for our increased capacity 
for surviving disease, trauma or iatrogenic aggressions intended to extend or improve quality of life. In 
such environments pain no longer is a helpful feature but becomes the disease itself. Nonetheless it is 
natural to think about pain as a homogeneous entity, this is unduly simplistic. In fact there are different 
types of pain, each with diverse pathophysiological and neurobiological mechanisms. The most recognised 
classification divides pain into two main types: nociceptive and neuropathic pain; however this 
classification is again over simplistic. Therefore, recently the new ICD category for "Chronic Pain” tried to 
include and divide the most common clinically relevant disorders. These disorders were separated into 7 
groups: (1) chronic primary pain, (2) chronic cancer pain, (3) chronic posttraumatic and postsurgical pain, 
(4) chronic neuropathic pain, (5) chronic headache and orofacial pain, (6) chronic visceral pain, and (7) 
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chronic musculoskeletal pain. This division is important because it not only indicate the ethology and the 
neurobiological mechanisms, but also point treatment. Nociceptive pain can be categorised as visceral or 
somatic (Treede et al. 2015). 
Neuropathic Pain (NP) is defined as pain resulting from injury to, or dysfunction of, the somatosensory 
system (Treede et al. 2008), thus tissue damage directly affects the nervous system, resulting in the 
generation of ectopic discharges that bypass transduction (Baron et al. 2010). NP is widely identified as 
one of the most complicated pain syndromes to manage, and outcomes are often disappointing. This is 
partly because the contribution of neuropathy to pain presenting in primary care may be unrecognised 
(Rodríguez et al. 2007, Leadley et al. 2012) and there is evidence of suboptimal drug use in the treatment 
of NP (Smith et al. 2007, Jongen et al. 2013, Helfert et al. 2014). Epidemiological research within the field 
of NP is problematic, and the reasons for this are diverse: the lack of a legitimate case definition that truly 
indicate the condition(s) under consideration, and that would be feasible to use in population-based 
studies; the heterogeneous quality of the studies, using inconsistent means of case ascertainment, and 
inclusion or exclusion criteria in which pain is not the major complaint (Torrance et al. 2006, Smith, 
Macfarlane, et al. 2007, Smith et al. 2012, van Hecke et al. 2013). Existing calculations of the general 
population prevalence therefore differ widely, and it is plausible that people experience neuropathic 
symptoms to a greater extent than have been diagnosed with a neuropathic pain-related condition 
(Torrance et al. 2006, Freynhagen and Baron 2009). Epidemiological NP studies are of great value in 
order to decide resource needs (educational, economical and clinical) in primary care and hospital 
settings, and to inform the prevention strategies and management targeting. As validated screening tools 
to identify NP have been developed (Torrance et al. 2006, Bennett et al. 2007, Haanpää et al. 2011, Mick 
et al. 2014), these have enabled questionnaire-based epidemiological studies, and there is a growing body 
of literature investigating the epidemiology of NP symptoms and conditions in the society. To date, the 
finest estimation of population prevalence of pain with neuropathic features is probable to lie between 7% 
and 10% (van Hecke et al. 2014). 
NP is characterised by positive and negative symptoms embracing pain, hypoesthesia to touch, tingling, 
electric shocks and pins and needles (Woolf and Mannion 1999). Several nerve harmful stimuli at the 
central or peripheral nervous system can lead to NP, though the clinical features of the pain can be alike 
across the different neuropathic syndromes and aetiologies (Freeman et al. 2013). Although many forms of 
nociceptive pain, and some forms of neuropathic pain, may confer evolutionary benefits, chronic NP is at 
all times maladaptive. NP sufferers regularly manifest paradoxical sensory perceptions accompanied by 
pain as a paramount positive symptom combined with damaged induced downgraded sensations. These 
sensations are typically very unique and have not been felt previously by patients. This combination of 
signs of hyposensitivity and hypersensitivity is not unusual in neurological disorders; for instance, when 
spasticity appears after spinal cord injury or when parkinsonian tremor develops following degradation of 
the substantia nigra. Nevertheless, compared with these motor disruptions, pain as a subjective sensory 
symptom is difficult to measure and embrace not only physical features, but also psychological and 
emotional attributes (Gustin et al. 2015, Thacker 2015). The distinctive sensory abnormalities are key 
findings to diagnose and classify NP appropriately, and to differentiate this from other pain patterns. Major 
challenges in development of a targeted holistic approach to NP management cover appropriate diagnosis 
of the aetiology and mechanisms underneath, recognition of the type of pain and assessment of its pattern 
and its sensory profile, and determination of the right treatment. 
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2. Pathophysiology 
 
NP is a highly complex clinical issue and has behaved as an enigma for pain researchers and doctors for a 
long time, being really complicated to identify and manage. To appreciate the complexity of NP, we should 
recognise the physiological transmission of the nociceptive signal. Noxious stimuli such as chemicals, 
inflammation, heat and pressure activate nociceptors, namely the prostaglandin receptors or acid-sensing 
ion channels (ASIC). This leads to influx of calcium and sodium ions, following in depolarisation of the cell. 
When the membrane depolarisation reach the threshold potential, this depolarisation is transmitted to the 
cell body, which is located in the dorsal root ganglion (DRG), and next carried up to the dorsal horn within 
the spinal cord. At this point, the neurones release neurotransmitters (mostly glutamate and substance P) 
into the synaptic cleft, which consequently depolarises the postsynaptic neurones and has both excitatory 
and inhibitory interneuronal reactions. Following, the depolarisation is transmitted to higher areas within 
the CNS by the ascending tracts, where it may be processed as the experience of pain. The higher centres 
may then respond by sending an inhibitory or excitatory signal back to the spinal cord by the descending 
pathways (Woolf and Ma 2007, D'mello and Dickenson 2008, Stein et al. 2009). 
The scenario described above is very different to the one in NP, where numerous changes take place 
following damage to a sensory nerve. There can be peripheral disruptions generating abnormal impulse 
origin and transmission or/and central disturbances, causing abnormal processing of the nervous input. 
 
2.1. Peripheral mechanisms 
Once tissue damage occur, inflammation and reparatory processes arise, guiding to a hyperexcitable state 
recognised as peripheral sensitization. In the majority of people, this situation settles as healing occurs 
and inflammation reduces. But, when nociception perseveres because of repeated stimulation from 
ongoing disease or tissue damage, the alterations in primary afferent neurons may continue. 
Numerous circumstances can play a part in peripheral sensitization. Inflammatory mediators like 
substance P or calcitonin gene related peptide (CGRP), which are released from the neurone, elevate 
vascular permeability, resulting in increasing the oedema and the release of other products with pro-
inflamatory features such as prostaglandins, bradykinin, growth factors, and cytokines. These substances 
sensitise nociceptors, leading to lowered firing thresholds and contributing to ectopic discharges (Woolf 
and Ma 2007, Stein et al. 2009). 
Ectopic discharges can lead to spontaneous pain and may arise from the DRG to any other sites along an 
injured nerve, or even from uninjured adjacent fibres (Chen and Devor 1998). The process by which 
adjacent uninjured nerve fibres become excited as a result of non-synaptic "cross talk" is known as 
ephaptic transmission (Devor and Wall 1990). Allodynia apply to pain originated by normally non-painful 
stimuli, and it usually ensues from decreased stimulation thresholds. Hyperalgesia apply to magnified pain 
perception as an outcome of injured peripheral nerve nociceptive fibres, and it can be divided as primary 
or secondary. Primary hyperalgesia results in damaged tissue as a consequence of sensitisation of 
peripheral nociceptors; while secondary hyperalgesia appears in proximate undamaged tissue due to 
sensitization within the CNS. To a certain degree, this can be originated by ephaptic transmission or the 
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enlargement of receptive fields of injured nerves, or both (Costigan et al. 2009). 
Following nerve damage, numerous genes that influence nerve function are down-regulated or up-
regulated, and this can have an important effect on membrane excitability, transmission and transduction. 
Since gene expression modifies cellular features, this may result in a nerve phenotype transformation, 
demonstrating changes such as the expression of neurotransmitters usually expressed by C fibres (such 
as substance P or CGRP) now expressed in other type of fibres (Navarro et al. 2007). The phenotype 
switch has been proposed as one of the main mechanism underlying the pathogenesis of NP, and more 
particularly of allodynia (Sandkühler 2009, Jensen & Finnerup 2014). 
One of the most notable changes after nerve injury - and phenotype switching - is the unregulated 
expression of sodium channels around the terminal injury site of injured axons and within the DRG (Wang 
et al. 2011). During the last two decades preclinical studies have revealed that several types of sodium 
channels play an important role in pain. Following nerve damage, the expression of various of these 
channels decrease, the expression of others turns up de novo, and some others channels change their 
location at other cellular compartments. The rapid increase of heterotopic sodium channels, like Nav1.3, 
Nav1.7, and Nav1.8, can reduce the stimulation threshold and give rise to ectopic discharges, ending in 
spontaneous pain (Lai et al. 2003, Levinson et al. 2012). Additionally, the proliferation of sodium channels 
may precipitate central sensitization (Basbaum et al. 2009, Jensen and Finnerup 2014). 
Certain types of potassium and calcium channels also play an important part in NP. After nerve damage, 
the expression of α2δ calcium channels is upregulated in and around the DRG, increasing excitability 
(Takahashi et al. 2010, Nieto-Rostro et al. 2014). These voltage gated calcium channels are the primary 
site of action for gabapentinoids, a first-line treatment for NP, which have been shown in preclinical studies 
to reduce hyperalgesia and spontaneous pain (Perret and Luo 2009, Taylor 2009, Pexton et al. 2011). 
Within the physiological neuronal activation potassium channels facilitate a rapid transmembrane 
potassium efflux that affect action potential threshold, frequency and waveform. Since potassium channel 
opening repolarizes (or hyperpolarizes) the cell membrane, this property can restrict action potential 
generation and firing rate. Depending on the biophysical features and specific subcellular site in sensory 
neurons, potassium channel conduction is proposed to inhibit peripheral excitability by counteracting 
action potential generation at peripheral nerve terminals, lessen conduction accuracy across the axon, or 
bounding neurotransmitter release at central terminals. Besides, despite physiological sensory 
transduction does not depend on cell soma spiking, in some ChP conditions potassium channels can act 
as a brake to the spontaneous activity developing within the DRG or other ectopic loci as the neuroma 
(Rasband et al. 2001, Ocaña et al. 2004). After nerve injury a dramatic decrease in potassium 
conductance of peripheral nerve has been shown, correlating with the rising of hyperexcitability and pain 
behaviours in animal studies (Costigan et al. 2010, Tsantoulas and Mcmahon 2014). In the periphery, 
Kv1.1 and Kv1.2 are mainly detected in the soma and juxtaparanodes of medium-large DRG neurones, 
and are to a great extent reduced after axotomy; this may play a crucial role in the novel phenotype of 
hyperexcitability (Kim et al. 2002, Park et al. 2003, Costigan et al. 2010). Indeed, Kv1.1 loss-of-function 
outcomes in reduced firing thresholds, diminished heat and mechanical pain, while produce an increase of 
sensitivity thresholds (Chi and Nicol 2007). Conversely, decreased Kv1.2 activity is a factor in cold and 
mechanical NP by depolarising the resting membrane potential, diminishing threshold current, and 
boosting firing rates in myelinated neurones. In the CNS, potassium channel opening may contribute to 
increase nociception when, for example, the damaged neurone is part of an inhibitory circuit. Nonetheless, 
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the scientific evidence so far suggest that a collection of antinociceptive drugs act, or moderate their 
action, by opening potassium channels located at the CNS, brain or spinal cord (Hehn et al. 2012, 
Tsantoulas and Mcmahon 2014, Tsantoulas 2015). 
Nerve injury also leads to upregulation of several receptor proteins like the transient receptor potential V1 
(TRPV1). TRPV1 is placed on specific peripheral nociceptive endings and is physiologically activated by 
noxious heat at about 41°C (Christoph et al. 2006). Following nerve damage, TRPV1 is downregulated on 
damaged fibres but upregulated on undamaged unmyelinated fibres. The adjusted situation of TRPV1 and 
further sensitisation to heat stimuli by intracellular signalling may lead to spontaneous nerve activity 
generated by normal body temperature, if the threshold of TRPV1 is reduced to below 38°C (Fischer and 
Reeh 2007, Biggs et al. 2008). Clinically, people with the described pathophysiology can be identified by 
the presence of heat hyperalgesia in addition to ongoing burning pain. Likewise, abnormal responses to 
cold and topical application of menthol in these patients indicate that a nerve lesion triggered irregular 
function or expression of TRPM8, a cold-sensitive receptor of the TRP family(Staaf et al. 2009, Kambiz et 
al. 2014). 
After nerve damage atrophic changes may cause a reduction in the size of the axon diameter and cell 
body, and eventually neuronal death (Wallerian degeneration) (Dubový 2011). Such changes may lead to 
a drop in intraepidermal nerve fibre density. Depending on the severity of the damage, this may result in 
negative signs and symptoms as loss of sensation or, paradoxically, increased pain and hypersensitivity, 
deafferentation pain (Costigan et al. 2009, Haanpää et al. 2011). Breaking the connection between a nerve 
and its end organ also disposes the nerve of nerve growth factor and other important substances and 
signals, which are crucial for the development and stability of the nerve (Dubový 2011). Nonetheless, 
electrodiagnostic studies may be normal in patients with a reduce intradermal nerve counting, where in 
response to local release of nerve growth factor, collateral sprouting may follow neuronal loss (Navarro et 
al. 2007). 
Also within the periphery we should include the importance of the autonomic nervous system for the 
maintenance or enhancement of the pain by an abnormality in the sympathetic nervous system. Functional 
coupling between the sympathetic nervous system and somatosensory nerves after nerve damage dates 
back to 1864, when Silas Weir Mitchell reported his impressions during the American Civil War. Although 
the concept of sympathetically maintained pain usually associated to complex regional pain syndrome 
(CRPS), the same principles can be identified in other pain disorders, such as postherpetic neuralgia 
(Johnson and Rice 2014). The complex relationship between the somatosensory and autonomic systems 
most likely includes sympathetic sprouting into dorsal root ganglia, the expression of α-adrenoceptors on 
primary afferent sensory fibres, and decrease oxygenation and signalling in response to sympathetically 
mediated vasoconstriction (Nickel et al. 2012). Clinically, this situation can be expressed as colour and 
temperature changes in an affected body area, swelling, tissue atrophy, and pain worsened by cold 
weather or stress, which enhances sympathetic outflow (Gierthmühlen et al. 2014). 
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2.2. Central Mechanisms 
Neuropathic pain modulates and modifies the neuronal spinal networks under pathological conditions, 
such as peripheral nerve injury and peripheral tissue inflammation (Todd 2010, Ellis and Bennett 2013). 
Some significant spinal components of NP mechanisms are synaptic plasticity in the form of temporal and 
spatial summation, augmented neuronal excitability of ascending nociceptive pathways that send pain 
signals to supra-spinal sites, and expansion of receptive fields of nociceptors and second order neurons 
(Dougherty and Willis 1992, Price 2000, Willis 2001). To a major extent these neuroplastic changes occur 
along nociceptive pathways in the spinal cord and in several brain areas, where nociceptive signals 
resulting by nerve damage are modulated by supra-spinal descending facilitation or inhibition (or both) that 
converges onto dorsal horn neurones. One consequence of this modulation is that the relationship 
between stimulus and response to pain is not always straightforward. The response of output neurones 
may be hugely modified via the interaction of numerous neurotransmitter systems within the spinal cord, all 
of which can be subject to plasticity and changes, especially during pathological conditions (Wu et al. 
2010). 
Accumulating evidence from various animal models of NP propose that NP might involve aberrant 
excitability in the dorsal horn, consequence of multiple functional changes following nerve damage (Woolf 
and Salter 2000). In addition, numerous studies have demonstrate that hyperexcitability induced by 
peripheral nerve injury might not be a result merely of changes in neurons, but rather of multiple alterations 
in glial cells, such as microglia, the immune cells of the CNS (Calvo and Bennett 2011, Calvo et al. 2012). 
In the dorsal horn glutamate is released from sensory afferents after an acute and more persistent noxious 
stimuli activates it, and it is fast AMPA receptor activation that is necessary for setting the initial baseline 
reaction of spinal dorsal horn cells to both tactile and noxious stimuli. Besides, if a repetitive and high-
frequency stimulation of C-fibres happen, there is then a boost and prolongation of the response of spinal 
dorsal horn neurones to future inputs, so-called wind-up. In this circumstances it is likely that the co-
release of peptidergic neurotransmitters, like substance P and CGRP, which are found in C-fibres together 
with glutamate, is behind the prolonged slow depolarization of the neurone and following removal of the 
NMDA block, thus allowing wind-up to happen. This augmented activity results from the activation of the 
NMDA receptor, which has been clearly demonstrate to play an important role in the hyperalgesia and 
enhancement of pain signalling seen in NP. The main mechanism by which the NMDA receptor acts is 
through the large influx of calcium ions happening when the channel is activated. Once inside the cell, 
calcium ions activate several effectors and encourage downstream cascades, such as nitric oxide 
synthase or ERK which can develop mechanisms of plasticity such as long-term potentiation (LTP). Similar 
plastic changes occur following acute high intensity C-fibre stimulation, peripheral nerve damage, and 
inflammation, and can conclude in the elevated responsiveness and activity of dorsal horn neurones. This 
phenomenon, known as central sensitization, is clinically present in NP sufferers as an increased response 
to painful stimuli (hyperalgesia), and pain arising from normally non-painful tactile stimuli (allodynia) 
(D'mello and Dickenson 2008, Costigan et al. 2009, Gao and Ji 2010). In addition, transmission at the level 
of the dorsal horn is under strong descending control from the brainstem, which can have facilitatory and 
inhibitory components. Accordingly, it seems clear that the final common pathological outcome of NP in 
the dorsal horn is enhanced excitatory transmission leading to pain; where the amplified excitability take 
place through a complex four-way communication between primary afferent terminals, dorsal horn 
neurons, microglial and astrocytes (and might also involve extra cell types like B-lymphocytes). 
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Immune cells of the CNS, microglia and astrocytes, contribute to the release of numerous growth factors, 
neuromodulators and inflammatory mediators. This, far from being a straightforward passive procedure 
triggered by degeneration of axon terminals; it is an active process started by injury signals released from 
damaged neurones. Scientific evidence is now clear when disclose that NP states can be linked with an 
intense inflammatory response which is not just a bystander phenomenon but, in some cases, lead the 
development and persistence of NP (Inoue and Tsuda 2009, Thacker et al. 2009, Calvo et al. 2012, Tsuda 
2016). Glial cells can account for over 70% of the total cell population in the CNS, and are classified into 
astrocytes, microglia and oligodendrocytes. Microglia are known as resident macrophages within the CNS, 
and derive from primitive macrophages in the yolk sac (Ginhoux et al. 2010). During adulthood, microglia 
are present everywhere throughout the CNS and have small cell bodies showing branched and mobile 
processes, which might monitor the local environment in the CNS. Microglia react fast to a broad range of 
stimuli that threaten physiological homeostasis, including peripheral nerve injury. Numerous studies in the 
last decade have revealed how peripheral nerve injury lead to a substantial activation of microglia not only 
in the spinal dorsal horn, but also in supra spinal locations within the CNS (Inoue and Tsuda 2009, Ellis 
and Bennett 2013, Tsuda 2016). It has been showed that there is an astrocytic and microglial reaction 
within the rostral ventromedula (RVM) at the brainstem, which contributes to descending facilitation and 
enhanced pain related hypersensitivity after nerve injury (Banati 2002, Calvo et al. 2012). The 
disproportioned immune reaction is usually displayed among several models of NP including diabetic 
neuropathy, where activated microglia show dramatic changes in the expression of various genes, 
including cell-surface receptors for neurotransmission (e.g., purinergic receptors) and intracellular 
signaling molecules (e.g., mitogen-activated protein kinases [MAPKs]) and bioactive diffusible factors (e.g., 
pro-inflammatory cytokines and neurotrophic factors). Unfortunately, mechanisms underlying the spatial-
specific activation of microglia either in the dorsal horn or in the brain remain to be determined (Milligan 
and Watkins 2009, Gao and Ji 2010).  Importantly, molecular, pharmacological, and genetic manipulations 
of the function or expression of these microglial molecules have a large influence in pain behaviours and 
hyperexcitability of the dorsal horn pain pathway. Consequently, spinal microglia play a critical part in the 
pathologically enhanced pain processing in the dorsal horn, and microglial molecules might be potential 
targets for treating NP (Wen et al. 2011). 
In addition to microglia, recent studies have also identified astrocyte-specific molecules, and have shown a 
critical role of spinal astrocytes in NP (Kawasaki et al. 2008, Tsuda et al. 2011, Xu et al. 2014). Under 
physiological conditions, astrocytes behave to 'mop up' molecules that are toxic or are in excessively high 
concentration, preserving extracellular homeostasis. In addition, astrocytes are important modulators of 
synaptic function (Kofuji and Newman 2004, De Leo et al. 2006). Astrocytic activation in animal models of 
pain take place various days following the damage or stimulus but is much longer lasting (Romero-
Sandoval et al. 2008). 
The output from the dorsal horn to higher centres in the brain is transmitted by spinal projection neurones 
along ascending pathways. A significant number of projection neurones is placed superficially in lamina I. 
It is estimated that approximately the 80% of such cells express the neurokinin 1 (NK1) receptor for 
substance P, a molecule largely released by nociceptive afferents, indicating that these neurones respond 
to noxious stimulation (Mantyh et al. 1997, Doyle and Hunt 1999). NK1-positive cells in lamina I have been 
shown to project to areas in the brain such as the periaqueductal grey (PAG) and thalamus (Baron et al. 
2014, Wilcox et al. 2015), and into brainstem areas such as the RVM (Villanueva 2009, De Felice et al. 
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2011). In addition, a great number of projecting cells are also based deeper in the dorsal horn from lamina 
III-VI and these projects mainly to the thalamus, thereby making up a significant proportion of the 
spinothalamic tract. This ascending pathway transmits first and foremost sensory information, providing the 
sensory component of the pain experience. Descending pathways from higher centres as the brainstem 
are able to influence nociceptive signalling in the dorsal horn. These descending influences are both 
facilitatory and inhibitory in nature (Vanegas and Schaible 2004, D'mello and Dickenson 2008). 
Descending facilitatory pathways from the RVM in the brainstem have been proved to be implicated in the 
maintenance of pain following nerve damage (Vera-Portocarrero et al. 2006, Ossipov et al. 2010). Such 
excitatory influences encourage spinal central sensitization and assist nociceptive reflexes and their 
inappropriate tonic activation contributes to the pathophysiology of NP. The supraspinal descending 
facilitatory mechanisms have been proposed to play an important role in the a central mechanism by which 
the loss of sensory input resulting from the nerve damage is compensated (Dickenson et al. 2004). 
Like descending facilitation, inhibitory pathways from the brainstem and other higher nucleus to the spinal 
cord may also undergo plastic changes in chronic NP. Various piece of research after peripheral 
inflammation shown several plastic modifications that can facilitate the inhibitory drive such as an increase 
in descending noradrenergic inhibition, coupled with an augmented efficacy of spinally administered a2-
adrenoceptor agonists, as well as variations in other neurotransmitters such as serotonin or GABA (Green 
et al. 1998, Tsuruoka et al. 2003, Rahman et al. 2008, Dogrul et al. 2009). This enhanced inhibitory drive 
is presumably a homeostatic mechanism originated in an attempt to counteract an increased facilitatory 
drive and augmented spinal hyperexcitability (Fields and Basbaum 1979, Treede 2016). This dual control 
of the spinal cord by plastic circuits in the brain may be one important way in which the brain can modify 
pain processing, and could be the way by which anxiety, sleep, catastrophizing and coping can influence 
upon the level of pain perceived. 
When the nociceptive signal reaches supra spinal structures it gets embraced in a complex 
multidimensional experience that do not only includes nocifensive and nociceptive but also cognitive and 
emotional-affective components. ChP is associated with functional and morphological changes in cortical 
and subcortical brain areas where to find objective markers for pain and related dysfunctions is unfeasible. 
NP as mentioned above should be understood as a progressive nervous system disease that results from 
poorly-defined neurophysiological and neurochemical changes. One critical challenge to understanding NP 
is determining to what degree the CNS, particularly the brain, contributes to NP's generation and 
maintenance. Neuroimaging has recently provided important clues to these challenges (Moisset and 
Bouhassira 2007). According to the current scientific evidence chronic NP may be a consequence of long-
term plastic changes along the entire brain network associated to pain, formerly known "pain matrix" 
(Iannetti and Mouraux 2010). Besides peripheral nociceptors and the spinal cord, morphological and 
functional plastic changes also take occur in cortical and subcortical areas that participate in pain 
processing. Indeed, growing evidence now suggests that long-term plastic modifications in cortical 
networks may represent a possible basic mechanism underlying ChP, but unfortunately the 
neurobiological mechanisms of the various features of pain are only starting to emerge. A network of brain 
structures that process pain-related information has come to light due to numerous neuroimaging studies 
within the field (Apkarian 2004, Baliki et al. 2008, Tracey 2008, Apkarian et al. 2011, Lomakina et al. 
2012). This complex network, former "pain matrix, uniformly incorporates primary (S1) and secondary (S2) 
somatosensory cortices, insular cortex, anterior cingulate cortex (ACC), and thalamic nuclei among other 
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less reported areas. Some of these locations have been associated with distinct features of pain, as S1 
cortex is usually linked to sensory-discriminative aspects (Craig 2003), S2 associated with additional 
affective/ cognitive functions, or the insula and ACC are considered to be of great value for affective and 
cognitive aspects of pain (Ohara et al. 2005, Baliki et al. 2008, Sugimine et al. 2016). Yet scientific 
literature clearly shows how prefrontal cortical areas other than ACC and subcortical areas such as the 
amygdala have also an important place within the brain network for pain.  
These brain areas may play a role in "secondary pain affect", which comprise the cognitive evaluation and 
the conscious awareness of pain (Wiech et al. 2008). Pain-related changes in these brain locations may 
be partly responsible for the emotional-affective and emotion-based cognitive consequences of pain. On 
the contrary, pain can be modulated by emotional - fear and anxiety- and cognitive -attention, expectation, 
or memory- factors (Baliki et al. 2006, Tracey and Mantyh 2007, Seminowicz et al. 2011). Unluckily, 
changes within the brain networks in NP are not always the same, activity changes in the thalamus and 
medial pain system are more homogeneous in spontaneous NP, whereas data on the involvement of 
cortical areas in allodynia appear more variable (Moisset and Bouhassira 2007). Non-identical 
presentations of allodynia may lead to different patterns of brain activity, indicating various 
pathophysiological mechanisms and suggesting that specific "allodynia networks" in the cortex may exist 
(Apkarian et al. 2005). 
In addition to functional changes, morphological alterations at spinal and supraspinal levels have been 
reported in ChP. NP is associated with sprouting of nerve terminals in somatosensory cortex (Flor et al. 
2006), apoptosis of spinal cord cells (de Novellis et al. 2004), grey matter density decrease in PFC 
associated with reduced cognitive abilities and thalamic atrophy (Apkarian 2004, Apkarian et al. 2011). 
Morphometric analysis demonstrated that chronic back pain specially in patients with a NP component is 
linked with approximately 10% of brain grey matter atrophy in prefrontal cortex and thalamus (Apkarian 
2004). The reduction in grey matter was also detected in somatosensory cortex, temporal lobe and brain 
stem in addition to prefrontal cortex.  
Nowadays, it remains to be found if decreased grey matter density is related exclusively or predominantly 
to a specific cell population (projection neurons, inhibitory interneurons, and microglia) or if different cell 
types are affected equally. In fact, numerous studies provide clear evidence of the maladaptive immune 
response is not just a bystander phenomenon within the brain but actively play an important role to 
persistent pain. The evidence for a part of the immune system in the origin and development of NP in 
patients is more circumstantial. Recruitment of immune cells and increased expression of pro-inflammatory 
cytokines in different areas of the brain has been shown in several studies (Ji et al. 2013, Loggia et al. 
2015). However, the exact role of microglia and astrocytes in human pain disorders remains unknown. 
In summary, neuropathic pain is a highly complex clinical situation developed after a series of maladaptive 
changes in neurones along the entire nociceptive pathway following nervous system damage. A 
substantial body of NP research points to various important contributory mechanisms including aberrant 
peripheral and central sensitisation, ectopic activity in nociceptive nerves, decreased inhibitory modulation, 
and pathological activation of microglia. The multitude of different mechanisms makes NP a highly 
complex condition, with a broad spectrum of presentations and notoriously refractory to treatment. 
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3. Clinical features 
 
After peripheral tissue damage or inflammation, reversible modifications in the sensory nervous system 
result in the generation of pain hypersensitivity, a protective process that ensures appropriate healing of 
damaged tissue. Opposite, NP is originated after a real or potential damage to the nerve system itself and 
changes in its sensitivity may become persistent, leading to spontaneous pain, pain threshold may suffer a 
substantial drop such that innocuous stimuli lead to pain, and the amplitude and duration of its response to 
noxious stimuli are intensify. Because these changes in the somatosensory system in susceptible 
individuals can be irreversible, NP, once established, should be considered as an independent 
pathological condition of the nervous system in its own right (van Hecke et al. 2014). The majority of 
individuals do not develop NP after nerve damage and spite of the fact that only a few genetic 
polymorphisms have been reported that confer either an augmented susceptibility to development of NP, it 
is evident that genotype is an important contributor (Kehlet et al. 2006, Møller and Jensen 2010, Tremblay 
and Hamet 2010, Binder et al. 2011, van Hecke et al. 2015). 
The first step in the clinical diagnosis of NP is to register the lesion or disease that is believed to be the 
source of it, and its anatomical location. Until not long ago, this was the entire diagnostic process, and 
frequently no effort was made to establish the actual neural mechanisms accountable for the development 
of the individual pain profile and how they may reflect in treatment options. A usual supposition is that a 
single aetiology origin NP in constant way. However, NP is highly heterogeneous, with multitude of 
presentation patterns revealing different combinations of genetic, environmental and aetiological factors, 
and specifically, the neurobiological processes they engage. Due to their mechanistic variety and 
dissimilar manifestations, these mechanisms originate a complex somatosensory profile that can be 
reflected as a constellation of negative and positive sensory signs and symptoms, a ''pain fingerprint'' 
(Scholz et al. 2009, Mahn et al. 2011, Freeman et al. 2013). 
Commonly, negative symptoms are the earlier manifestation of damage to the somatosensory system and 
can be noticed by quantitative sensory testing in addition to clinical examination and to a more limited 
degree with the history or specific questionnaire. The origin of negative symptoms in peripheral 
neuropathies is direct damage to primary sensory neurones. This may lead cell death or altered 
transduction, conduction or transmission (or all of them) of sensory information. Loss of function can be 
showed across the whole sensory spectrum, being clinically proved by global numbness after a traumatic 
nerve injury for example, or it can affect specific modalities; for instance, we can associate an increased 
heat threshold due to deterioration of intraepithelial C-fibres is a common early manifestation of peripheral 
diabetic neuropathy or HIV neuropathy (Orstavik and Jørum 2010, Phillips et al. 2014). 
A great number of patients with nerve damage only develop negative symptoms; some others also have 
disturbing positive manifestations due to aberrant plastic changes are engaged that boost pain sensitivity 
or guide spontaneous activation of the nociceptive pathway. Peripheral sensitisation typically take place 
after peripheral inflammation and involves a threshold drop and an enhancement in the excitability of the 
peripheral endings of nociceptors in response to sensitizing inflammatory mediators. This lead to stimuli 
that usually are felt as uncomfortable or slightly painful, such as a pinprick, becoming extremely painful 
(hyperalgesia) in the primary area of inflammation, and innocuous stimuli at the site of inflammation, such 
as light touch, warm or cool temperatures, being perceived as painful (Jensen and Finnerup 2014). The 
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presence of hyperalgesia and allodynia are debilitating consequences of peripheral nerve injury, and they 
can, potentially at least, arise as a result of spontaneous and aberrant activity raised anywhere along the 
nociceptive pathway. However, spontaneous sensations following peripheral nerve damage usually 
emerged as a result of hyperexcitability in the primary sensory neurone, resulting in ectopic abnormal 
activity not only at the injury site, but also at the soma or anywhere along the axon. Ectopic activity is a 
capital constituent of the spontaneous sensations that manifest following nerve damage originating 
paraesthesia, dysthesia, and pain. The sensations may be superficial or deep, continuous or episodic, and 
often has shock-like bursts and a burning quality, all of which may indicate engagement of ectopic activity 
in several type of fibres with distinct patterns of firing, in addition to subsequent central neuroplastic 
changes (Latremoliere and Woolf 2009, Sandkühler 2009). Simultaneously to the changes occurring at the 
damaged fibres, uninjured neighbouring fibres can potentially generate afferent input and consequently 
cause painful sensations (Wu et al. 2002); actually, it is postulated that this mechanism is an important 
source of neuropathic ectopic activity (Hehn et al. 2012, Jensen and finnerup 2014). 
The discovery of central sensitization, a form of long-lasting synaptic plasticity in the dorsal horn triggered 
by nociceptors that facilitates nociceptive processing (Woolf 1983), led to the realization that amplification 
of incoming signals within the CNS has a very substantial role in the generation of clinical pain 
hypersensitivity in NP. In fact, central sensitisation account for a closer understanding of how low threshold 
A or C fibres can origin pain sensations, why repeated stimuli at a fixed intensity can lead to a progressive 
increase in pain, why there is a spread of sensitivity beyond areas of tissue injury or outside a damaged 
nerve territory, and why pain may long outlast a peripheral stimulus (Latremoliere and Woolf 2009, Woolf 
2011, Hehn et al. 2012). Therefore, central sensitisation accounts for a mechanism that recruits naturally 
subthreshold synaptic input into a novel output from nociceptive neurones, lessen their threshold, 
increasing receptive field size, and altering firing temporal dynamics. All these changes give rise to the 
generation of dynamic mechanical allodynia in response to low threshold mechanoreceptor activation, 
pinprick or mechanical hyperalgesia and temporal summation. 
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4. Diagnosis 
 
In the setting of clinical care for a patient suspected of having NP, careful history and physical examination 
and special laboratory tests serve physicians to formulate a differential diagnosis of the current condition; 
to allow better decisions making in management choice; and to follow-up individual responses to 
management (Haanpää et al. 2009, 2011). Diagnosis of NP is primarily found on history and physical 
examination even though other particular assessments are usually quite helpful. Clinical assessment 
should focus on excluding treatable conditions (for instance spinal cord compression or tumours), 
asserting the diagnosis of NP, and identifying clinical features that could contribute individualise therapy. 
Alike in other ChP conditions, assessment of a plausible neuropathic condition should include an 
evaluation of pain intensity, quality, location, temporal variation, functional impact on mood, sleep, and 
other activities of daily living and responses to previously attempted therapies (Gilron et al. 2013). 
Accumulating evidence over the two decades has associated a collection of sensory signs and symptoms 
that are expected to be linked to NP conditions versus other non neuropathic conditions (Woolf and 
Mannion 1999, Bennett et al. 2006, 2007). Much of this information has emerged from the development 
and released of different NP screening tools including the Neuropathic Pain Scale (Feldman et al. 1994), 
the Neuropathic Pain Questionnaire (Krause and Backonja 2003), the pain DETECT (Freynhagen et al. 
2006), or the Short-Form McGill Pain Questionnaire (Dworkin et al. 2009). Despite notable variability exist, 
the sensory quality descriptors "burning" (or "hot"), "tingling" (or " pins and needles " or " prickling), and 
"shooting" (or “electrical shocks") are included in all these tools, and these 3 descriptors are very likely the 
most distinctive of NP. Additionally it is clear that no single sign or symptom is pathognomonic of NP. The 
above, self-report, NP assessment tools can be of great help for the diagnostic characterisation of NP. 
Nevertheless, some of them have also been used to describe subgroups of NP patients in whom specific 
underlying mechanisms are operant. For instance, Baron et al. detect 5 different subgroups of sensory 
profiles evaluated using the pain DETECT questionnaire (Baron et al. 2009). In addition, pain quality 
descriptors can give more attributes in characterising therapy outcome beyond just global measures of 
pain intensity. By way of illustration secondary analyses of NP clinical studies show that drug therapy can 
specially lessen certain pain quality descriptors and have little effect on others (Jensen et al. 2009, Gilron 
et al. 2013, Bouhassira et al. 2014). 
There is an important role of sensory testing in classifying a pain syndrome as neuropathic. The 
importance to the sensory evaluation is also reflected by the grading system for NP that has additionally 
been developed (Treede et al. 2008). It is based on four criteria: pain distribution (criterion 1), the link 
between pain distribution and the patient's history (criterion 2), confirmatory tests of neurologic status 
demonstrating positive or negative sensory signs enclosed to the innervation area of the damaged nervous 
structure (criterion 3), and further confirmatory diagnostic tests to identify the lesion or disease entity 
underlying the NP (criterion 4). Criteria 1 and 2 must be met to initiate the working hypothesis of plausible 
NP. Either criterion 3 or 4 must be met additionally to reach the grade of probable NP, while the grade of 
definite NP is achieved only when both criteria 3 and 4 are satisfied. Regarding those criteria, a 
reasonable QST result is, together with assessment of intraepidermal nerve fibre density and 
electrophysiological test procedures, regarded as a confirmatory diagnostic test to verify sensory signs in 
addition to sensory mapping (Haanpää et al. 2011). 
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4.1. Primary Sensory Assessment. 
Reasonably basic bedside techniques can be applied to assess sensory abnormalities such as 
hyperalgesia to pinprick, blunt pressure, heat, or cold, hypoesthesia cold or touch, hypoalgesia or even 
allodynia (Haanpää et al. 2011, Freeman et al. 2013). Bedside sensory examination should include touch, 
pinprick, pressure, cold, heat, vibration and temporal summation. Responses can be graded as normal, 
decreased or increased to determine whether negative or positive sensory phenomena are involved. At 
present, it is generally agreed that assessment should be carried out in the area of maximal pain, using the 
contralateral area as control. Contralateral segmental changes following a unilateral nerve or root lesion 
cannot be excluded, however, so an examination at mirror sites might not necessarily represent a true 
control. Additional efforts should be made to understand how the identified sensory abnormalities account 
for a suspected neurological lesion. We must always have in mind that sensory nerve first assessed by 
clinical examination includes A-beta touch fibres (assessed for example with fingers, wisp of cotton, or soft 
brush), A-delta fibres (assessed with a metal straight pin or sharp wooden stick), and C fibres (assessed 
with a warm 40Cº object for example). To give an instance, postherpetic neuralgia or lumbar radiculopathy 
are quite focal conditions thus they are often associated with abnormalities along the affected dermatome, 
whereas other conditions such diabetic or HIV neuropathy are often related to distal and symmetrical 
sensory abnormalities (Baron and Binder 2004, Davies et al. 2006, Phillips et al. 2014). 
 
4.2. Quantitative Sensory Testing (QST) 
Patients with NP suffer from various sensory abnormalities that can develop in different combinations. It is 
thought that sensory signs and symptoms are closely linked to underlying mechanisms of pain generation, 
and it is therefore likely that precise analysis of the individual somatosensory pattern might facilitate a 
mechanism-based treatment strategy. Thus, it is important to assess the individual sensory phenotype as 
precisely as possible. Additionally to the self-report instruments and the basic bedside methods discussed 
above, the use of QST to assess sensory signs has manifested promising results in characterising 
underlying "mechanistic clusters" in NP as well as in predicting response to analgesic treatment with 
certain drugs. The term quantitative sensory testing refers to diagnostic procedures in which perceived 
stimulus intensities are referenced to test stimuli applied with defined intensities (Shy et al. 2003). Hence, 
QST is a "semi-objective" method, and therefore, a high grade of standardization is needed. A 
standardised QST protocol for routine use and clinical trials was launched by the German Research 
Network on Neuropathic Pain (Deutscher For-schungsverbund Neuropathischer Schmerz[DFNS]) in 2006 
because standardisation is key to compare study results (Rolke et al. 2006). Sensory stimuli are applied to 
the skin or deep somatic anatomy to evoke a non-painful or painful sensation that can be quantified on a 
rating scale. QST uses a battery of mechanical and thermal stimuli (graded von Frey hairs, several pinprick 
stimuli, pressure algometry, quantitative thermal testing, etc) and assesses both positive signs (gain of 
function) and negative signs (loss of function) in the nociceptive and non-nociceptive afferent nervous 
systems. On the basis of QST, a novel classification and subgroupings of NP syndromes have been 
proposed. Similar to the way tumors are graded, patients are classified (LoGa classification) according to 
their function of small and large afferent fibres (Maier et al. 2008). Sensory phenotyping can also unravel 
subgroups of people with an anomalous endogenous pain modulation. The capacity to activate the 
descending pain modulatory pathways is individually variable and it can be quantified experimentally by 
measuring a reduction in pain perception with QST during simultaneous administration of a conditioning 
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painful stimulus at a distant body site (Yarnitsky et al. 2012). 
If used properly, QST has started to play an important role in pain research. It has bridged a gap between 
basic researches, experimental studies using models of NP and pain patients, using the same test stimuli 
in all three contexts. This is contributing to understand the underlying mechanisms in NP syndromes 
(Arendt-Nielsen and Yarnitsky 2009, Chen et al. 2009, Cruz Almeida and Fillingim 2014). Additionally it is 
being a pivotal tool for transferring the mechanism-based treatment concept into clinical practice, where 
subgrouping sensory phenotypes, as an indicator of the pain processing pathway, is the basis to 
demonstrate that subgroups of patients with a distinct sensory phenotype certainly respond differently to a 
particular treatment. To give a recent instance of the advances in this area I can mention the work of 
Dumont et al. that published a clinical trial that explore in a randomized, double-blind, placebo controlled 
study the pain-relieving effect of oxcarbazepine in patients with surgical or traumatic nerve injury, 
polyneuropathy or postherpetic neuralgia. The investigators performed QST according to the LoGa 
classification in the beginning of the trial and stratified the individuals according to their sensory phenotype 
into 2 different groups: (1) "irritable nociceptor" with predominantly a "gain of function" and a preserved 
small-fibre nerve function and (2) "deafferentation type" dominated by sensory loss. This stratification 
stands on the hypothesis that ectopic activity from up-regulated sodium channels is primary responsible for 
hyperalgesia ("irritable nociceptor"), and therefore oxcarbazepine as a sodium channel blocker should 
have an effect in these patients. Despite oxcarbazepine is recommended as first-line therapy for trigeminal 
neuralgia, it plays a minor role in the treatment of other NP syndromes because of equivocal study results 
(Deng et al. 2016). This study evidence positive results and a treatment response depending on the 
sensory phenotype. For all patients, the number needed to treat (NNT) for 50% pain relief was 6.9. The 
NNT in the group with the "irritable nociceptor phenotype" was only 3.9, whereas the NNT was 13 for the 
"nonirritable nociceptor" phenotype (Demant et al. 2014). 
 
4.3. Additional tests 
Clinical neurophysiological techniques are crucial assessment tools in founding a diagnosis of NP with 
involvement of peripheral nerves. Nevertheless, clinical neurophysiology assess large fibres but is 
generally not useful in determining the possible involvement of small nerve fibres within NP. Various other 
techniques can be used in individuals with suspected small-fibre neuropathy. Aside from 
electrophysiological and clinical examination, other assessments comprise both structural tests such as 
structural imaging examinations of larger structures, skin biopsy analyses and sural nerve. The functional 
evaluations comprise, apart from QST, quantitative axon reflex measures, sudomotor function test, heart 
rate variability, contact heat-evoked potentials (CHEPs) and laser- evoked potentials (LEPs). An abnormal 
function of the sudomotor nerves with altered sweat has been identified as an initial neurophysiologic 
irregularity in neuropathies. There are several techniques to assess sudomotor functionality, being the 
most commonly used the quantitative sudomotor axon reflex test.  
Furthermore, a novel devised objective "sweat test" has revealed the potential to identify and quantify early 
changes in sudomotor nerves due to partial denervation of single sweat glands (Provitera et al. 2010, 
Thaisetthawatkul et al. 2013). LEPs and contact heat-evoked potentials intend to evaluate noxious thermal 
information, transmitted by Ad fibres and C-fibres, employing in the case of the potentials contact heat 
stimulation, which stimulate a great number of nociceptors in the skin, whereas LEPs use high-energy 
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lasers to selectively activate individual nociceptors (Valeriani et al. 2012). Both methods are considered 
reliable techniques to study nociceptive pathways. Nevertheless, there is no definite correlation between 
LEPs and structural changes such as the intraepidermal nerve fibre density, indicating that loss of nerve 
fibres is not necessarily linked with loss of function of remaining nerve fibres (Truini et al. 2014). 
Additionally to these mentioned above, punch skin biopsy is a quick and minimally invasive technique with 
a high diagnostic yield and is at the present time a commonly used procedure in patients suspected of 
having small- fibre neuropathy (Ebenezer et al. 2007, Devigili et al. 2008, Malik 2014).  
Over the past years, there has been some progress in obtaining additional quantitative measurements 
from the skin biopsies, including nerve fibre length densities, sweat gland innervation or axonal swellings. 
A strong point of skin biopsies is that they can be reproduced over time and allow the examiner to follow 
the progression of the disease quantitatively, and they can reveal changes in the small nerve fibres, which 
a standard neurological assessment is not capable of. An alike and entirely noninvasive technique is 
confocal microscopy of the cornea in which corneal small nerve fibres are quantified. This technique has 
been proved to be reproducible, sensitive, and very specific. Nevertheless, it only show loss of nerve 
fibres, leaving aside the ability to assess functionality of the remaining nerve fibres that can be intact, 
damaged, or overactive( Malik 2014, Petropoulos et al. 2014). 
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5. Treatment 
 
NP management is still a great challenge because a large number of sufferers do not experience sufficient 
pain relief, as deduced from clinical trial outcomes and from clinical experience. This complexity in 
treatment might be consequence of the heterogeneity of NP pathophysiological mechanisms and the 
commonly coexisting emotional and psychological facets of ChP. Firstly, a rigorous diagnosis can disclose 
the source of pain; therefore, an appropriate management of it can result in partial or entire pain relief. 
When beginning symptomatic treatment, education of patients, embracing information on NP, the 
management plan, and feasible side-effects of any treatment -pharmacological or non pharmacological-, is 
indispensable to increase patient compliance. To avoid unrealistic expectations from NP sufferers on 
tolerability and efficacy, realistic management targets should be determined. Pain depletion of at least 25% 
is usually welcomed to be a clinically meaningful outcome (Attal 2011). Additionally to pain, both health-
related quality of life and sleep disturbance should be assessed when evaluating analgesic efficacy (Smith 
et al. 2007, Gustorff et al. 2008). Furthermore, coexisting anxiety and depression might hamper successful 
pain management and should be recognised and targeted for specific treatment (Maletic and Raison 2009, 
Brod et al. 2014). In clinical settings, this complexity is taken into account by a multimodal therapeutic 
approach, involving pharmacological and non-pharmacological management options, such as physical 
therapy, psychological interventions such as cognitive behavioural, and occupational therapy (Kerns et al. 
2010, Kozma et al. 2014, Casanova-García et al. 2015). In spite of the fact that the efficacy of such a 
multimodal biopsychosocial view has been routinely reported in ChP conditions other than NP, its strength 
in NP patients is well accepted (Garven et al. 2011). In those who develop phantom limb pain and CRPS, 
non-pharmacological treatments such as cognitive behavioural therapy and occupational therapy, as well 
as new methods such as graded motor imagery (including mirror therapy), have been shown to reduce 
pain and improve functionality (Katholi et al. 2014, Simons 2016). Likewise, invasive treatments have been 
reported as useful methods in neuropathic states when appropriately used (Slavin 2008, Pereira and Aziz 
2014). 
5.1. Mechanism-based therapy 
ChP conditions are heterogeneous states with a large number of genetic, pathophysiological and 
psychosocial features, all of which are capriciously expressed in each person. As a result, current scientific 
and clinical approaches should study the different underlying elements as detailed as possible with the 
objective of tailor the management to the unique patient, a strategy which is called personalized pain 
medicine. NP was suggested in which pain syndromes are clustered based on the underlying 
pathophysiological mechanisms of pain causation rather than on the cause of the disease (Woolf et al. 
1998). The idea supporting this was that it could be feasible and more appropriate to conduct specific 
treatments towards specific conditions looking at its particular nociceptive processing. Establishing a 
mechanism-based treatment. 
Current understanding about pain mechanisms has grown exceptionally over the past years, becoming 
clear that numerous mechanisms both in the central or peripheral nervous system act alone or in 
combination in a single person. As a necessary condition for transferring the mechanism-based treatment 
idea into clinical practice, it is essential to develop diagnostic instruments that contribute determining pain 
mechanisms in patients and to cluster individuals accordingly. Until now, there is no biomarkers of pain 
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mechanisms, for that reason, clinicians have to rely on surrogate markers that are believed to be evenly 
matched to mechanisms of pain generation. A potential strategy to subgroup patients is to employ the 
profile of sensory symptoms and pain features, the so-called sensory phenotype, as a measure of 
abnormalities in the pain processing pathways. Both, animal and human scientific evidence support this 
approach in NP. It is clear now that nerve lesion triggers multitude of molecular and functional changes in 
every constituent of the nociceptive pathway. As a result, the nociceptive fibres develop irregular sensitivity 
and spontaneous activity. Presumably this changes in the patient nervous system lead to the perception of 
shooting pain sensations, spontaneous pain, in addition to thermal hyperalgesia. Following further 
somatosensory abnormalities, peripherally and central, can occur developing a unique and distinctive 
somatosensory profile for each individual. 
In order to validate the mechanism-based treatment idea, it has to be proved that clusters of people with a 
specific sensory phenotype truly respond differently to a determined treatment. To date, the prospectively 
designed clinical trials that have been conducted using the method of sensory phenotyping as a 
stratification criterion and the retrospective response analyses using sensory phenotyping of NP patients 
at baseline of a trial are very promising (Herrmann et al. 2006, Baron et al. 2012, Yarnitsky et al. 2012, 
Kalliomäki et al. 2013, Martinez et al. 2013, Cruz Almeida and Fillingim 2014, Höper et al. 2014, Mainka et 
al. 2016). However, this technique should be implemented in following studies designs to eventually 
validate the mechanism-based treatment concept. Besides, simpler assessment techniques should be 
developed for reliably identifies subgroups of NP patients in the general practice. 
 
5.2. Drug therapy for Neuropathic Pain 
Over the last decade, several recommendations have been suggested for the pharmacotherapy of NP or 
certain NP conditions, especially post-herpetic neuralgia and painful diabetic neuropathies (Finnerup et al. 
2015, Dubinsky et al. 2004, Dworkin et al. 2007, Attal et al. 2010, Bril et al. 2011). At the same time, novel 
pharmacological therapies have evolved and high-standard clinical trials have been completed. Besides, 
the risk of bias in collection, analysis and reporting data have been reduced due to the analysis of 
publication bias, together with the easier identification online of undisclosed or unpublished 
pharmacological studies. Different types of medications with analgesic effects have been shown to work 
better than placebo in clinical trials including patients with diverse NP conditions covering opioids, local 
anesthetic drugs, NMDA receptor antagonists, cannabinoids, antidepressants, anticonvulsants, botulinum 
toxin, topical capsaicin, and several other agents (Finnerup et al. 2015). Many of these drugs were initially 
developed for other indications, such as epilepsy or depression, and later on assessed in NP. Meta-
analysis and systematic reviews of NP trials and development of management guides by several 
associations and societies have led to the current recommendations for gabapentin, pregabalin, tricyclic 
antidepressants, and serotonin-norepinephrine reuptake inhibitor (SNRI) antidepressants as first-line 
therapies; weak recommendations for lidocaine patches, high-concentration capsaicin patches, opioids, 
botulinum toxin A, and combinations of selected first-line agents; and weak recommendations against the 
use of cannabinoids and valproate (Finnerup et al. 2015). It seems clear then that the array of 
medications, and other treatment interventions, with demonstrated efficacy in NP is expanding. Therefore 
future research should not only define the finest use of existing drugs alone and in association, but should 
also determine medications that augment the magnitude of pain alleviation or the likelihood of a beneficial 
response. 
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5.3. Invasive Therapy for Neuropathic Pain 
Patients with NP frequently do not respond sufficiently to the medication used alone or in combination with 
non-pharmacologic treatments and their pain is usually as a result termed refractory (Smith et al. 2012). 
Rather than continue endless pharmacological rotation that does not offer the wanted pain reduction or 
origin undesirable side effects, interventional treatments might be contemplated. Interventional pain 
management techniques embrace neural blockade, spinal cord stimulation, intrathecal medication, and 
neurosurgical interventions (Day 2008, Dworkin et al. 2013, Pereira and Aziz 2014). An up to date 
systematic review analysed the efficacy of various invasive techniques in several neuropathic pain 
conditions, such as post- herpetic neuralgia, spinal cord injury neuropathic pain and central poststroke 
pain, painful diabetic and other peripheral neuropathies, radiculopathy and failed back surgery syndrome, 
trigeminal neuralgia and trigeminal neuropathy and CRPS (Dworkin et al. 2013). This study concluded that 
evidence for the effectiveness of interventional techniques in NP is limited. It showed that just about half of 
the patients obtain lasting partial pain relief, an even a smaller number those whose relief was complete. 
However, it is important to highlight that careful evaluation of interventional and surgical pain options are 
fraught with numerous risks of bias associated to ethical and practical obstacle to treatment blinding and 
the employ of optimal sham, or other, control interventions; study patient dropouts attributable to 
intractability or severity and treated individuals; and the logistics and costs of follow-up and study duration. 
In addition, it must be remember that relative deficit of evidence of efficacy does not compulsory indicate 
evidence of lack of efficacy and therefore, rational interventional management of NP states should be 
contemplated an integral component of a more comprehensive approach that embraces pharmacologic 
and non-pharmacologic, non-interventional treatments. 
 
5.4. The multimodal approach and non-pharmacological therapies 
No single pharmacologic or interventional treatment abolishes symptoms of NP entirely. A complete 
management approach preferably involves the use of additional treatment strategies in an effort to 
ameliorate the situation. The objectives of any pain therapy comprise not only improve the symptoms but 
also recover physical function, reduce psychological distress, and enhance overall quality of life. It is 
necessary for clinicians then to clarify these goals to patients, set up appropriate expectations for pain 
relief, and engage individuals as active player in their management. Additionally, the physician should 
made comprehend the benefits of multidisciplinary management, making easier the active involvement in 
this multifaceted approach. It has been showed that people treated in multidisciplinary pain centres 
reduced pain intensity quicker, have reduced use of opioids, and enhance health-related quality of life 
compared with patients treated by general practitioners even when adhering to a pain management plan 
delineated by a pain specialist (Becker et al. 2000). Neurology, psychology, physical therapy, occupational 
therapy, and social support all contribute to the ultimate outcome of patients with ChP. 
Attending the psychological component of chronic NP is crucial to success. Clinicians can support patients 
very easily, just by focusing on functionality and normal engagement in activities. Pain catastrophizing, is a 
well known predictor of poor response to pharmacotherapy and higher likelihood of treatment 
discontinuation; catastrophizing also predicts more extensive duration of pain, higher degree of disability, 
and poorer quality of life (Smeets et al. 2006, Toth et al. 2014). Cognitive behavioural therapy directly 
Introduction 
 21 
addresses this maladaptive behaviour, aiding patients refine emotions and thoughts through education and 
training in coping skills and/or conscious confrontation of harming behaviours and thoughts (Turk 2003, 
Turk et al. 2010, Nijs et al. 2014). This kind of psychological approach has been demonstrated to provide 
benefit in NP patients not only reducing pain intensity but also providing a durable improvement in 
functionality, coping, pain related behavior, anxiety, and participation for patients suffering with chronic 
neuropathic spinal cord injury pain (Evans et al. 2003, Heutink et al. 2014). In addition any psychological 
intervention is being improved by the presence of an adequate social support. For that reason support 
group therapies have been embraced in pain management, easing patient engagement in the 
management strategy, allowing patients to share coping techniques and provide a supportive environment 
for positive reinforcement. Further psychoeducational wellness programs that augment awareness of 
social, intellectual, emotional, and spiritual factors are also effective in enhancing the overall quality of life 
and well-being of individuals with pain (Subramaniam et al. 1999, McGuire et al. 2015). 
NP, as mentioned above, usually leads to reduce physical activity and functionality. Effective treatment 
must target both improvement in symptoms and functional restoration and mobilisation. A multidisciplinary 
approach to any NP condition is important; for instance in diabetic neuropathy recovering mobility and 
functionality is crucial for avoiding ulcers, contractures, and loss of sensation. In addition, exercise training 
in these patients improved perceived functional limitations, muscle strength and blood glucose regulation 
(Otterman et al. 2011). Other physical modalities such as transcutaneous electrical nerve stimulation or 
the use of osteopathic techniques may be applied to improve chronic NP (Kumar and Marshall 1997, 
Kuchera 2007, Arienti et al. 2011). Physical therapy for functional restoration is also commonly accepted 
as one the pillars in CRPS management (Zernikow et al. 2012). 
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6. Neuropathic Pain in Children 
 
ChP affects approximately 6% of children and adolescents (van Dijk et al. 2006). The percentage of these 
children who develop NP is unknown. Some people suggest that the prevalence of ChP with neuropathic 
features in adulthood is similar to the one found in children (5%-10%) (Torrance et al. 2006, van Hecke et 
al. 2014). However, current evidence indicate that despite the fact that NP is seen in a remarkable part of 
referrals to paediatric ChP clinics the prevalence is much lower (Martin et al. 2010, Borsook 2012), and the 
conditions with which it is linked vary from those usually described in adulthood. 
Accepted causes of NP during childhood embrace from situations where nerve damage has occurred, for 
instance, post-traumatic, phantom limb pain, postchemotherapy, and in some chronic states or infections 
such as HIV/ AIDS to genetic conditions affecting sensory nerve function such as Fabry ' s disease and 
erythromelalgia (Ramaswami 2008, Fischer and Waxman 2010, Walco et al. 2010). CRPS is an important 
idiopathic condition that occurs in both children and adults that is generally thought to be characterised by 
NP. 
Thus evidence of NP has been detected in childhood, being neuropathy and sensory nerve dysfunction 
main features of most neuropathic conditions. However it is clear from our current knowledge of 
prevalence and prognosis that there are significant differences in the sensory response to nerve injury and 
CNS damages that appear to strongly relate to developmental age. By way of illustration, several clinical 
trials in animals have studied the effects of various types of nerve injury at different NP conditions and 
developmental ages, showing how mechanisms operating in childhood NP may vary from that in older 
age. Laboratory models of traumatic peripheral nerve injury have confirmed a diminished susceptibility to 
NP if the damage appear at a younger age; additionally this findings have been used to improve 
understanding of age-related changes in the pathophysiology of NP (Howard et al. 2005, Walker et al. 
2009). Likewise, current literature suggest that symptoms of NP in childhood are generally less frequent 
and their severity relates to the underlying cause, age at onset or duration of disease (Vogel et al. 2002, 
Atherton et al. 2008). 
Current recommendations for the assessment and diagnosis of NP are configured for adults, however they 
are usually extrapolated to children or adolescents. As there are no definite biomarker tests for NP the 
diagnosis is made on the basis of clinical indicators which is a well known issue of pain assessment in 
young children. Clinical history remains in childhood the centrepiece of diagnosis; nevertheless children 
may employ qualitative descriptors that are considered indicative of NP, such as shooting, radiating, 
burning, pricking, tingling, electricity-shock, stabbing, pins and needles, and pinching (Krane and Heller 
1995, Wilkins et al. 1998, Walco et al. 2010). Obviously, numerous children may be unable to describe 
their pain using such terms but in any case pain history should contain the assessment of intensity, quality, 
temporal aspects of pain and response to treatment (Haanpää et al. 2011). Preferably all of these features 
-but most importantly pain intensity- should be evaluated using a validated scale; unfortunately, 
observational scales have mainly been designed for apply in adult acute pain settings and may not be 
reliable. 
Like in adults physical assessment should aim to identify, confirm and locate the damage of the 
somatosensory system and report any associated neurological signs. Sensory abnormalities are more 
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complicated to acquire in children for many reasons such as communication or lack of previous data. For 
instance, reliable methods such as QST assess patterns of change in association with NP in adults, plus it 
is very important to establish a good communication between the patient and the investigator, both 
features that are usually diminish when assessing a child. Microneurography, functional brain imaging, 
electroneuromyography and skin biopsy may be indicated although again their use is mostly limited to 
research (Lebel et al. 2008). In addition, assessment of pain-related disability, sleep, quality of life, role 
functioning and mood should be usual assessments for children suffering of NP. 
NP management at young ages is even more challenging and refractory than in adults. As mentioned 
above, chronic NP on rare occasions responds acceptably to a single analgesic medication or pain 
management strategy. Most pain states are highly modulated by activity in the CNS -brain and spinal cord-
, which are in turn affected by cognitive and emotional factors and therefore a multimodal approach ground 
on a biopsychosocial pain model may always be engaged (Gatchel et al. 2007).Therefore, advances in NP 
management are likely to happen from a better understanding of the heterogenous mechanisms that are 
implicated at different stages of development, improvements in the accuracy of clinical diagnosis and a 
much more systematic and cautious documented approach to therapy. Correct management should 
embrace certain analgesic drugs ideally chosen on the basis of the pain mechanisms that are thought to 
be implicated, and a range of pain management strategies suitable to the clinical assessment of pain and 
any related functional impairment. Pharmacotherapy in NP is usually empirical and disappointing, as the 
particular underlying mechanism is rarely fully understood. Even so, a general approach based on an 
assessment of predictable benefits balanced against side effects is sensible. 
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7. Special Conditions. CRPS 
 
Complex regional pain syndrome (CRPS) is a term coined by the International Association for the Study of 
Pain (IASP) to designate states characterised by spontaneous or stimulus-induced pain that is out of 
proportion to the inciting event and associated with a wide variety of motor and autonomic disruptions in 
highly variable combinations (Harden et al. 2007). The evidence points to CRPS etiology being a 
multifactorial disorder that is associated with an aberrant host response to tissue injury. Variation in 
susceptibility to perturbed regulation of any of the underlying biological pathways probably accounts for the 
clinical heterogeneity of CRPS (Marinus et al. 2011). There are many etiological pathophysiological affairs 
that have been accused in development of CRPS, however three major pathophysiological pathways have 
been identified: aberrant inflammatory mechanisms, vasomotor dysfunction, and maladaptive 
neuroplasticity. Additionally, it seems clear that inter-individual differences in the extent to which these 
mechanisms are affected account for the clinical heterogeneity of the disorder (Bruehl 2010). This 
syndrome steeped in uncertainty and commonly inaccuracy. There are no fully accepted guidelines that 
can be used to the diagnosis and would filled definitions of evidence-based medicine. Indeed, there are 
nearly as many diagnostic criteria as there are denominations to this condition. The umbrella term CRPS 
can be currently separated into type I and type II. CRPS I is meant to embrace the formerly known 
sympathetic dystrophy and similar disorders without a nerve injury; while CRPS II take place following 
damage to a peripheral nerve (Harden et al. 2007, Borchers and Gershwin 2014). To date the amount of 
trials that have included appropriate controls and have enough numbers of participants to permit statistical 
analysis with acceptable power calculations is minor. This has result in over-diagnosing and often use of 
excessive pharmacotherapy and even unneeded surgical interventions (Maihöfner et al. 2010). 
In the last decade it has also become a well-established entity in children and adolescents although it 
counts with similar problems than it adults (Berde and Lebel 2005). CRPS remains probably under 
diagnosed and failure to distinguish CRPS leads to delayed management, unneeded diagnostic tests and 
inadequate treatment, which can worsen the situation and aggravate suffering. Early diagnosis, 
appropriate referral and treatment are essential in diminishing pain and improving function in children with 
CRPS (Stanton-Hicks 2010, Logan et al. 2013). 
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REASONING FOR THIS STUDY AND HYPOTHESIS 
 
Neuropathic pain embraces a broad range of conditions linked with a disease or lesion of the peripheral or 
central somatosensory system and its prevalence in the general population may be as high as 7-10%. The 
attraction in the pathophysiology of NP has augmented over the last decades with an exponential growth 
in the amount of clinical trials. Up to the present, the larger part of our understanding of pain mechanisms 
come from basic sciences studies which has resulted in a vast increase in our knowledge, these 
information require to be interpreted with carefulness due to the limitations associated with preclinical 
trials. The obvious issues in translational pain research reveal the limitations of certain experimental 
models, and on that account result of limitations in clinical research. In spite of such difficulties, the 
scientific community wish for a better understanding of pain mechanisms helped by the new insights of 
basic research. For that reason, the first part of this work aim to recognise additional changes in the 
somatosensory system through a series of experiments done in an experimental model of NP, which help 
us to acquire a better understanding of pain mechanisms. 
To date, both basic and human data suggest that a lesion of afferent pathways is required for development 
of NP. In addition, numerous studies demonstrate that not one but various mechanisms can induce to NP. 
Significantly, a great number of these mechanisms are not based on the cause of the disease, the same 
mechanism can be detected in different conditions. In one single patient, several mechanisms can be 
implicated and diverse mechanisms could be the origin of the same symptom. This not only evidence the 
complexity of NP, but also underline the clinical significance of identifying underlying pain mechanisms in 
every single patient. Because different management plans are required for different pain mechanisms, a 
mechanism-based treatment approach can guide clinicians to better outcomes. 
One of the main problems in the management of these syndromes is presumably the fact that treatments 
are apply in a uniform manner whatever the clinical picture, while these neuropathic states are in fact very 
heterogeneous. Important clinical progress has been made in this area in the last few years, following the 
validation of novel clinical tools and the standardisation of sensory profile paradigms enable improvements 
in the clinical characterisation of these conditions. Numerous studies have proved that NP is a consistent 
clinical entity, but it is multidimensional with regards to its clinical expression, with dissimilar sensory 
profiles, potentially indicating particular pathophysiological mechanisms. This new concept of NP should 
refine the characterization of the patient profiles in clinical trials and make available essential data for the 
development of new and more clinically sound translational approaches. 
A route to advance at this stage in research clinical settings is to hypothesise that pain mechanisms can 
be deduced by studying individual symptoms and signs patterns with the above-mentioned methods. By 
studying the effect of treatment that targets these proposed mechanisms, the concept of mechanism-
based treatment can be validated. This approach will allow design of clinical studies more focused on a 
mechanism-related symptoms and signs treatment approach instead of aetiology-based trials. So far, the 
current data contribute to understand the links between at least some clinical symptoms and suggested 
underlying mechanisms, however there is still a long pathway to walk in this field. The second part of this 
thesis aim to establish or clarify some links between QST and clinical symptoms manifested by NP 
patients. 
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NP is also an important issue during childhood and during adolescence, however many of the underlying 
aetiologies in which it occurs are uncommon or never encountered in children. However, several causes of 
NP have been described to date including traumatic injury, neurological and metabolic disease, inherited 
sensory nerve dysfunction, and CRPS. The evidence in basic and clinical studies of NP has disclosed 
significant age-related differences in clinical presentation and prognosis. Clinically, diagnosis, assessment 
and treatment of NP in children are based on methods, experience and evidence acquired from data in 
adults. Therefore, and due to the complexity when setting up any clinical trials involving children, it is 
especially important to increase the data available in children sharing every experience that can help 
clinicians to improve the knowledge when managing neuropathic states during childhood. The third, and 
last part of this work, focus its attention in the management of NP in children; particularly in the invasive 
management of CRPS. 
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MAIN OBJECTIVES 
 
 
First Study: Altered potassium channel distribution and composition in myelinated axons 
suppresses hyperexcitability following injury. 
 
1. To determine neuroma’ expression levels of Kv1.1 and 1.2 at juxtaparanode and paranode after  
traumatic nerve injury and its repercussion at the neurone’ electrophysiological function and  
behavior. 
 
Second Study: Symptom profiles in the painDETECT questionnaire in patients with peripheral 
neuropathic pain stratified according to sensory loss in quantitative sensory testing. 
 
1. To analyze if the overall  painDETECT Questionnaire (PDQ) score or its items reflect phenotypes 
of sensory loss in neuropathic pain as determined by Quantitative sensory testing (QST) testing 
related pain thresholds in patients suffering from radiculopathy and fibromyalgia. 
2. To investigate whether different types of sensory loss is present with different PDQ profiles, or if 
single PDQ items are sensitive to different types of sensory loss in clinical examination. 
3. To analyze the possible correlation between QST obtained somato-sensory profiles of thermal 
and/or mechanical loss of function and PDQ profiles results of patients with neuropathic pain. 
 
Third Study: Complex Regional Pain Syndrome in Children 
1. To examine the efficacy of a proposed multidisciplinary approach for the management of 
Paediatric Complex Regional Pain Syndrome in patients non-responders to conventional 
management.  
2. To review the literature group experience looking for clinical evidence for invasive management in 
Paediatric Complex Regional Pain Syndrome in order to elaborate a guideline. 
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Altered potassium channel distribution and composition in 
myelinated axons suppresses hyperexcitability following injury. 
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1. Introduction 
 
Following traumatic nerve injury spontaneous activity develops initially in myelinated and subsequently in 
unmyelinated sensory axons (Wall and Gutnick, 1974; Kajander and Bennett, 1992; Boucher et al., 2000; 
Michaelis et al., 2000; Wu et al., 2001; Liu et al., 2000a). The onset of this spontaneous activity is 
associated with the emergence of pain-related sensory changes in animal models and is critical for the 
maintenance of peripheral neuropathic pain (NP) (Haroutounian et al., 2014) in patients where selective 
blockade suggests the involvement of myelinated axons (Campbell et al., 1988). Ectopic activity is 
particularly prominent in myelinated afferents and peaks within the first few days post injury and then 
declines over subsequent weeks (Kajander and Bennett, 1992; Liu et al., 2000a; 2000b; Han et al., 2000). 
Such ectopic activity arises both at the neuroma site and also at the level of the dorsal root ganglion 
(DRG) (Han et al., 2000; Liu et al., 2000b; Amir et al., 1999; 2005; Wall and Devor, 1983). 
Altered expression, function and trafficking of voltage-gated ion channels are key determinants of these 
excitability changes. Shaker type voltage-gated potassium channels (Kv1 channels) are important 
determinants of neuronal excitability. They are formed by heteromultimers of a and b subunits 
(MacKinnon, 1991). The characteristics of the outward currents they carry depend on subunit composition. 
Sensory neurons are known to express Kv1 channels and functionally these channels have been shown to 
limit excitability of sensory neurons: For instance Kv1.2 suppresses excitability at the level of the sensory 
neuron cell body (Gold et al., 1996; Rasband et al., 2001; Zhao et al., 2013; Everill et al., 1998) and Kv1.1 
acts as a ‘brake’ on mechanosensitivity at the terminals of C- mechanonociceptor and Ab-
mechanoreceptors (Hao et al., 2013). Kv1 channels also act as excitability brakes for cold thermal 
sensitivity in intact and damaged axons of primary sensory neurons (many of such fibres are also 
mechanosensitive) (Roza et al., 2006; Madrid et al., 2009). Kv1 channels are known to be expressed in 
the juxtaparanodal region of myelinated sensory axons. An unexplored issue, however, is whether the 
distribution of these channels changes under pathological neuropathic states. 
Saltatory conduction in myelinated fibres depends on the molecular organization of channel domains 
within the axon (Chang and Rasband, 2013): voltage-gated sodium channels (Nav) are clustered at the 
node of Ranvier. Nodes are flanked by the paranode, which is an important point of attachment between 
the axon and the terminal loops of the Schwann cell. Just inside the innermost axoglial junction of the 
paranode is the juxtaparanode a domain enriched in Kv1 channels Kv1.1 and 1.2. The localisation of 
Kv1.1 and 1.2 to the juxtaparanode is dependent on the formation of a molecular scaffold, which includes 
the adhesion molecules caspr2 and TAG-1 (Poliak et al., 2003).  In the naive state in adulthood, the 
juxtaparanodal Kv1 channels are thought not to have a major influence on axon conduction properties of 
peripheral myelinated axons (Poliak et al., 2003; Chiu and Ritchie, 1980; Sherratt et al., 1980; Rasband et 
al., 1998), probably because they are electrically insulated from the node of Ranvier under the myelin 
sheath. However during development (Vabnick et al., 1999) and following primary demyelination (Rasband 
et al., 1998) (during which myelin is removed but the axon remains intact), Kv1.1 and 1.2 become more 
widely distributed to include the paranode and even the node (Arroyo et al., 2004), and can act to 
suppress excitability. Although Kv1.1 and 1.2 expression within the soma is known to be down-regulated 
following axon transection, and this leads to hyperexcitability at the soma (Rasband et al., 1998; Ishikawa 
et al., 1999; Park et al., 2003), the distribution of these channels at the nodal complex and damaged nerve 
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terminal (in the neuroma that forms) has not been examined. Furthermore, little is known regarding the 
distribution of other members of the shaker type Kv1 channels family such as Kv1.4 and 1.6 following 
nerve injury. 
 
Aim 
Here, this work shows that within a neuroma, expression levels of Kv1.1 and 1.2 are markedly reduced but 
over time Kv1.4 and1.6 expression increases within juxtaparanodes and paranodes. At sites remote from 
injury, there is also a gradual redistribution of Kv1 channels to the paranode. Electrophysiological and 
behavioural experiments suggest that changes in subunit expression and redistribution of Kv1 channels 
act a ‘brake’ on the hyperexcitable state that arises in myelinated axons following traumatic nerve injury. 
 
2. Materials and Methods  
 
Animals and surgery  
Adult male Sprague-Dawley rats were used in accordance with UK Home Office and Pontificia Universidad 
Catolica’s regulations (animals in the UK were purchased from Charles-River UK, animals from Chile were 
purchased onsite). Rats were group housed and placed on a 12 hour-light 12 hour-dark cycles. Two 
different nerve injury models were used: the neuroma model and the L5 spinal nerve transection (SNT) 
model. The neuroma model of NP was based on the TNT model (Dorsi et al., 2008), but performed with 
some modifications. Briefly, the sciatic nerve was dissected free of adjacent tissue, ligated with a suture, 
and cut proximal to its bifurcation. The needle from the suture was passed through a subcutaneous tunnel 
to the lateral aspect of the hindlimb where it was pushed through the skin. The nerve was drawn into the 
tunnel until the ligature is adjacent to the skin. The suture was cut, and the incision closed. The suture tied 
to the distal end of the sciatic nerve was visible through the skin and served as the target for mechanical 
stimuli. An analogous site served as the target on the contralateral hindlimb. For the L5 SNT model (Kim 
and Chung, 1992), one-third of the L6 transverse process was removed and the L5 spinal nerve was 
identified and dissected free from the adjacent L4 spinal nerve and then tightly ligated using 6–0 silk and 
then transacted distally to the suture. Sham-operated animals served as a control. We used these two 
different models as the neuroma model is the most adequate for performing behavioural tests as the 
injured nerve can be directly stimulated, while the L5 SNT model has the advantage that it gives certainty 
that all the dorsal root axons studied had their peripheral terminals injured. For both models animals were 
deeply anaesthetised with a mix of isofluorane and oxygen. Postoperative analgesia was given for the first 
5 days postop (tramadol 50 mg/kg/day p.o). Animals were checked every day after surgery to check for 
self-mutilation behaviour (autotomy), which prompted us to sacrifice the animal. Calculation of the sample 
size needed was done for each experiment as described below. Experimental protocols were reviewed 
and approved by ’Coordinación de Ética, Bioética y Seguridad de las investigaciones UC’ (experiments 
done in Chile) and were performed in accordance with the UK Home Office regulations (experiments done 
in the UK). We report this study in compliance with the ARRIVE guidelines (Kilkenny et al., 2010) (20 
points checklist).  
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Patients and controls  
The study was conducted at Hospital Clínico UC-Christus in Santiago, Chile. Morton’s neuroma patients 
that were due surgery for resection of painful neuromas were recruited for donating a small sample of the 
tissue resected during surgery. Control samples were obtained from subjects undergoing hand 
reconstructive surgery in where the sural nerve is harvested and used as a bridge to connect disrupted 
ends of motor nerves in the hand. A small sample for these healthy sural nerves was collected to use as 
control in this study. We used the Numeric Rating Scale (NRS; which is a self-reporting scale where 0 is 
no pain and 10 is the worst imaginable pain) to assess for pain before surgery. Informed consent was 
obtained from all subjects before surgery. The study protocol was assessed and approved by the Ethics 
Scientific Committee of the School of Medicine Pontificia Universidad Católica de Chile. The sample sizes 
were calculated using a power of 80% and an a error of 0.05%, assuming a 2 times increase or decrease 
in Kv channel expression with a variance of 0.6 from the mean, which resulted in a sample needed of 3 
patients per group.  
 
Histology  
After a defined survival time (7 and 21 days), animals were terminally anaesthetized with pentobarbital and 
transcardially perfused with 0.9% heparinised saline. The L5 DRG, the L5 spinal nerve, and the sciatic 
nerve were removed. We dissected the sciatic nerve free from connective tissue and collected 5 mm from 
the site of the neuroma and 5 mm from a site 1 cm proximal. Tissue for immunohistochemistry was post 
fixed in 4% paraformaldehyde (PFA) in 0.1 M phosphate buffer (PB) for 30 min and cryoprotected in 20% 
sucrose for 3 days. Tissue obtained from patients was fixed immediately after resection in 4% PFA for 30 
min and then cryoprotected in 20% sucrose for 3 days. The samples were embedded in OCT, cryostat cut 
(8 mm) and thaw-mounted onto glass slides. Sections were pre-incubated in buffer (PBS, pH 7.4, 
containing 0.2% Triton X-100 and 0.1% sodium azide) containing 10% normal donkey serum for 30 min 
and then incubated with primary antibodies over-night at room temperature. Primary antibodies used are 
shown in Table 1. Following primary anti- body incubation, sections were washed and incubated for 2 hrs. 
with secondary antibody solution (donkey anti-rabbit Cy3 1:400; goat anti guinea pig AMCA 1:100, donkey 
anti mouse FITC 1:400; all from Stratech, UK). Slides were washed with PBS, cover-slipped with 
Vectashield mounting medium (Vector Laboratories, UK) and visualised under a Zeiss Axioplan 2 
fluorescent microscope (Zeiss, UK). All quantification of different IHC parameters was done with the 
investigator blinded to the identity of the group to which the animals belonged. Nodal quantification was 
done by assessing on average 31 nodes per animal, and using 4–5 animals per condition. For 
quantification of bII spectrin the intensity of the immunofluorescence of the axonal paranodal area 
(identified by caspr staining) was measured and the background of each section was subtracted. Then, 
measurements were normalised against the mean of the controls (naıve axons). The sample sizes were 
calculated using a power of 80% and an a error of 0.05%, assuming a 2 times increase or decrease in 
expression with a variance of 0.5 from the mean, which resulted in a sample needed of 4 animals per 
group.  
We quantified sodium channel clusters following the following criteria: (1) typical nodes were nodes where 
the Nav channels fill the gap at the node of Ranvier as identified by the paranodal staining of caspr on both 
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sides of the node, (2) split nodes were nodes that had two distinct Nav channels accumulations, separated 
by a gap in the Nav channel staining within the same fibre and with each Nav channels accumulation 
flanked on one side with caspr staining, or (3) heminodes were nodes where the caspr staining located on 
only one side of a contiguous Nav channel accumulation, (4) while those Nav channel accumulations 
lacked an association with caspr were classified as ‘naked’ accumulations.  
 
Western blot analysis  
Tissue was collected, quickly frozen in liquid nitrogen and was homogenized in NP40 lysis buffer (20 mM 
Tris, pH 8, 137 mM NaCl, 10% glycerol, 1% NP-40, 2 mM EDTA), 20 mM leupeptin, 5 mM sodium fluoride, 
1 mM sodium orthovanadate, 1 mM PMSF and protease inhibitor cocktail). The lysate were spun at 13,000 
rpm at 4 ̊C for 15 min and the protein concentration of supernatant was determined using a BCA Protein 
Assay kit (Thermo Scientific). 50 mg of each sample was separated using 8% or 10% SDS-PAGE, and 
transferred to nitrocellulose membranes. Membranes were then blocked in 10% skimmed milk in PBS-T 
(PBS+ 0.1% Tween 20) for 1 hr at room temperature. Membranes were incubated with primary antibody 
(anti mouse Kv1.1, Kv1.2, Kv1.4, Kv1.6, GAPDH, PGP9.5 and anti-rabbit Caspr2 as shown in Table 1), 
diluted in PBS-T at 4 ̊C overnight. After washing with PBS-T for 6 times and5 min each time, membranes 
were incubated with sheep anti-mouse or donkey anti rabbit HRP-conjugated secondary antibody 
(1:10,000–1:20,000; ECL, GE Healthcare, Amersham, UK) at room temperature for 1 hr. After several 
PBS-T washes as described above membranes were revealed using ECL-prime reagent (GE Healthcare) 
for 5 min for detection by autoradiography.  
For WB of Kv1.4 and Kv1.6 in rat tissue (sciatic nerve and DRG) the membranes were cut in three pieces; 
the top piece was probed with Kv1.4 antibody, the middle one was probed with Kv1.6 anti- body and the 
bottom one probed with GAPDH antibody. For WB of Kv1.1 and for Kv1.2 the membranes were cut in 2 
pieces: the top one was probed with either Kv1.1 or Kv1.2 antibody and the bottom one was probed with 
GAPDH antibody. The 2 or 3 pieces of the membranes were lined up as a single membrane before 
exposing it to the film so that the molecular weight can be calculated by measuring the running distance of 
the molecular weight marker and the target bands. This could be done as the bands labelled by the 
antibodies have quite different molecular weights. This allowed us to optimize the use of the tissue 
obtained from animals and reduce the number of animals needed (in accordance with our obligations 
under animal licensing procedures).  
 
Quantification and analysis  
For Western Blots analysis, films were scanned with Cannon Scanner (LiDE 210), and the intensity of 
specific bands was quantified using Quantity One software (Bio-Rad). The same size rectangle was drawn 
around each band to measure intensity, and the background was subtracted. Target band detected was 
normalized against loading control GAPDH or PGP9.5 correspondingly for analysis. The sample sizes 
were calculated using a power of 80% and an a error of 0.05%, assuming a 2 times increase or decrease 
in expression with a variance of 0.5 from the mean, which resulted in a sample needed of 4 animals per 
group (we used 6 animals per group in case we had to put any animal down due to autotomy).  
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Table 1. 
Antibody Concentration used 
IHC                                         WB 
Company 
Rabbit anti Pan voltage gated 
sodium channel (Cat No. 
S6936) 
1:1000 Sigma-Aldrich 
Mouse anti Kv1.2 (K14/16.2) 1:100                                  1:500 UC Davis/NIH NeuroMab Facility 
Mouse anti Kv1.1 (K36/15.1) 1:100                                  1:200 UC Davis/NIH NeuroMab Facility 
Mouse anti Kv1.4 (K13/31) 1:100                                  1:200 UC Davis/NIH NeuroMab Facility 
Mouse anti Kv1.6 (K19/36) 1:100                                  1:500 UC Davis/NIH NeuroMab Facility 
Guinea Pig anti Caspr 1:1000                              1:1000 From Dr Manzoor Bhat - UT 
Health Science Center San 
Antonio (PMID: 11395000) 
Rabbit anti Caspr2 (ab105581) 1:500                              1:400 Abcam 
Rabbit anti Pan Neurofascin 1:500 Gift from Prof Peter Brophy- 
University of Edinburgh 
(20129933) 
Mouse anti βII spectrin 
(Clone  42) 
1:500                                1:1000 BD Bioscience 
 
Table 1: Different antibodies used in the study. IHC: Immunohistochemistry WB: Western Blot analysis. 
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Electron microscopy  
Sciatic nerves were dissected at the site of the neuroma and were processed for resin embedding as 
previously described (Huang et al). Briefly nerves were post fixed in 3% glutaraldehyde at 4Cº over-night, 
washed in 0.1 M PB, osmicated, dehydrated, and embedded in epoxy resin (TAAB Embed- ding Materials, 
UK). Longitudinal sections 1 mm thick were cut on a microtome and stained with toludine blue before 
being examined on a light microscope. Ultrathin sections were cut on an ultra-microtome and stained with 
lead uranyl acetate. Sections were mounted on unsupported 100 mesh grids. Sections were visualised on 
a PHILIPS TECNAI 12 BIOTWIN transmission electron microscope at the Unidad de microscopia 
avanzada, Pontificia Universidad Católica de Chile. We measured the diameter of the axons at the site of 
the node, the maximal and minimal distance between interloops, the distance between the glia and the 
axon, the number of detached loops, and the number of everted loops using Image J (NIH, USA) and a 
135000x magnification. We quantified between 8 and 14 nodes per animal, and we used 5 animals per 
condition (sample sizes were calculated using a power of 80% and an a error of 0.05%, assuming a 
change in distance of 50% with a variance of 0.4, which resulted in a sample needed of 4 animals per 
group, however due to the difficulty in the technique we included one more animals in each group). The 
investigator was blinded to the treatment group of each specimen, however, this was sometimes difficult to 
conceal as the anatomy in the injured nerves was much more disrupted than in naive nerves.  
 
In vivo electrophysiological recording  
Recordings were performed under anaesthesia (urethane, 1.5 g/Kg, i.p.) on naive rats (n = 10, 222 
neurons), or after sciatic nerve ligation at 2 days (n = 4, 291 neurons), at 7 days (n = 7, 241 neurons), and 
at 21 days (n = 7, 237 neurons). A tracheotomy was performed and the L5 dorsal roots and DRGs were 
exposed via laminectomy. Sciatic nerve neuroma with proximal nerve (5–6 mm long) and contralateral 
uninjured sciatic nerve were exposed. The contralateral sciatic nerve was acutely cut to disconnect from 
the periphery just before recording. The entire site was covered in agarose gel and four chambers created 
by removing blocks of this gel. These were 1) neuroma chamber, containing ipsilateral neuroma and part 
of sciatic nerve which is subjected to stimulation; 2) acutely cut nerve end chamber, containing 
contralateral sciatic nerve proximal end; 3) DRGs chamber, containing L5 DRGs from both sides; 4) spinal 
recording chamber, containing part of L5 dorsal roots from both sides near entry zone to spinal cord. The 
neuroma chamber and nerve cut end chamber were filled with mineral oil during stimulation, and the oil 
was replaced with aDTx (100 nM in saline) during toxin application. The DRGs chamber was filled with 
saline or aDTx/saline solution, and the recording chamber was always filled with mineral oil. The pool 
temperatures were not controlled, but as animals were warmed using an infrared lamp from the back, the 
pool was therefore heated, and typically was at 34–35Cº. Just before recording, the L5 dorsal root was cut 
near entry zone, a filament was teased out and hooked up for recording. Each filament was stimulated 
electrically with increasing current to recruit sequentially each conducting axon in that filament. The 
conduction velocity of each conducting axon was noted. Thus, the number of functioning axons in each 
filament was deter- mined (typically, 6–10). Spike discrimination was used to detect the number different 
axons firing spontaneously in each filament (typically 0–3) during a pre-treatment baseline and under 3 
different treatment conditions: 1) no aDTx in any of the chambers; 2) aDTx in neuroma or nerve cut end 
chamber; 3) aDTx in neuroma or nerve cut end chamber and DRGs chambers. The aDTx was applied for 
at least 20 min before recording. An independent investigator prepared the drugs individually and labelled 
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them for each animal according to the randomization schedule. Data analysts were blinded as the 
conditions under which all recording were made.  
Signals were amplified with an AC-coupled amplifier (Neurolog NL104A with headstage NL100AK), then 
high-pass and low-pass filtered (Neurolog NL125) at 500 Hz and 5 KHz frequencies. The filtered signals 
were passed through a Humbug 50 Hz noise eliminator (Quest scientific, Vancouver, BC, Canada), further 
amplified (Neurolog NL 106), fed to an analog-to-digital converter Power- Lab, and sampled at 20 KHz with 
Labchart software (ADinstruments, UK). Stimulation (200 ms square-wave pulses) was delivered from a 
stimulus isolator (Neurolog, NL800A). The filter settings used strongly favours recordings from A-fibres and 
not C-fibres. All the fibres recorded to nerve stimulation conducted in the A fibre range (>2 m/sec). The 
size of the filaments recorded was also unfavourable for detecting clear single unit C fibre activity.  
Three minutes baseline was recorded to examine spontaneous activity. The percentage of spontaneously 
firing units was calculated as the number of spontaneously active units divided by the number of 
conducting fibres determined in recruitment recording. The firing rate was calculated as the total number of 
spikes during recording divided by the time recorded. The mean firing rate per unit was the firing rate 
divided by the total number of different units recorded in each treatment group.  
For the axonal mechanosensitivity experiments (n= 4,259 neurons), mechanical stimulation was applied to 
the neuroma using increasing forces of von Frey filaments (4, 8, and 15 g), and the number of distinct 
spikes (neurons) firing in response were counted following spike discrimination. The total number of 
conducting axons in each filament was determined by incremental electrical stimulation of the sciatic 
nerve. The percentage of mechanosensitive units was calculated as the number of different neurons 
responding by firing action potentials upon mechanical stimulation, divided by the number of conducting 
fibres (which was determined in the same way as for the spontaneous activity experiments). Axonal 
mechanosensitivity was assessed before and after toxin application at 21 days after axotomy. 
Mechanosensitivity experiments were carried out on separate animals to spontaneous activity experiments 
to ensure that any spontaneous activity encountered was not caused acutely by the repeated mechanical 
stimulation of the neuroma.  
Data was analysed using software Labchart. Statistics comparing proportions of neurons exhibiting either 
spontaneous activity or mechanosensitivity were performed using chi-square test with Yates correction. 
Values were reported as percentages, calculated from the proportions.  
 
Assessments of mechanical sensitivity  
Mechanical withdrawal thresholds were assessed by applying a range of Von Frey hairs (Somedic, 
Sweden) to the skin over the neuroma site (labelled with a suture as previously described). Animals were 
randomised to receive either subcutaneous aDTX (0.5 ml at 100 nM in saline, Alomone, UK) or saline 
(which was administered locally at the site of the neuroma) using a computer-generated random 
sequence. The sample sizes were calculated using a power of 80% and an a error of 0.05%, assuming a 
60% decrease in withdrawal threshold with a variance of 25% from the mean, which resulted in a sample 
needed of 7 animals per group. Experimental groups were the following: base- line with vehicle, baseline 
with toxin; day 3 after surgery with vehicle, day 3 with toxin; day 7 with vehicle, day 7 with toxin; day 21 
with vehicle, day 21 with toxin. To reduce the amount of animals of the study the animals that received 
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saline only were used again for the consecutive time-points. The animals that received toxin had to be 
sacrificed after testing, as the toxin is irreversible. The toxin or saline were injected 30 min before testing. 
Autotomy after nerve injury (especially neuroma model) appears at around 10 days after injury. Therefore, 
we allocated 2 extra animals for the saline group, and 2 extra for toxin day 21. We had to sacrifice 1 
animal from the saline group at day 6, and 2 animals from the toxin group day 21 (at day 15 and 17 after 
injury respectively), due to self-mutilating behaviour. For testing, rats were gently restrained using a towel 
on a table. Calibrated von Frey hairs were applied to the skin covering the neuroma until the fibre bent. 
Withdrawal of the limb by the animal was recorded as a response. The 50% withdrawal threshold was 
determined using the up- down method (Dixon, 1980). An independent investigator prepared the drugs 
individually and labelled them for each animal according to the randomization schedule. Operators and 
data analysts were blinded throughout the study. The data were distributed normally and the differences 
between groups was analysed using a 2 way ANOVA repeated measures. Values were reported as mean 
± SEM.  
This experiment was repeated for testing CP339818 (Kv1.4 blocker; #C-115, 0.5 ml at 300 nM in saline 
Alomone Labs UK). We randomly allocated 8 animals per group, and we had to put one animal from the 
saline group down due to autotomy at day 12.  
 
Ethics  
Human subjects: Informed consent, and consent to publish, was obtained from all subjects to collect and 
analyse nerve samples before surgery. Subjects underwent surgery by indication of their physician and 
samples were obtained from biological tissue that was otherwise due to be incinerated. The study protocol 
was assessed and approved by the Ethics Scientific Committee of the School of Medicine Pontificia 
Universidad Católica de Chile (reference number 14-389).  
Animal experimentation: This study was performed in strict accordance with UK Home Office and Pontificia 
Universidad Católica’s regulations. Experimental protocols were reviewed and approved by "Coordinación 
de Ética, Bioética y Seguridad de las investigaciones UC" (experiments done in Chile- Protocol 
CBB230/2013) and were performed in accordance to the UK Home Office regulations (experiments done 
in the UK). We report this study in compliance with the ARRIVE guidelines (20 points checklist).  
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3. Results  
 
Expression of Kv1 channels subunits switches at nodal regions after nerve injury .  
To investigate the role of Kv1 channels in hypersensitivity after nerve injury we used a model of complete 
sciatic nerve transection followed by positioning of the proximal stump superficially under the skin of the 
leg [modified version of Dorsi et al. (2008)]. This model enables us to study both the expression of Kv1 
channels within the neuroma and undertake behavioural analysis using specific blockers of Kv1 channels.  
To study how the localisation of Kv1 channels changes within the nodal complex, we used a pan-Nav 
channel antibody to label the node of Ranvier, a Caspr antibody to label the paranode and Kv1.2 and 
Caspr2 antibodies to label the juxtaparanode. In the naıve axon, we observed that over 90% (mean 91 ± 
SEM 2.9%, n = 4 animals) of the nodes presented a characteristic morphology with Nav clustering in the 
centre, surrounded by caspr at both sides and Kv1.2 clustered within the juxtaparanode. Other members 
of the Kv1 channels family, Kv1.4 and 1.6 are expressed by DRG cells (Everill et al., 1998; Thakur et al., 
2014; Chiu et al., 2014). We found that in the naıve state Kv1.4 was only expressed within a very small 
proportion of nodes (5.5 ± 4.6%, n = 4 animals) within the juxtaparanode and Kv1.6 was not present within 
the nodal complex (Figure 1).  
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Figure 1. 
 
 
 
Figure 1. Kv1 channels expression in the naive nerve and 21 days after sciatic nerve axotomy (note that 
the samples were collected from the neuroma site). (a) Representative images of longitudinal nerve 
sections immunostained with Kv1 channels in green (Kv1.2, Kv1.4 and Kv1.6 respectively), a panNav 
antibody in red (to identify the node), and caspr in blue (to identify the paranode). Kv1.2 is expressed in 
the juxtaparanode in naıve nerves but it is not present at 21 days after nerve injury. Kv1.4 and kv1.6 are 
not present in uninjured nerve but are expressed after nerve injury. Note that when Kv1.4 and Kv1.6 are 
expressed, they are not confined to the juxtaparanode only but invade the paranode. (b) Western blots 
showing expression of Kv1 channels in the naıve nerve, at 7 and 21 days after axotomy. Kv1.1 and Kv1.2 
are expressed in the naıve nerve and down-regulated after axotomy, while Kv1.4 and Kv1.6 have a 
low/null expression in the naıve nerve and are up-regulated after injury (*p<0.05, **p<0.001, one Way 
ANOVA, n=6 per group). Scale bars = 5 mm. 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At the site of the neuroma (day 7 and 21), only half of the nodes demonstrated this typical morphology 
(day 7 = 47.5 ± 5.1%, day 21 = 46 ± 6%, n = 4 animals per group, 36–64 nodes per animal); the rest were 
split (day 7 = 23.3 ± 5.9%, day 21 = 13.5 ± 2.7%), presented as heminodes (caspr at one side only, day 7 
= 21.8 ± 4.4%, day 21 = 28.9 ± 5.5%), or were ‘naked’ (Nav clusters alone, with no caspr, day 7 = 7.2 ± 
3%, day 21 = 11.4 ± 3.2%, Figure 2). This is in accordance with previous literature examining the 
localisation of voltage-gated sodium channels (Henry et al., 2006; Thakur et al., 2014). At day 7 after 
injury, Kv1.2 channels were not located strictly not only in the juxtaparanodal regions but also overlapped 
with paranodal proteins. To objectively measure this, we quantified the distance between the Nav channels 
staining and the distal end of the caspr staining, and the distance between the Nav channels staining and 
the proximal end of Kv1 channels. The difference between these two distances was indicative of the level 
of overlap between Kv1 channels and paranodal proteins (note that ‘naked’ nodes were not included in the 
analysis of the spatial distribution of Kv1 channels because by definition these only consist of Nav clusters 
without paranodal and juxtaparanodal proteins). In naıve axons the distance between Nav channels 
staining and the end of caspr was 3.8 ± 0.2 mm, and the distance between Nav channels staining and the 
start of Kv1.2 staining was 4.2 ± 0.2 mm, resulting in a relatively small, albeit positive, difference between 
these distances (0.5 ± 0.08 mm, n = 4 animals, 25–40 nodes per animal), indicating there was no overlap. 
At day 7 after injury, the distance between Nav channels staining and the end of caspr was 4 ± 0.1 mm, 
and the distance between Nav channels staining and the start of Kv1.2 staining was 3.2 ± 0.2 mm, giving a 
negative value for the difference between both distances (-0.8 ± 0.1 mm, n = 3 animals, 32–35 nodes per 
animal), which indicates that the Kv1 channels were co-localised with caspr staining and moving closer to 
the node (Figure 3). Note that the distance between Nav channels staining and the end of caspr staining 
remained unchanged after injury, while the distance between Nav channels staining and the start of Kv1.2 
staining was significantly reduced. Contactin-associated protein-like 2 (Caspr2) forms a complex with Kv1 
channels at the juxtaparanode (Chiu et al., 2014). We evaluated if caspr2 moves closer to the node 
together with Kv1 channels. We measured the distance between the Nav channels staining and the distal 
end of the caspr staining, and the distance between the Nav channels staining and the proximal end of 
caspr2. In naıve axons, the distance between Nav channels staining and the end of caspr was 3.8 ± 0.3 
mm, and the distance between Nav channels staining and the start of caspr2 staining was 4.3 ± 0.0 mm, 
resulting in a small difference between these distances (0.49 ± 0.09 mm, n = 4 animals, 25–30 nodes per 
animal), indicating there was no overlap. At day 7 after injury, the distance between Nav channels staining 
and the end of caspr was 4.1 ± 0.2 mm, and the distance between Nav channels staining and the start of 
caspr2 staining was 2.8 ± 0.2 mm, giving a negative value for the difference between both distances (-1.2 
± 0.1 mm, n = 3 animals, 30 nodes per animal), which indicates that the caspr2 co-localised with caspr 
staining and had moved closer to the node together with Kv1 channels (Figure 3). 
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Figure 2. 
 
 
 
 
Figure 2. Nav channel expression. 
Representative sections of longitudinal nerves immunostained with Kv1.2 in green, a panNav antibody in 
red (to identify the node), and caspr in blue (to identify the paranode) from neuroma day 21. (a) A typical 
pattern of Nav expression localized at the node of Ranvier and flanked by caspr staining is shown. The 
altered forms of Nav channel accumulations seen in the injured nerve included (b) split nodes: These were 
nodes that had two distinct Nav channels accumulations, separated by a gap in the Nav channels staining 
within the same fibre and with each Nav channels accumulation flanked on one side with caspr staining, or 
(c) naked nodes: those Nav channel accumulations that lacked an association with caspr (d) heminodes: 
nodes where the caspr staining was located on only one side of a contiguous Nav channel accumulation. 
(e) Quantification of different types of sodium cluster accumulation in the naïve state and after nerve injury 
is shown. 
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Figure 3. 
 
 
 
Figure 3. Relocalisation ok Kv1.2 and caspr2 at 7 days after neuroma. 
(a) Representative longitudinal sections of nerves immuno-stained with Kv1.2 in green, a panNav antibody 
in red (to identify the node) and caspr in blue (to identify the paranode). Kv1.2 is expressed in the 
juxtaparanode in naïve nerves but it also co-localized with caspr staining at 7 days after injury. 
Representative longitudinal sections of nerves immuno-stained with caspr2 in green and caspr in red. 
Caspr2 is confined to the juxtaparanode in naïve nerve but co-localized with caspr at 7 days after injury. 
(b) We quantified the distance between the sodium channel staining (Nav) and the end of the caspr 
staining, distance between the sodium channel staining (Nav) and the start of the Kv1.2/1caspr2 staining, 
and difference between these distances. A negative value represents an overlap of paranodal and 
juxtaparanodal proteins. Note that he distance between the sodium channel staining (Nav) and the end of 
the caspr staining remains unchanged after nerve injury, while the distance between the sodium channel 
staining (Nav) and the start of the Kv1.2/caspr2 staining is significantly shortened after nerve injury, 
indicating co-localization of Kv1.2 and caspr2 with caspr (n = 5 animals, 20–41 nodes per animal), 
p<0.001, one way ANOVA Tukey post hoc tests). We analysed uninjured (naïve) nerve, nerve at the site of 
the neuroma (day 7), and nerve 1 cm proximal to the neuroma (day 7). The effect on Kv1.2 re-localization 
remains the same at the site far from the neuroma. The effect on caspr2 re-localization is slightly smaller at 
the site 1 cm proximal to the neuroma compared with the neuroma site, but it is still significantly different 
from the naïve **p<0.001, *p<0.05, PRN = paranode, JXP = juxtaparanode. Scale bars = 5 μm. 
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The redistribution of the channels seen could simply be a reflection of direct injury at the site of axotomy. 
We therefore, studied a site proximal to the neuroma (1 cm) and compared it to the neuroma site. The 
effect on Kv12 re-localization remains the same at the site far from the neuroma: The difference between 
Nav channels staining and the end of caspr distance and Nav channels staining and the start of Kv1.2 
distance was -1 ± 0.09 mm, at the site close to the neuroma and -1.1 ± 0.09 mm, at the site far from the 
neuroma (p = 0.6, n = 5 animals, 24–26 nodes per animal). The effect on caspr2 relocalization is slightly 
smaller at the site 1cm proximal to the neuroma compared with the site close to the neuroma, but it is still 
significantly different from the naıve (p<0.001): The difference between Nav channels staining and the end 
of caspr distance and Nav channels staining and the start of caspr2 distance was -1 ± 0.1 mm, at the site 
close to the neuroma and -0.5 ± 0.1 mm, at the site far from the neuroma (p = 0.06, n = 5 animals, 21–26 
nodes per animal, Figure 3c). This change on juxtaparanode proteins localisation could be due to a 
disorganisation of the paranodal axoglial junctions (paranode loops). Therefore, we examined their 
ultrastructural anatomy using electron-microscopy and measured the distance between the axon and the 
paranodal loops (axoglial distance), the number of detached and everted loops and the minimal and 
maximal distance between loops. We analysed sciatic nerves from sham-operated and neuroma animals 
and we observed very few detached or everted loops, with no differences between groups. The close 
apposition between the axon and the paranodal loop was unchanged as the axoglial distance was not 
significantly changed (sham = 9.7 ± 0.4 nm, neuroma = 11.4 ± 0.7 nm, n = 4–5 animals per group, 6– 9 
nodes per animal one way ANOVA p = 0.08). We observed a small but significant increase in the maximal 
distance between loops (sham = 12.5 ± 1 nm, neuroma = 18.9 ± 1.4 nm, one way ANOVA, p = 0.005). In 
summary, these results suggest that although there was no major disruption of the septate axoglial 
junctions there was a small but significant increased separation between the paranodal loops (Figure 4). 
Note that the axonal diameter at the node did not change (Figure 4d). 
bII spectrin is a cytoskeletal protein that has recently been shown to be essential for the localization of Kv1 
channels to the juxtaparanode and is proposed to form a sub-membranous barrier to lateral diffusion of 
Kv1 channels into the paranode (Zhang et al., 2013). Using IHC, we looked at bII spectrin in the neuroma 
and found that it is expressed at the paranode and juxtaparanode. We quantified the staining at the 
paranodal domain and found that the expression of this protein was reduced by more than half compared 
to naive (immunofluorescence normalised to naıve: 0.4 ± 0.02, p<0.001, t-test, n = 50–83 heminodes, a–
b). bII spectrin is also expressed in the sub-membranous regions of Schwann cells where it does not 
appear to change with nerve injury. To further quantify the change of expression of this protein in the 
neuron, we performed Western blotting in the soma of sensory neurons (dorsal root ganglia- DRG) and 
observed a 30% decrease following nerve injury compared to naive (expression relative to naıve: 0.7 ± 
0.08, p = 0.04, t-test, n = 4, Figure 5c–d). 
At day 21 after injury, in marked contrast with the naıve axons, very few of the nodes at the neuroma site 
(day 21) showed Kv1.2 immunostaining (8.3 ± 0.8% in neuroma vs. 86.1 ± 4.4% in naive, n = 4 animals 
per group, 25 nodes per animal p<0.001 t-test). Conversely, most of the nodes at the neuroma site (day 
21) showed intense Kv1.4 immunostaining (73.3 ± 12% in injured vs. 5.5 ± 4 in naive, n = 4 animals per 
group, 30 nodes per animal p<0.001 t-test) and Kv1.6 immunostaining (66.6 ± 14% vs. in injured vs. none 
in naive, n= 4 animals per group, 30 nodes per animal p<0.001 t-test) (Figure 1).  
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Figure 4 
 
 
 
 
Figure 4. Ultrastructural anatomy of the node of Ranvier within the sciatic nerve following axotomy. We 
used electron microscopy to look at the ultrastructure anatomy of the node. (a) Shows a diagram of the 
node, paranode and juxtaparanode and a low magnification section of this area in a sham-operated nerve. 
The red box denotes the area that was used for quantification as seen in b. (b) High magnification views of 
the paranodal loops are shown in the sham and 21 days following axotomy (magnification 135 000x) (c) 
We quantified different aspects of the attachment of the Schwann cell paranodal loops to the axon. This is 
illustrated in right panel which denotes the different parameters measured: The maximal and minimal 
distance between interloops, the distance between the glia and the axon, the number of detached loops 
and the number of everted loops. We found a significant increase in the maximal distance between loops 
in the neuroma compared to sham nerves (one way ANOVA, p = 0.005). There were no significant 
differences in any of the other measurements. (d) We quantified the diameter of the axons at the site of the 
node and found no difference between the uninjured and injured axons. Scare bars: 200 nm 
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Figure 5. 
 
 
Figure 5. βII spectrin expression in naïve and neuroma nerves. 
(a) Representative sections of longitudinal nerves immunostained with βII spectrin in green, a panNav 
antibody in red (to identify the node), and caspr in blue (to identify the paranode). βII spectrin is expressed 
both in the surface of Schwann cells (arrows) and in the axon at the paranodal and juxtaparanodal region 
(arrow heads) in naïve nerves. At 21 days after axotomy (neuroma), βII spectrin can be only seen in the 
Schwann cell (arrows) but not in the axonal domains. (b) Quantification of βII spectrin immunofluorescence 
in the paranode (identified by caspr staining) showing a significant reduction in neuroma versus naïve 
(immunofluorescence normalised to naïve: 0.4 ± 0.02, p<0.001, t-test, n = 50–83 heminodes). (c) Western 
blots showing expression of βII spectrin in the DRG of naïve and day 21 neuroma. (d) Quantification of 
WBs. Expression of βII spectrin in the DRG was reduced by 30% after nerve injury. PGP9.5 was used as a 
loading control (expression relative to naïve: 0.7 ± 0.08, p = 0.04, t-test). **p<0.001, *p<0.05. Error bars 
denote SEM. 
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We used Western blotting to quantify the expression of the different a subunits and found that Kv1.1 and 
Kv1.2 expression were significantly reduced at days 7 and 21 following nerve injury, while Kv1.4 and Kv1.6 
were significantly upregulated at the neuroma site (Figure 1). We looked at Kv1 channel expression in the 
DRG using IHC and we observed that Kv1.2 expression is reduced after injury, while Kv1.4 and Kv1.6 
expression remains unchanged (Figure 6a) (this is at the DRG soma, although expression could be seen 
to increase within paranodes/juxtaparanodes after injury). We also quantified protein expression within the 
DRG over the same time course using Western blot analysis. The expression of Kv1.2 was significantly 
reduced following nerve injury (Figure 6b–e) consistent with previous findings, (Everill et al., 1998; 
Ishikawa et al., 1999; Kim et al., 2002; Yang et al., 2004), and there was a trend for a reduction in Kv1.1 
although this did not reach significance. The expression of Kv1.4 and 1.6 within the DRG did not 
significantly change following injury (one Way ANOVA, n = 6 per group) suggesting that increased 
expression within the juxtaparanode and paranode at the neuroma site is a likely consequence of altered 
trafficking of these proteins rather than global changes in expression. 
We next looked into human nerve tissue to see if these changes were relevant to patients with NP We 
collected 6 control samples (from subjects having their sural nerves removed to use as a bridge for hand 
reconstructive surgery) and 6 samples obtained from patients undergoing removal of Morton’s neuroma 
(interdigital nerve entrapment neuropathy). IHC (n = 3 per group, 8–10 nodes per patient) showed that only 
Kv1.2 is expressed in the juxtaparanode of healthy subjects (90 ± 10% of nodes were Kv1.2 positive) with 
absent Kv1.4 and 1.6 staining as observed in the rat. However, in neuroma Kv1.2 expression in the 
juxtaparanode was minimal (13.3 ± 8.1%) whilst Kv1.4 and Kv1.6 were expressed in most of the nodes 
(92.5 ± 7.4% for Kv1.4; 73.5 ± 8.8 for Kv1.6) (Figure 7a–b). We used western blotting to quantify Kv1 
channels proteins in the nerves of the patients (n = 6 per group) and found that Kv1.2 expression was 
significantly decreased in neuroma compared to control nerve (to 0.48 ± 0.1 of the control, Mann-Whitney 
U-Test, p 0.005). In contrast, expression of Kv1.4 and Kv1.6 were significantly increased in neuroma 
compared to controls (to 6.3 ± 3.5, and 9.4 ± 6.6 of the control respectively, Mann-Whitney U-Test p = 
0.005 both) (Figure 7c–d). 
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Figure 6. 
 
 
 
 
Figure 6. Expression of Kv1 channels in the DRG in the naıve state, 7 and 21 days after axotomy 
(neuroma). (a) Representative sections of naive and neuroma day 21 DRG immuno-stained with Kv1.2, 
Kv1.4, and Kv1.6. Note that Kv1.2 expression in DRG cells and axonal juxtaparanodes (arrow heads) is 
reduced after injury, while Kv1.4 and Kv1.6 expression remains unchanged in DRG cells, and it is present 
in axonal juxtaparanodes (arrow heads) after injury. In each panel (b–e), a representative blot is shown for 
each time point with GAPDH as a loading control. Quantification of 6 animals per condition is shown below 
(b, d, e) Expression of Kv1.1, Kv1.4 and Kv1.6 within the DRG does not significantly change after 
axotomy. (c) Kv1.2 expression is significantly decreased after axotomy. (*p<0.05, one Way ANOVA, n = 6 
per group).  
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Figure 7. 
 
 
 
 
Figure 7. Kv1 channels expression in the sural nerve of healthy volunteers (control) and from patients with 
painful Morton neuroma. 
(a) Representative sections of longitudinal nerves immunostained with Kv1 channels in green (Kv1.2, 
Kv1.4 and Kv1.6 respectively), a panNav antibody in red (to identify the node), and caspr in blue (to 
identify the paranode). Kv1.2 is expressed in the juxtaparanode in control nerves but it is not present in the 
injured nerve. Kv1.4 and kv1.6 are not present in control nerve but are expressed in neuroma within the 
juxtaparanode and encroaching on the paranode nodes. (b) Quantification of the percentage of Kv1.2, 
Kv1.4, and Kv1.6 positive nodes in control and neuroma nodes (n = 3 per group, one way ANOVA). (c) 
Western blots showing expression of Kv1 channels in control and neuroma nerve. (d) Quantification of 
WBs (n = 6 per group, one way ANOVA). Kv1.2 is expressed in the control nerve and down regulated after 
axotomy, while Kv1.4 and Kv1.6 have a low/null expression in the control nerve and are up-regulated in 
neuroma. PGP9.5 was used as a loading control. Error bars denote (e) Patients and control subjects 
demographic data. The female/male ratio is different in patients with Morton neuroma and controls 
(patients with traumatic lesion of the hand) reflecting the F/M ratio of these different conditions. The mean 
age of patients with Morton neuroma is slightly higher than in control subjects, although it is not significant 
(t-test). All patients with Morton neuroma presented with pain (mean NRS 4.6), while control presented no 
pain in the area innervated by the sural nerve (Mann Whitney test). NRS: numerical rate score. Error bars 
denote SEM. Scale bars = 5 μm, **p<0.001, *p<0.05. 
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Kv1 channels change their distribution in the nodal regions at sites distant from the injury. 
We investigated the localisation of Kv1 channels at a site distant from the injury site. To do so, we used a 
model of L5 spinal nerve transection (SNT) (Kim and Chung, 1992) and studied the dorsal roots (ie. 
proximal to the DRG). We used this model instead of the neuroma model to have certainty that all the 
dorsal root axons studied had their peripheral terminals injured. 
In the dorsal roots from naıve animals, the distance between Nav channels staining and the end of caspr 
was 3.5 ± 0.2 mm, and the distance between Nav channels staining and the start of Kv1.2 staining was 4 ± 
0.2 mm, resulting in a small positive difference between these distances (0.5 ± 0.1 mm, n = 4 animals, 25–
32 nodes per animal), indicating there was no overlap. Seven days after transection of L5 spinal nerve this 
distance was still positive (0.24 ± 0.05 mm, n = 4 animals; distance Nav-end caspr 3.7 ± 0.2 mm, distance 
Nav-start Kv1.2 3.9 ± 0.1 mm; 30–40 nodes per animal). However, at 21 days after nerve injury, we noted 
a significant overlap between the end of caspr staining and the start of the Kv1.2 staining (-1.4 ± 0.3 mm, n 
= 4 animals, 38–40 nodes per animal, one way ANOVA, p<0.001; distance between Nav-end caspr 3.9 ± 
0.4 mm, distance between Nav-start Kv1.2 2.5 ± 0.4 mm). We observed this novel localisation of Kv1.2 in 
the paranode which (in contrast to the neuroma site) is still clearly present after nerve injury within the 
dorsal root. We also observed novel expression of Kv1.4 and 1.6 in the dorsal root of injured animals, and 
these were localised to the par- anode in addition to the juxtaparanode (the distance between end of caspr 
and start of Kv1.4 and 1.6 staining was -1.7 ± 0.6 mm and -1.07 ± 0.2 mm respectively; for Kv1.4 distance 
between Nav-end caspr 3.6 ± 0.4 mm, distance between Nav-start Kv1.4 1.9 ± 0.6 mm; for Kv1.6: distance 
between Nav-end caspr 3.4 ± 0.4 mm, distance between Nav-start Kv1.6 1.6 ± 0.4 mm n = 4 animals per 
group, 30–35 nodes per animal Figure 8).  
Contactin-associated protein-like 2 (Caspr2) is normally localized at the juxtaparanode and associates with 
K+ channels (Chiu et al., 2014). Interestingly, we observed that caspr2 is mobilized into the paranode 
regions in a similar way to Kv1 channels; the difference between the Nav-caspr stain- ing distance and the 
Nav-caspr2 distance is minimal in naı ̈ve roots (0.5 ± 0.1 mm; distance between Nav-end caspr 3.8 ± 0.3 
mm, distance between Nav-start caspr2 4.3 ± 0.4 mm, 30–38 nodes per ani- mal 4 animals), and after 
SNT, this distance becomes negative (-0.88 ± 0.1 mm, n = 5 animals; dis- tance between Nav-end caspr 
3.4 ± 0.3 mm, distance between Nav-start caspr2 2.5 ± 0.3 mm 35–40 nodes per animal p<0.001, t-test) 
indicating an overlap between caspr and caspr2 immuno-labeling (Figure 8). 
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Figure 8. 
 
 
 
 
Figure 8. Kv1 channels expression in the dorsal roots of na ̈ıve animals and 21 days after spinal nerve 
transection (SNT). (a) Representative sections of longitudinal dorsal roots immunostained with Kv1 
channels in green (Kv1.2, Kv1.4 and Kv1.6, respectively), a panNav antibody in red (to identify the node), 
and caspr in blue (to identify the paranode). Kv1.2 is expressed only in the juxtaparanode in naı ̈ve nerves 
but after injury it invades the paranode. Kv1.4 and kv1.6 are not present in uninjured nerve but are 
expressed within the juxtaparanode after nerve injury and also invade the paranode. (b) Relocalization of 
caspr2 at 21 days after spinal nerve transection (SNT). Representative sections of longitudinal L5 dorsal 
roots immuno-stained with caspr2 in red, Kv1.2 in green, and caspr in blue. Kv1.2 and caspr2 are 
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expressed in the juxtaparanode in naı ̈ve nerves but co-localized with caspr staining at 21 days after injury. 
(c) Quantification of: distance between the sodium channel staining (Nav) and the end of the caspr 
staining, distance between the sodium channel staining (Nav) and the start of the Kv1.2/1.4/1.6/caspr2 
staining, and difference between these distances. A negative value in this difference represents an overlap 
of paranodal and juxtaparanodal proteins. Note that the distance between the sodium channel staining 
(Nav) and the end of the caspr staining remains unchanged after nerve injury, while the distance between 
the sodium channel staining (Nav) and the start of the Kv1.2/1.4/1.6/caspr2 staining is significantly 
shortened after nerve injury. Kv1.4 and Kv1.6 were absent in naive (n = 5 animals/4 sections per animal, 
*p<0.05, **p<0.001). Scale bars = 5 mm.  
 
 
 
Effect of Kv1 channels redistribution and change in expression on the incidence of spontaneous activity 
 Spontaneous activity in naı ̈ve axons was present in less than 5% of A-fibres (4.5%). We assessed the 
effect of blocking the Kv1 channels using a-DTX, a toxin isolated from black and green mamba snakes 
which is a selective and effective blocker of Kv1-containing oligomers composed of Kv1.1, Kv1.2, or Kv1.6 
subunits (Harvey, 2001). We applied the toxin at the neuroma site (or, in control ani- mals, acutely cut 
sciatic nerve stump) and to the L5 DRG and recorded from sensory axons in thin strands dissected from 
the dorsal root. In the naı ̈ve situation (n = 222 neurons, 10 animals, Figure 9a), the incidence of 
spontaneous activity did not significantly change after a-DTX (5.4 and 9.8% of myelinated afferents when 
the toxin was applied to nerve stump or L5 DRG, respectively). Two days after transecting the sciatic nerve 
(n = 291 neurons, 4 animals), spontaneous activity at the injured nerve increased to 22% of myelinated 
afferents, and it was similar with or without toxin (toxin applied to neuroma 26.1%, toxin applied to the L5 
DRG 26%). However, at 7 days after nerve injury (n = 241 neurons, 7 animals) the proportion of 
spontaneously active afferents had decreased to 6.2%, and application of the toxin now induced a 
significant increase in proportion of spontaneously firing myelinated afferents (11.2% toxin at the neuroma 
p = 0.07, and 15.6% toxin to L5 DRG, p = 0.002, chi-square test). At day 21 after injury (n = 237 neurons, 
7 animals) spontaneous activity has decreased to baseline levels (2.5% of afferents within the dorsal root), 
but application of the toxin to both neuroma site or L5 DRG significantly increased the proportion of 
myelinated afferents demonstrating spontaneous activity (7.2% p = 0.03 and 17.7 ±% p<0.001 
respectively, chi-square test) (Figure 9a). In summary, we observed an acute increase in spontaneous 
activity following nerve injury, which was reversed with time. However, at this later time, blockade of Kv1 
channels (which had no effect in the na ı̈ve state) could reinstate spontaneous activity almost to levels 
seen acutely after nerve injury. Therefore, Kv1 channels appear to have a role in the recovery from 
increased excitability following nerve injury (Figure 9b–d).  
 
Effect of Kv1 channel redistribution and change in expression on mechanical sensitivity  
Because Kv1 channels have been shown to have a crucial role in mechano-sensitivity (Hao et al., 2013), 
we tested their role in hypersensitivity following nerve injury. In the presence of a-DTX,  significantly more 
neurons responded to mechanical stimulation using a 15g von Frey filament at the neuroma site at day 21 
(with 4 g: pre 17.9% post 21.8%; with 8 g: pre 22.1% post 26%; with 15 g: pre 24.7%, post 30.5%, p = 
0.006, chi-square test; n = 259 neurons; Figure 9e–f).  
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Figure 9. 
 
 
 
 
Figure 9. Local application of a-DTX reinstates primary afferent hyperexcitability at later time points 
following nerve injury. (a) Schematic illustration of 3-chamber recording system. 1) Recording chamber, 2) 
middle chamber, 3) stimulating chamber. The toxin was applied in chambers 1 or 2, respectively. (b) 
Following sciatic nerve transection, there is a large increase in the proportion of primary afferents 
demonstrating spontaneous activity at day 2, which is suppressed at days 7 and 21 post injury; Local 
application of a-DTX to the neuroma and L5 DRG at these later time points (days 7 and 21) significantly 
increases the proportion of afferents, which are spontaneously active (total proportions per group, chi-
square tests, *p<0.05, **p<0.01, ***p<0.001) (c) neuroma application and (d) DRG application of a-DTX. 
Both recordings were carried out 21 days post-surgery. (e) In the presence of a- DTX, significantly more 
neurons respond to mechanical stimulation at the neuroma site using a 15 g von Frey filament (*p<0.05; 
total proportions per group, chi-square tests, all neuroma day 21). (f) Representative traces showing 
greater responsiveness to mechanical stimulation with von Frey filaments after local a-DTX application.  
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Kv1 channels are responsible for the partial recovery of mechanical hypersensitivity seen chronically after 
nerve injury 
 We subsequently used behavioural measures to examine mechanical sensitivity after nerve injury. For 
this purpose, we used the sciatic neuroma model used before in which the sciatic nerve of rats is 
transacted and the proximal end was sutured superficially below the skin on the animal’s leg. We applied 
von Frey filaments of increasing forces to the site of the skin covering the neuroma. To test the role of Kv1 
channels on hypersensitivity, we applied a DTX subcutaneously at the site of neuroma. At baseline, the 
withdrawal threshold was high and did not change with the application of a DTX (vehicle: 142.9 ± 13 g, 
toxin 150 ± 17.7 g, n = 9 animals per group). Three days after injury, this threshold dropped to 8.2 ± 0.6 g 
and was not changed by applying the toxin (9.7 ± 1.1 g) (n = 9 animals per group). However, with time this 
threshold began to normalise reaching 12.9 ± 0.6 g at 7 days (n = 8) and 44.8 ± 1.6 g at 21 days (n = 8). 
When we injected aDTX, this recovery was not seen and thresholds stayed low (day 7: 6.9 ± 0.9 g, p = 
0.003, n = 9; day 21: 13 ± 2.1 g, p<0.001, n = 7, RM two way ANOVA Figure 10).  
The time point when the mechanical hypersensitivity began to recover in injured animals coincides with the 
time when Kv1.1 and Kv1.2 are reduced but Kv1.4 and Kv1.6 are being expressed. a-DTX is a selective 
blocker for Kv1.1, Kv1.2 and Kv1.6 but has little activity against Kv1.4. CP 339818 hydro- chloride 
however, which is a selective blocker of Kv1.3 and Kv1.4 (Nguyen et al., 1996), did not have any effect on 
mechanical hypersensitivity at early or late time-points post injury suggesting that Kv1.4 is dispensable for 
the suppression of hyperexcitability. (baselines: saline 133 ± 21 g, CP339818 164 ± 38 g; neuroma day 3: 
saline 51 ± 2 g, CP339818 44 ± 5 g; neuroma day 7: saline 41 ± 3 g, CP339818 39 ± 4 g; neuroma day 21: 
73 ± 13 g, CP339818 91 ± 4 g, RM two way ANOVA, p>0.05, n = 8–7 for saline at day 21]).  
 
Figure 10. 
 
 
 
Figure 10. Mechanical hypersensitivity is restored by blocking Kv1 channels. Mechanical withdrawal 
thresholds were assessed by applying a range of Von Frey hairs to the skin over the neuroma site 
(labelled with a suture). Animals were randomised to receive either subcutaneous aDTX or saline 30 min 
before testing. Hypersensitivity after nerve injury is very pronounced until day 7, when it slowly starts 
recovering. At this time point, perineuromal application of aDTX reversed this early recovery. At 3 weeks 
after nerve injury hypersensitivity is much recovered and perineuromal injection of aDTX restored 
mechanical hypersensitivity to levels seen acutely after injury (RM two way ANOVA, *p<0.05, **p<0.001).  
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4. Discussion  
 
We have focussed on the distribution of Kv1 channels within the axolemma of myelinated axons in rodent 
models of NP as well as in human neuroma tissue. We show that both at the site of injury (using the 
neuroma model) and within the dorsal root (remote from the injury site) that there is a major change in the 
a-subunit composition of Kv1 channels (with increased expression of Kv1.4 and 1.6) and furthermore that 
Kv1 channels are no longer restricted to the juxtaparanode but also re-distribute to the paranode following 
injury. Blockade of these ion channels using a-DTX reveals that following axonal injury Kv1 channels act to 
suppress axonal hyperexcitability and hence hypersensitivity to sensory stimuli (Figure 11).  
 
 
Figure 11. 
 
 
Figure 11. Schematic illustration of the changes in Kv1 channels subunit composition and distribution 
within the nodal complex and the relationship to hyperexcitability. In the na ̈ıve state, Kv1 channels (Kv1.1 
and 1.2 shown in green) are localised to the juxtaparanode and separated from voltage-gated sodium 
channels at the node (red) by the paranode (blue). Acutely following axotomy myelinated primary afferents 
show a marked increase in spontaneous activity as a consequence of complex changes in increased pro-
excitatory drive (for instance from voltage-gated sodium channels) as well as reduced ’brakes’ on 
excitability At later stages within the neuroma, although there is less expression of Kv1.1 and Kv1.2, the 
expression of Kv1.4 and 1.6 increases. Remote from the injury within the dorsal root expression of Kv1.1 
and 1.2 is maintained and the expression of Kv1.4 and Kv1.4 also increases. Furthermore Kv1 channels 
are redistributed to the paranode as well as being expressed within the juxtaparanode. These changes are 
associated with a suppression of hyperexcitability. 
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We initially examined the distribution of Kv1 channels within the juxtaparanode of axons within the 
neuroma at the the injury site. Following traumatic nerve injury there is an initial inflammatory response, 
demyelination and axonal dieback within the proximal nerve stump. This is followed by axonal sprouting 
(Fried and Devor, 1988; DeFelipe, 1991) (which is often misdirected) as well as proliferation of connective 
tissue and glial cells. This can lead to a region of nerve swelling, a neuroma, the development of which is 
well documented in patients (Scadding, 1981; DeFelipe, 1991; Young, 1942). Nerve injury is often 
associated with ongoing pain, dysaesthesia and evoked pain; many patients report that touching the skin 
overlying or compression of the neuroma site can elicit pain and dysaesthesia (Nikolajsen et al., 2010). 
Unfortunately in many patients, the treatment of NP remains inadequate (Finnerup et al., 2015) and is 
associated with significant dis- ability (Stokvis et al., 2010). Neuroma pain can be modelled in the rodent 
using a modified version of the tibial transposition neuroma model (Dorsi et al., 2008).  
 
Altered distribution of Kv1 channels in nodal complexes of the neuroma and dorsal root 
 It has previously been documented that within a neuroma nodes of Ranvier become disorganised 
(Levinson et al., 2012) and we confirm that here with the majority nodes showing abnormalities such as 
being elongated, split, heminodes or showing Nav in the absence of caspr. Voltage-gated sodium 
channels are known to accumulate particularly within axon tips and on denuded axons of the neuroma 
(England et al., 1996). Much less is known regarding the distribution of Kv1 channels changes within the 
neuroma. This is an important issue as such channels could potentially act as ‘brakes’ on excitability. At an 
early time point after injury, we found that Kv1.2 is no longer confined to the juxtaparanode but extended 
into the paranode. As this could be only a reflection of direct injury, we also looked into a site in the injured 
nerve 1 cm proximal to the neuroma and found similar changes in distribution, suggesting this is likely to 
reflect widespread changes within the axon/axoglial signalling (further supported by changes within the 
dorsal root and discussed below). At a later time-point following injury, we found a striking reduction in the 
expression of Kv1.1 and 1.2 which are normally localised to the juxtaparanode. In contrast Kv1.4 and 1.6 
which are present at a low level in the naıve state are up-regulated and are present both in the paranode 
and the juxtaparanode. We found broadly similar changes in rodent and human neuroma. This altered 
expression and localisation is likely to partially reflect the altered relationship between axons and 
myelinating Schwann cells. Within the neuroma new nodes of Ranvier will be formed as a consequence of 
myelination of new axon sprouts and remyelination of denuded axons (Dorsi et al., 2008; Dyck et al., 
1985). During developmental myelination and remyelination following primary demyelination (in which the 
axon remains intact) Kv1.1 and 1.2 can at early time points be observed in other regions apart from the 
juxtaparanode (at the node of Ranvier and the paranode) before being restricted to the juxtaparanode as 
the nodal complex matures (Rasband et al., 1998; Vabnick et al., 1999; Poliak et al., 2001). Kv1.4 and 1.6 
expression has not to our knowledge been examined during myelination/remyelination.  
We also studied the dorsal root, which is remote from the injury site to establish whether there were 
changes in Kv1 channels composition of the juxtaparanode that reflect the general response of the axon to 
injury rather than local effects such as inflammation and remyelination at the injury site. We also found 
striking changes within the nodal complex of sensory axons within the dorsal root. Kv1.2 was no longer 
down regulated as had been noted at the neuroma site but its localisation changed following injury: They 
could be observed in the paranode as well as the juxtaparanode. In the naıve state, very little Kv1.4 and 
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1.6 expression was noted in the juxtaparanode of the dorsal roots. This is in agreement with previous 
studies that reported a low frequency of Kv1.4 immunoreactive juxtaparanodes (Everill et al., 1998) and no 
expression of Kv1.6 (Utsunomiya et al., 2008). We found however that nerve transection led to markedly 
increased expression of these a-subunits and they were localised both to juxtaparanode and paranode.  
 
Factors governing localisation of Kv1 channels to axonal domains in the naıve and injured state 
 What factors are responsible for the altered distribution of Kv1 channels within the juxtaparanode? We 
used ultrastructural examination of the juxtaparanode in the dorsal root to examine whether structural 
changes within the paranode could explain the movement of Kv1 channels into this region (from which 
they are normally excluded). The transverse bands are important points of attachment between the axon 
and the paranodal loops of the Schwann cell. These axoglial septate-like junctions are formed by the 
interaction of caspr (Bhat et al., 2001) and contactin (Boyle et al., 2001) on the axolemma binding with the 
155Kd isoform of Neurofascin expressed on the Schwann cell paranodal loops (Tait et al., 2000). These 
junctions act as diffusion barriers between the nodal and juxtaparanodal membrane. Mice lacking caspr 
(Bhat et al., 2001), contactin (Boyle et al., 2001) or NF155 (Pillai et al., 2009; Sherman et al., 2005) have 
absent transverse bands, increased distance between the axon and Schwann cell membrane, 
disorganisation of the paranodal loops and probably as a consequence of the loss of this lateral diffusion 
barrier Kv1 channels are noted to extend into the paranode. Similarly in mice lacking ceramide galactosyl 
transferase in which all-putative adhesion components of the paranodal junction are lacking, Kv1.2 and 
caspr2 are also mislocalised to the paranodes (Poliak et al., 2001; 2003). On ultrastructural examination of 
the paranodes within the sciatic nerve following injury, we did not see major structural changes and there 
was no increase in the distance between the axon and the Schwann cell membrane at the site of 
attachment of the paranodal loops. We noted an increase in the maximum distance between paranodal 
loops, which is unlikely to alter the ability of molecules to passively diffuse between the membrane 
domains of the juxtaparanode and paranode (however it will increase the diameter of the helical pathway 
between paranodal loops connecting the extracellular space to the axonal internode. One potential 
consequence of which would be reduced passive resistance to current flow between the node and volt- 
age-gated potassium channel (VGKC) in the juxtaparanode and paranode, which could then have a 
greater influence on nodal excitability (Shroff et al., 2011). A recent publication has demonstrated that in 
mice lacking bII spectrin expression in axons Kv1 channels were no longer restricted to the juxtaparanode 
but could also be observed in the paranode even though the structural integrity of axoglial junctions was 
intact (Zhang et al., 2013). bII spectrin contributes to the sub-membranous cytoskeleton of the axon-linking 
membrane proteins to actin and appears to act as a barrier limiting the lateral diffusion of membrane 
proteins. We found that paranodal expression of bII spectrin was reduced following axotomy and a 
reduction in this sub-membranous barrier is compatible with the lateral movement of Kv1 channels into this 
region that we observed. As well as Kv1 channels we also see caspr2 overlapping with paranodal markers 
following nerve injury and again such paranodal localisation of caspr2 was also reported in mice in which 
axonal bII spectrin is conditionally ablated. Caspr2 complexes with and is important for the correct 
localisation of Kv1 channels (Poliak et al., 1999; 2003) suggesting that this whole protein complex is 
mislocalised following nerve injury. Although loss of a sub-membranous barrier to diffusion of the VGKC-
complex is one explanation for their paranodal localisation, we do not yet have a full understanding of the 
regulation of Kv1 channels trafficking. Phosphorylation events may have a role to play as Kv1.2 can 
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undergo phosphorylation, which impacts on surface expression/localisation (Gu and Gu, 2011; Yang et al., 
2007).  
The effect of altered Kv1 channels subunit composition and localisation on axonal excitability and NP 
Following axonal injury sensory axons become hyper-excitable and this is important in driving and 
maintaining NP (Han et al., 2000). A recent study showed that myelinated sensory fibres are key in 
maintaining mechanical allodynia in several NP models (Xu et al., 2015). Spontaneous activity and 
mechanical stimulus evoked activity has been recorded in myelinated afferents innervating neuroma using 
microneurography (Nystro m̈ and Hagbarth, 1981). The role of Kv1 channels has mainly focussed on their 
importance in suppressing excitability at the soma rather than the axon following injury. The expression of 
a number of a Kv1 channels sub-units has been documented to decrease following peripheral axotomy 
including Kv1.1, 1.2 (Everill et al., 1998; Hao et al., 2013; Ishikawa et al., 1999; Kim et al., 2002; Yang et 
al., 2004) and in some reports Kv1.4 (we did not see a reduction in Kv1.4 using western blot analysis of 
DRG lysate following sciatic axotomy, however, this is a less proximal lesion compared to spinal nerve 
ligation [Everill et al., 1998]). Correspondingly, the K currents mediated by such channels are reduced 
when measured at the soma (Yang et al., 2004) both in small and large diameter DRG cells. The focus 
has therefore been on the loss of K currents within the soma which normally act as a ‘break’ on excitability, 
and combined with increased excitatory drive for instance due to the dysfunction of voltage- gated sodium 
channels and hyperpolarization-activated cyclic nucleotide-gated (HCN) channels this leads to ectopic 
activity (Waxman and Zamponi, 2014). While changes at the soma are undoubtedly important, ectopic 
impulses also arise along the axon. There has been much less focus on the distribution and function of 
Kv1 channels within the axon following peripheral nerve injury.  
The function of Kv1 channels is critically dependent on their targeting to specific neuronal compartments 
(Trimmer, 2015). The expression of Kv1 channels within the DRG soma and the axon should not be 
assumed to be the same: For instance the expression of Kv1.6 remains stable within the DRG both at the 
level of mRNA and protein (see Kim et al. (2002), Yang et al. (2004) and our own data) but as we show 
here expression markedly increases in axons within peripheral nerve and dorsal root. Altered a subunit 
composition and localisation of Kv1 channels is likely to have functional implications. In the naıve state, the 
Kv1 channels Kv1.1 and 1.2 are located within the juxtaparanode, below the insulating myelin sheath and 
at least in peripheral nerves have little functional impact on nodal excitability and conduction (Poliak et al., 
2003; Chiu and Ritchie, 1980; Sherratt et al., 1980; Rasband et al., 1998). During development when Kv1 
channels are observed in the node and paranode using specific blockers of this K current suggests that 
these Kv1 channels prevent re-entrant excitation in motor axons (Vabnick et al., 1999). Following primary 
demyelination, the redistribution of Kv1 channels to the paranode acts to suppress continuous conduction 
in demyelinated axons (Rasband et al., 1998). In certain contexts therefore and especially when Kv1 
channels begin to encroach on the paranodal regions there is evidence that these channels can sup- press 
excitability of the axon. As has been previously demonstrated we have found that the rate of ectopic 
activity within myelinated axons is very high in the first week and then decreases the longer the time 
elapsed following the initial injury (Campbell et al., 1988). Understanding adaptive mechanisms to 
suppress such hyper-excitability will potentially provide insight as to why in certain patients such 
mechanisms fail leading to chronic pain states. Over a similar time period as this reduction in spontaneous 
activity we have observed increased expression of Kv1.4 and 1.6 as well as redistribution of Kv1 channels 
to the paranode and juxtaparanode domains. Selective inhibition of Kv1 channels with a-DTX reinstates a 
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higher level of ectopic activity, increases mechanosensitivity of afferents innervating the neuroma and on 
behavioural testing also exacerbates mechanical hypersensitivity, which had begun to normalise at 3 
weeks post injury. a-DTX blocks Kv1.1, Kv1.2 and Kv1.6. As expression of Kv1.1 and 1.2 are decreased 
while Kv1.6 is increased, most probably the effect seen with the toxin is through Kv1.6. Selective inhibition 
of Kv1.4 did not recapitulate these events emphasising the role of Kv1.6 (and subunits with which it 
complexes) in suppressing hyperexcitability. Neuronal Kv1 proteins form heterotetramerization of a 
subunits, which also associate with auxiliary Kv b subunits (Jan and Jan, 2012), adding complexity in 
ascribing function to individual a subunits. a subunits confer particular pharmacological and biophysical 
properties on these channels and in addition there may be interactions between subunits. For instance 
Kv1.4, usually shows N- type rapid inactivation through an N-terminal inactivation ball however this can be 
over-ridden if associated with a Kv1.6 a subunit (Roeper et al., 1998), due to its NIP (N-type inactivation 
prevention) domain.  
 
 
5. Conclusion 
In conclusion, we have found major changes in Kv1 channels subunit composition and distribution within 
the axolemma of myelinated axons following traumatic nerve injury. In contrast to the soma in which Kv1 
channels expression is reduced this increased availability of Kv1 channels within the paranodes and 
altered subunit composition appears to fulfil an adaptive role in suppressing excessive excitability in 
myelinated afferents.  
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1. Introduction  
 
Neuropathic pain (NP) is defined as pain resulting from a lesion or disease of the somatosensory system 
(Treede et al. 2008, Baron et al. 2010) and can be caused by many clinical etiological entities such as 
nerve injury, herpes zoster or polyneuropathy (Baron et al. 2010, Maier et al. 2010). Identification of 
probable NP is based on a plausible medical history with the distribution of pain consistent with the 
innervation territory of the suspected lesioned nerve structure. Further, a clinical examination including the 
assessment of negative (loss- of-function) or positive (gain-of-function) sensory signs is required. The 
sensory phenotype can be assessed via bedside testing (Leffler and Hansson 2008) or Quantitative 
Sensory Testing (QST) (Krumova et al. 2012a, Drangholt et al. 2013). The underlying lesion or disease of 
the somatosensory system can then be further examined by a diagnostic test, e.g. electroneurography, 
skin biopsy or corneal confocal microscopy (CCM) (Lacomis 2002, Treede et al. 2008, Haanpää et al. 
2011). Loss of sensation implies a dysfunction, lesion or disease in different types of nerve fibers: loss of 
function of the thickly myelinated Aβ-fibers can be demonstrated by clinical testing of the sensation of 
touch and vibration (Leffler and Hansson 2008) or tactile and vibration detection threshold (e. g. in QST). 
Loss of small fiber (Aδ- and C-fiber) function is characterized by hypoesthesia to thermal stimuli, which can 
be tested by using QST by assessing the cold and warm detection threshold or in bedside testing by cold 
and warm metallic rollers or water tubes and pins (Lacomis 2002, Lauria et al. 2012). Both types of 
sensory loss may appear in patients suffering from NP separately, in combination or might not appear at 
all. It has been shown that they may be important predictors for the response of patients to certain 
medications (Demant et al. 2014, Mainka et al. 2016). For use in primary health care practice, a simpler 
tool, such as a questionnaire that could identify patients with core symptoms of neuropathic pain would be 
valuable.  
The painDETECT Questionnaire (PDQ) was developed and validated to support the identification of 
neuropathic pain components in patients suffering from chronic pain of different origin (Freynhagen et al. 
2006). It has previously been shown that pain descriptors of the PDQ correlate with QST items testing 
related pain thresholds in patients suffering from radiculopathy, but not in patients suffering from 
fibromyalgia (Tampin et al. 2013). We undertook this exploratory analysis in a larger sample prospective 
study because the PDQ was developed before a clear definition of NP was established (Treede et al. 
2008). Therefore, it was never part of the validation process of PDQ to investigate whether different types 
of sensory loss (as described above) present with different PDQ profiles or if single PDQ items are 
sensitive to types of sensory loss in a clinical examination. This would be useful to validate the PDQ not 
only as a screening tool for NP itself, but also for different sensory subtypes of NP. The aim of the study 
was to analyze if the overall PDQ score or its items reflect phenotypes of sensory loss in NP as 
determined by QST.  
Within the European consortia IMI (Innovative Medicines Initiative) Europain and Neuropain, both QST 
data and PDQ results of patients with neuropathic pain assessed by pain research units across Europe 
were gathered in a central database, enabling an analysis of the correlation between QST obtained 
somato-sensory profiles of thermal and/or mechanical loss of function and PDQ profiles.  
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2. Methods  
Patient cohort  
The joint European database of the IMI-Europain and Neuropain consortia, two prospectively collected 
cohorts using identical study protocols conducted in parallel, contains 580 data records of patients with 
lesions or diseases of the somatosensory nervous system. The recruitment of these two prospective 
studies started in March 2011 and the database was merged and finally closed in December 2013. Both 
studies were approved by local ethics committees according to local regulations. All subjects provided a 
signed written informed consent according to the current version of the Declaration of Helsinki for 
participation in the respective study and transfer of the study records into the central database. Only 
patients with complete QST and PDQ (unless in the case of a painless neuropathy) were included into the 
database. All centers and investigators underwent a strict quality assessment and certification process to 
ensure that we were able to pool future data across sites and countries (Magerl et al. 2010, Vollert et al. 
2015). A confirmatory analysis of heterogeneity between the participating centers in healthy subjects and 
patients with painful polyneuropathy or peripheral nerve injury showed a high degree of homogeneity 
among the different centers, making it possible to analyze the database as a homogenous group (Vollert et 
al. 2016). With only few exceptions, patients performed QST and PDQ on the same day. In case of 
deviation from the same day assessment, the PDQ was completed within a week after QST. QST and 
PainDETECT both are reported to be highly reliable to normal test-retest fluctuation within a few days 
(Geber et al. 2011, Keller et al. 2016).  
The main inclusion criterion for this analysis was that all patients in the central database had pain for more 
than 6 months, with a mean pain intensity in the last four weeks of ≥ 2 on a Numerical Rating Scale, NRS, 
0 – 10 and pain due to polyneuropathy (PNP), peripheral nerve injury, postherpetic neuralgia, 
radiculopathy or trigeminal neuropathy (n = 336). As we were aiming to specifically explore commonalities 
across neuropathic pain entities and to obtain as generalizable information as possible, diagnoses were 
pooled and not analyzed separately.  
 
Europain Consortium  
The EUROPAIN project (http://www.imieuropain.org) was founded in 2009 and aims to improve the 
treatment of patients with long-term pain and consists of academic study groups working on pain research 
from Germany, Denmark and the UK. A Spanish SME (small and medium sized enterprises) and Europe’s 
most active pharmaceutical companies working on pain also contributed. Data for this study was collected 
by the following centers: Ruhr-University Bochum, Germany, University of Schleswig Holstein, Kiel, 
Germany, Technische Universität München, Munich, Germany and Aarhus University, Denmark. The 
ethics committee of each center approved the study protocol separately.  
 
Neuropain Consortium  
The NEUROPAIN project is an investigator-initiated study consisting of several researchers in the field of 
Neuropathic Pain research within Europe (principal investigator: RB) and aims to characterize subgroups 
of patients with NP. Data for this study were collected by the following centers: Ruhr- University Bochum, 
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Germany, University of Schleswig Holstein, Kiel, Germany, Technische Universität München, Germany, 
Aarhus University, Denmark, Université Versailles-Saint-Quentin, Versailles, France, Helsinki University 
Central Hospital, Finland, Karolinska Institutet, Stockholm, Sweden, Benedictus Hospital Tutzing, 
Germany, Imperial College, London, UK, Heidelberg University, Germany, Neuroscience Technologies, 
Ltd., Barcelona, Spain. The ethics committee of each center approved the study protocol individually.  
 
Central database  
Each study centre used the computer-assisted program Neuroquast© (Statconsult, Magdeburg, Germany) 
for data entry locally. Study records were implemented into the central database on a monthly basis.  
 
Investigations  
Standardized patient assessments were performed by all the pain centers using the same case report 
forms (CRF).  
 
Inclusion / Exclusion Criteria  
For inclusion of patients in the central database, the diagnosis of underlying etiology and classification of 
pain as neuropathic was made by an experienced physician with a qualification in pain medicine and 
documented in the local center. Inclusion criteria for each diagnosis were as following:  
- polyneuropathy: pathological electroneurography or pathologically decreased vibration detection 
thresholds at two of four sites (< 5/8) at the lower limb (Hilz et al. 1998, Martin et al. 2010), which 
could not be explained by another disease, or pain with polyneuropathy-type location and evidence 
of small fiber neuropathy based on skin punch biopsy, laser-evoked potentials or bedside thermal 
testing, which could not be explained by another disease.    
- peripheral nerve injury: history of traumatic nerve injury of the distal upper or lower limb and 
sensory-motor abnormalities confined to the innervation territory of the injured nervous structure.   
- postherpetic neuralgia: unilateral zoster rash in the facial or thoracic area with post-zoster scarring, 
hypo- or hyperpigmentation in the affected dermatome or sensory deficit in the area of the previous 
zoster rash determined by bedside-testing.   
- radiculopathy: pain in the L5 and/or S1 dermatome and positive straight leg raising test or sensory 
deficit within the matching dermatome or diminished Achilles tendon reflex for S1 lesions and MRI 
of the lumbar spine confirming nerve root impairment by a herniated intervertebral disk or 
electromyography showing denervation in the L5 or S1 territory.   
- trigeminal neuropathy: idiopathic sensory trigeminal neuropathy or iatrogenic mandibular 
neuropathy (i.e., inferior alveolar or lingual nerve neuropathy after various kinds of intraoral 
procedures) or trigeminal neuropathy secondary to compression, trigeminal neuropathy secondary 
to percutaneous lesions of the Gasserian ganglion and sensory loss in the neuroanatomical 
adequate trigeminal territory.  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Exclusion criteria for entry in the database were age < 18 years, missing informed consent, insufficient 
language skills or other communication problems, pain treatment by topical local anesthetics for ≥ 7 days 
in the last 4 months or by topical capsaicin in the last 6 months, comorbidities treated by anticonvulsants 
or antidepressants, other pain locations with pain intensities ≥ 6 on ≥ 15 days/ month, other severe 
systemic or focal diseases of the central nervous system (e.g., stroke, spinal cord lesion), spinal canal 
stenosis, peripheral vascular disease (Fontaine stage II or higher), pending litigation and major cognitive or 
psychiatric disorders. In the cases of unilateral NP syndromes, patients with contralateral neuropathy or 
painful conditions of the contralateral limb were excluded. Datasets were excluded in the case of 
incomplete records (e.g., no precise diagnosis available, more than 2 missing variables of the QST in the 
affected area, no information about age, gender or other demographic data).  painDETECT Questionnaire 
 The PDQ is a validated screening tool developed to aid in identifying NP and NP components 
(Freynhagen et al. 2006, Cappelleri et al. 2014). It comprises 9 items regarding the severity, course, 
quality and nature of the patient's pain. It screens for symptoms like burning, tingling or prickling 
sensations, pain evoked by light touch, thermal stimuli or light pressure, spontaneous pain attacks and 
numbness, which are linked to neuropathic components of the pain. Patients can rate the intensity of 
symptoms on a 6 point-Likert-scale from  “never” to “very strongly”. For the present analysis, the seven 
questions for the grading of sensory symptoms were used (Freynhagen et al. 2006).  
 
Quantitative sensory testing  
In accordance to the DFNS protocol, QST comprises a standardized battery of 13 different thermal and 
mechanical parameters and assesses both afferent small fiber (un- and thinly myelinated C and Aδ fibers, 
respectively) and large fiber function of the thickly myelinated Aß-fibers (Rolke et al. 2006, Krumova, 
Geber, Westermann, and Maier 2012b). The following parameters are part of the protocol: cold and warm 
detection threshold (CDT and WDT), alternating warm and cold stimuli (TSL: thermal sensory limen) during 
which the number of paradoxical heat sensations (PHS) is counted, cold and heat pain thresholds (CPT 
and HPT), mechanical detection threshold (MDT), vibration detection threshold (VDT), mechanical pain 
threshold for pinprick (MPT), pressure pain threshold for blunt pressure (PPT), mechanical (pinprick) pain 
sensitivity (MPS), dynamic mechanical allodynia for brush, cotton wool and Q-tips (DMA) and pain 
sensation to repetitive pinprick stimuli in the so-called wind up ratio (WUR).  
 
Z-transformation of QST data  
After Z-transformation QST values can be directly compared between patients, across different testing 
areas, age decades and gender. All QST values were z-transformed separately for each parameter (with 
the exception of PHS and DMA) (Rolke et al. 2006, Magerl et al. 2010, Pfau et al. 2014). Z-values above 
1.96 indicate an individual level abnormal gain of function where the patient is significantly more sensitive 
to the tested stimuli compared to healthy controls of the same gender, of comparable age and tested in the 
same area (hyperesthesia, hyperalgesia). Z-scores below -1.96 indicate an individual level abnormal loss 
of function referring to a significantly lower sensitivity of the patient (hypoesthesia, hypoalgesia). A z-value 
of 0 indicates the mean of the healthy control group matched for age, gender and testing site; all values 
above 0 indicate gain of function, all values below 0 loss of function. This procedure leads to sensory 
Chapter 2 
 85 
profiles of groups of patients that can be graphically displayed on one common scale for sensory loss and 
gain.  
Subgrouping of Patients  
Based on their QST profile, all data sets were sub-grouped according to the type of sensory loss, partial or 
total:  
- i)  patients with no abnormal loss of sensation in thermal and mechanical detection parameters,   
- ii)  patients with isolated abnormal loss of thermal sensation (loss of detection in the CDT and/ or WDT, 
representing pure loss of small fiber function), 
- iii) patients with isolated abnormal loss of mechanical sensation (loss of detection in MDT and/ or VDT, 
representing pure loss of large fiber function),  
iv) patients with both abnormal loss of thermal and mechanical sensation (representing loss of small and 
large fiber function).  
 
Statistics  
The IBM Statistical Package for the Social Sciences (SPSS) Version 22 was used for all statistical 
analyses. We analyzed each PDQ item for significant fiber effects in a two-factor analysis of variance 
(ANOVA), where each factor represents either the function of small or large fibers. Factor one was an 
abnormal loss of thermal sensation (sub-groups ii and iv, loss of small fiber function), factor two was an 
abnormal loss of mechanical sensation (iii and iv, loss of large fiber function).  
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3. Results  
 
Characteristics of patients  
Neuropathic pain in this combined patient sample from three consortia was most frequently caused by 
polyneuropathy (49%), peripheral nerve injury (24%) and radiculopathy (18%) (table 1). Across the cohort 
and the different etiologies gender was almost equally distributed, the average age was 58 (±15) years.  
 
QST subgrouping  
According to the cutoff of z-values below -1.96 (95% confidence interval of values found in a healthy 
control group matched in age and gender, assessed in the same area), 79 patients had no sensory loss 
(Fig. 1a), 55 only thermal sensory loss (Fig. 1b, CDT and WDT), 69 only mechanical sensory loss (Fig. 1c, 
MDT, VDT), and 133 a combination of the two (Fig. 1d). Mean z-scores in the groups with significant 
sensory loss according to the cutoff were lower than -1.96. In 86 cases (46%), if a patient had loss in either 
CDT or WDT, the same was true for the other quality. For mechanical detection thresholds, this was 
similar, though slightly less pronounced (78 cases (39%)). Patients without individually diagnosed sensory 
loss nonetheless had slightly negative mean z-scores (around -1) for detection thresholds and slightly 
positive mean z-scores for pain measures; this group also had the most pronounced pinprick hyperalgesia 
and dynamic mechanical allodynia. Patients with loss of thermal sensation (subgroups ii and iv) also had a 
loss for heat pain sensitivity (HPT, mean value for loss of thermal sensation = -0.98, p < 0.001, mean HPT 
value for loss of both thermal and mechanical sensation = -1.25, p < 0.001). Patients with loss of 
mechanical sensation (subgroups iii and iv) also had minor loss of thermal sensation with mean z-values 
around -1.00 in CDT and WDT.  
Pain intensity did not differ between groups of sensory loss, neither current nor mean or maximum pain of 
the last four weeks. There were no significant differences in the frequency of intake of medication (table 2).  
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Table 1.  
 Disease Polyneuropahy 
Peripheral 
nerve 
injury 
Radiculopathy 
Postherpet 
.neuralgia 
Trigeminal 
neuralgia Total 
Demographics       
 
 
 
 
number of patients 164  (49%) 79 (24%) 61 (18%) 23 (7%) 9 (3%) 336 100%) 
female 88  (54%) 45 (57%) 24 (39%) 7 (30%) 1 (11%) 165 (49%) 
age (years: mean, ± SD) 62 ± 15 47 ± 11 59 ± 12 69 ± 12 54 ± 18 58 ± 15 
Subgroups (based on QST-    results) 
 
     
 
 
 
 
 
 
normal sensation 32 (20%) 20 (25%) 18 (30%) 7 (30%) 2 (22%) 79 (24%) 
loss of thermal sensation 24 (15%) 14 (18%) 13 (21%) 4 (17%) 0 (0%) 55 (16%) 
loss of mechanical sensation 38 (23%) 12 (15%) 14 (23%) 2 (9%) 3 (33%) 69 (21%) 
loss of mech. and thermal sens. 70 (43%) 33 (42%) 16 (26%) 10 (43%) 4 (44%) 133 (40%) 
 
Table 1. Characteristics of patients and QST results. 
Values are given as n (%). QST, quantitative sensory testing.  
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Figure. 1 
 
 
  
 
 
Figure 1. QST–z-profile separately for patients with no loss of sensation (A), loss of thermal sensation (B), 
loss of mechanical sensation (C), and loss of thermal and mechanical sensation (D). Values are presented 
as mean 6 SEM. Values between 21.96 and 11.96 represent the 95% confidence interval in an age-
matched and sex-matched healthy control population, tested at the same body region. Values below 0 
indicate a loss of function (eg, increased detection thresholds), whereas values above 0 indicate gain of 
function (eg, decreased pain thresholds). CDT, cold detection threshold; CPT, cold pain threshold; DMA, 
dynamic mechanical allodynia; HPT, heat pain threshold; MDT, mechanical detection threshold; MPS, 
mechanical pain sensitivity; MPT, mechanical pain threshold; NRS, Numerical Rating Scale; PHS, 
paradoxical heat sensations; PPT, pressure pain threshold; QST, quantitative sensory testing; TSL, 
thermal sensory limen; VDT, vibration detection threshold; WDT, warm detection threshold; WUR, wind-up 
rati 
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Table 2 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 2.  Pain intensity and medication in relation to sensory loss.  
Mean, maximum and current pain intensity are presented as mean ± standard deviation (0 - 10 numerical 
rating scale). For medication, multiple answers per patient were possible. *Result of a two-way ANOVA 
(pain) or chi-squared test (medication).  
 
  
Normal sensation 
Loss of 
thermal 
sensation 
Loss of 
mechanical 
sensation 
Loss of therm. + 
mech. sensation 
p* 
 
Current 4.8 ± 2.2 5.2 ± 2.3 4.6 ± 2.0 5.3 ± 2.2 0.126 
maximum (4 
weeks) 
7.7 ± 1.8 7.9 ± 1.8 7.7 ± 1.6 7.8 ± 2.0 0.943 
mean (4 
weeks) 
5.8 ± 1.9 6.1 ± 1.8 5.6 ± 1.8 6.2 ± 2.0 0.131 
Current medication 
NSAID 7 (9%) 13 (24%) 11 (16%) 30 (23%) 0.058 
SNRI 9 (12%) 6 (11%) 10 (14%) 13 (10%) 0.798 
SSRI 3 (4%) 5 (9%) 7 (10%) 21 (16%) 0.055 
Anticonvulsan
ts 
26 (33%) 19 (35%) 16 (23%) 45 (34%) 0.408 
Tricyclic 18 (23%) 15 (27%) 22 (32%) 52 (39%) 0.089 
opioid 13 (17%) 13 (24%) 13 (19%) 41 (31%) 0.081 
other 5 (6%) 4 (7%) 9 (13%) 17 (13%) 0.359 
Pain intensity 
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Figure 2. 
 
 
 
 
 
Figure 2. Interaction plot for effects of small and large fiber deficits on total PDQ score (A) and single PDQ 
item scores of evoked pain (B–D) and spontaneous sensations (E–H), presented as mean 6 SEM. For 
each item, the values on the left end of each line indicate normal small fiber function (no loss thermal 
sensation), and values on the right indicate impaired small fiber function (loss of thermal sensation). Black 
lines indicate normal large fiber function (no loss of mechanical sensation), and red lines indicate impaired 
large fiber function (loss of mechanical sensation). *Significant large fiber effect, ̊significant small fiber 
effect, ;significant interaction effect in the analysis of variance (P , 0.05; Table 3). #Significant post hoc test 
between patient groups with normal vs loss of mechanical sensation (#on the left or right end of the graph) 
or between patient groups with normal vs loss of thermal sensation (#in the middle of the graph). PDQ, 
painDETECT Questionnaire.  
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Effects of loss of sensation QST phenotype on PDQ items  
The values for the overall PDQ score (Fig. 2A) are very similar among the four subgroups. Consequently, 
there are no significant effects in the ANOVA (table 3). 
 
 
Table 3. 
 
 model 
small fiber  
effect 
large fiber  
effect 
small*large interaction 
PDQ Score 1.69 (0.168) 3.08 (0.080) 0.29 (0.593) 1.24 (0.267) 
Burning sensation 4.24 (0.006) 0.19 (0.665) 8.85 (0.003) 3.11 (0.079) 
Prickling sensation 0.90 (0.440) 1.60 (0.207) 0.29 (0.590) 1.00 (0.318) 
Sudden pain 0.73 (0.536) 1.18 (0.278) 0.63 (0.428) 1.18 (0.277) 
Numbness 6.98 (0.000) 3.64 (0.057) 11.59 (0.001) 0.02 (0.898) 
Light touch 3.16 (0.025) 7.82 (0.005) 4.43 (0.036) 0.00 (0.953) 
Cold or heat 1.62 (0.184) 1.04 (0.308) 0.16 (0.687) 4.25 (0.040) 
Slight pressure 0.64 (0.589) 0.03 (0.858) 1.39 (0.239) 0.01 (0.941) 
 
Values significant on P , 0.05 are given in bold. PDQ, painDETECT Questionnaire.  
Table 3. Results from the 2-way analysis of variance analyzing the effects of impaired small or large fiber 
function (abnormal loss of thermal or mechanical sensation) for the PDQ score and each PDQ item 
presented as F value (P value).  
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4.Discussion  
 
Although loss of nerve fiber function is an important sign of neuropathy, sensory loss is not represented 
well in the existing screening tools, possibly because they were created before the new definition of NP 
emphasized the importance of the clinical sensory examination (Treede et al. 2008). The present analysis 
reveals that the overall PDQ score, the primary outcome measure, is not related to presence or absence of 
sensory loss as determined by QST. However, four individual PDQ items were partly sensitive enough to 
reflect loss of small or large fiber function: numbness, burning sensations, pain evoked by light touch, pain 
evoked by cold or heat. Whereas numbness and burning sensation reflect perceptions without external 
stimulation, the other two items may be considered to reflect self- examination by the patient (Bennett et 
al. 2007).   
 
Subjective report of numbness  
In our data, "numbness" is more often reported by patients with loss of mechanical sensation than by those 
with intact mechanical perception. This is consistent with the interpretation that the subjective feeling of 
numbness is related to loss of large-fiber or dorsal column functions, for example in a case of unilateral 
damage to the spinal cord (Geber et al. 2009), where numbness was reported for the side with tactile loss 
and not the contralateral side with thermal loss. While our data support this concept, the association was 
not strong enough to allow identification of patients with large fiber loss using this PDQ item.  
 
Subjective report of burning  
Reports of "burning sensations" were most frequent in patients with intact mechanical and thermal 
sensitivity according to QST. This is also the only group where heat pain testing revealed heat 
hyperalgesia in QST (Fig. 1a), whereas thermal sensory loss was associated with hypoalgesia to heat (Fig. 
1b and d). These observations are consistent with the concept that discharges from "irritable nociceptors" 
may lead to burning sensations (Freynhagen, Baron, Tölle, et al. 2006, Demant et al. 2014). In previous 
studies, burning pain (and burning sensation) has been discussed as being associated with loss of thermal 
sensation (Lauria et al. 2012). Unexpectedly, there was no difference between patients without sensory 
loss and patients with isolated loss of thermal sensation on the item burning sensations. Based on the 
thermal grill illusion and on observations in patients with multiple sclerosis it had been suggested that 
burning pain may be due to a disinhibition of a heat-sensitive neural pathway that is normally suppressed 
by a cold-sensitive pathway (Craig and Bushnell 1994, Hansen et al. 1996). Our observations are at 
variance with this concept of a disinhibition at the thalamo- cortical level.  
 
Self-report of pain evoked by light touch  
The mean report of "pain evoked by light touch" is decreased in patients with mechanical sensory loss, 
and increased in patients with loss of thermal sensation in QST. Pain evoked by light touch is associated 
with static or dynamic mechanical allodynia, which has been described in patients with loss of thermal 
sensation (Heij et al. 2012, Hoeijmakers et al. 2012, Langley et al. 2012).  
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Sensory phenotype, medication and pain intensity  
Pain intensities did not differ significantly among the groups of sensory phenotypes. There are two reasons 
likely underlying this finding: 1) QST is not able to assess pain intensity itself, and loss of sensation is not 
correlated with pain intensity. 2) QST and parts of the PDQ describe evoked types of pain, while NRS and 
the rest of the PDQ capture ongoing pain. Medication also did not differ among the sensory phenotype 
groups, though there was a tendency for the use of NSAIDs and opioids to be associated with loss of 
thermal sensation and the use of tricyclic antidepressants and SSRIs to be associated with the large loss 
of mechanical sensation (all p < 0.1). These patterns may influence the results obtained, as 
pharmacological treatment has the potential to influence pain qualities and sensory descriptors (Mainka et 
al. 2016). The broad spectrum of analgesics taken reflects the situation in which the patients were 
recruited: when referred from primary care, where their pain could not be managed.  
 
 
5. Outlook and Conclusions  
NP results from heterogeneous etiological, genetic and environmental causes, possibly leading to different 
profiles in sensory testing and questionnaire data (Baron et al. 2010, 2012). This, in turn, leads to 
difficulties in predicting the outcome of currently available therapies (Baron et al. 2010). Several recently 
conducted proof-of-concept-controlled trials for promising drugs in clinical development have failed to 
demonstrate an effect superior to placebo (Katz et al. 2008, Dworkin et al. 2012). The reason for this may 
be that these drugs are aimed at specific targets that may only be relevant in a subgroup of patients with 
NP, leading to the inclusion of a large group of patients who are unlikely to respond to a drug targeting a 
pathomechanism that is not underlying their pain condition (Cruccu and Truini 2009, Demant et al. 2014, 
Mainka et al. 2016). Since pathophysiological mechanisms cannot readily be identified in patients, 
surrogate measures have been suggested that are likely to reflect underlying pathophysiological 
mechanisms: e.g., a classification strategy based on the functional gain or loss of mechanical and thermal 
sensations (LoGa) assessed by QST was introduced (Maier et al. 2010). Furthermore, PainDETECT has 
been used for sub-grouping of patients according to their pattern of sensory abnormalities. These studies 
used a hierarchical cluster analysis for segmentation and identified five subgroups of patients with diabetic 
painful neuropathy, postherpetic neuralgia and painful radiculopathy according to their sensory symptoms 
(Baron et al. 2009, 2012). Therefore, PainDetect may provide an easy and beneficial way of distinguishing 
patients according to their sensory profile. Patients could benefit from an early identification of NP and 
sensory dysfunction phenotype and could avoid insufficient treatment. This approach also could help in 
deciding whether further investigations are necessary, which may also reduce costs for the health care 
system.  
Questionnaires like the painDETECT are easy-to-use tools in daily clinical practice for gathering 
information on subjective reports and self-examination (Bennett et al. 2007), whereas bedside sensory 
testing and QST are validated methods to evaluate the sensory profile in selected pain areas in patients 
with NP. In contrast to, e.g., conventional nerve conduction studies, both bedside sensory testing and QST 
can assess the function of thin myelinated and unmyelinated (small) nerve fibers. QST and bedside 
sensory testing address the diagnostic dilemma, i.e. that patients suffering from isolated loss of small fiber 
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function cannot be identified by a standard neurological examination (Heij et al. 2012) or nerve conduction 
studies, which cannot distinguish between healthy subjects and patients suffering from neuropathies with 
isolated loss of small fiber function (Mendell and Sahenk 2003, Hoitsma et al. 2011). Additionally, QST is 
suitable for assessing pain thresholds, detection thresholds to non-painful stimuli, and evoked pain, but is 
unable to capture spontaneous pain, as are conventional electroneurographic techniques. Other diagnostic 
methods like skin biopsy or corneal confocal microscopy (CCM) reveal information about the structure of 
small nerve fibers only (Heij et al. 2012, Hoeijmakers et al. 2012, Lauria et al. 2012).  
The development of specialized questionnaires for the detection of neuropathic pain phenotypes may 
improve clinical practice in the treatment of NP outside specialized centers. A simple tool would be 
beneficial in assisting the primary care physician to select patients needing referral to a specialist for 
further testing. At present, such screening tools are not sensitive enough to document sensory loss, which 
is an important criterion in diagnosing neuropathic pain (Treede et al. 2008). It is important to note that 
QST or skin biopsy cannot be replaced but only supported by such screening tools, or rather a suggestion 
can be made, if a skin biopsy or QST would be useful. An additional improvement could be a validated and 
reliable battery of bedside testing(Spiegel et al. 2003) which could be compared in terms of sensitivity and 
specificity to both pain questionnaires and QST. Such an approach would go far towards working out the 
value of all three methods in relation to each other.  
In conclusion, these results demonstrate that the PDQ score is not sensitive enough to distinguish different 
types of sensory loss in patients with NP. While our results indicate that there are differences in the 
responses to four items between groups of patients with one or the other kind of QST-detected loss of 
sensation, they do not provide clear information on an individual patient basis, as the mean differences are 
comparably small (about one point on a zero to five scale) and show a huge overlap. PDQ is unable to 
clearly separate between patients with varying types of loss of sensation, because its questions for loss of 
function are limited to numbness (and are completely missing in other pain questionnaires), while loss of 
function can be detected for all sensory qualities in QST. A more complex analysis, identifying items that 
differentiate between types of sensory loss in a new battery of questions would be an interesting approach 
for a future study. Some domains may give more detailed information if they are divided into two items, 
e.g., the item cold or heat pain, one for pain evoked by cold and one for pain evoked by heat. Separate 
items for the different forms of hyperalgesia or allodynia might also be of value. Additionally, questions 
about autonomic disorders, which commonly appear in patients with small fiber neuropathy (Lacomis 
2002), would be helpful. Pursuing this next step in the development of a convenient screening tool could 
help identify different phenotypes involved in NP.  
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I. A Multidisciplinary Approach and Invasive Techniques for the 
Management of Nonresponders 
 
 
1. Introduction 
Complex regional pain syndrome (CRPS) is a term refined by the International Association for the Study of 
Pain (IASP) to describe disorders characterized by spontaneous or stimulus-induced pain that is 
disproportionate to the inciting event (Swart et al. 2009, Bruehl 2010, Borchers and Gershwin 2014) . The 
disease often includes a wide variety of autonomic and motor disturbances in highly variable combinations 
(Merskey 1994a, 1994b)  in addition to a mixture of noxious sensations (positive symptoms) and sensory 
loss (negative symptoms) (Swart et al. 2009, Gierthmühlen et al. 2011, Marinus et al. 2011).  
CRPS has been extensively studied in adults, but studies in children are scarce. Previously, it was doubtful 
that this condition even existed in children; however, numerous recent articles have reported CRPS in 
children (Finniss et al. 2006, Logan et al. 2013). Furthermore, several authors have highlighted differences 
in the pediatric presentation compared to that of adult CRPS (Tan et al. 2009). Approximately 90% of 
reported cases are girls between 8 and 16 years of age, with the lower limbs most commonly affected. 
Leading symptoms are intensely burning pain, along with cold and mechanical allodynia, dysesthesia and 
paresthesia. Additionally, signs of autonomic dysfunction, movement problems and psychological 
difficulties are also regularly present (Sherry and Weisman 1988, Berde and Lebel 2005, Finniss et al. 
2006, Stanton-Hicks 2010, Logan et al. 2013). 
Not only does diagnosing CRPS pose a significant challenge, but the timing of the diagnosis can also 
determine the prognosis (Murray et al. 2000, Lee et al. 2002, Berde and Lebel 2005, Finniss et al. 2006). 
Furthermore, prompt and accurate management is vital, since the cornerstone of therapy is to restore 
function of the affected limb. Recognized therapies include a combination of pharmacotherapy, physical 
therapies and psychotherapy where appropriate (Lee et al. 2002, Wilder 2006, Zernikow et al. 2012, 
Chopra and Cooper 2013, Borchers and Gershwin 2014). There is evidence that the pediatric population 
responds better to non-invasive approaches (Maillard et al. 2004) . As a result, this style of management is 
growing across Europe and the United States (Wilder 2006, Logan et al. 2013) . Nonetheless, an exact 
treatment model or algorithm has not yet been established. Unfortunately, not all patients respond 
successfully to conservative management, making further interventions a necessity. Many patients who fail 
to progress with physical therapy may require additional or more aggressive pain therapy, such as spinal 
cord stimulation (SCS) or intra-spinal analgesic infusion (Hord and Oaklander 2003, Stanton-Hicks 2010, 
Taylor et al. 2012) . The significance of invasive therapies in children who do not respond to conventional 
treatments or medications has not been established, although most therapies used in adult CRPS have 
been tested in children, including spinal stimulation or drug infusion, TENS and sympathetic blockade 
under general anesthesia. One can find numerous reports in the literature demonstrating success using 
these procedures (Kemler, de Vet, et al. 2008, Kemler et al. 2010, Kato et al. 2011, Olsson et al. 2012, 
Martin et al. 2013) , providing doctors with further alternatives when the non-invasive options are not 
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enough. Consequently, we hypothesized that children who do not respond adequately to conservative 
measures may have the same opportunity to reduce their symptoms with invasive treatments.  
The present article reports on the course and management of 10 children diagnosed with CRPS who did 
not respond successfully to conservative pain management therapies presenting to our Pain Clinic.  
 
 
2. Methods 
This is a clinical series reporting on 10 cases of children (5 males and 5 females) between 8 and 13 years 
old who presented to the Pain Treatment Unit of the Hospital Regional Universitario de Malaga between 
July 2010 and May 2014. These patients had been diagnosed with CRPS, but previous pain therapy was 
not successful. Approval from the hospital’s institutional Review Board was obtained before the study was 
conducted. For this study all CRPS patients were recruited and diagnosed at the pain unit. Next we 
followed a treatment pathway using conventional management first and invasive treatments if the patients 
did not respond, described in detail below.  Follow up appointments were carried every fourteen to twenty 
days until resolution of the symptoms or after a year from the diagnosis at the pain unit. 
All patients between 5 and 16 years old who were evaluated for long-lasting limb pain and possible CRPS 
in our Pain Treatment Unit from the May 2010 to May 2014 were included in a process to determine if they 
met the modified IASP Budapest criteria for the diagnosis of CRPS (Harden et al. 2007) . The final 
diagnosis was made in all cases by a senior pain medicine consultant using the clinical diagnostic criteria 
for CRPS proposed by the Budapest IASP consensus group; this was necessary for inclusion in the study. 
Children with neuropathic or limb pain who did not meet these criteria were excluded from the study. The 
10 children meeting the Budapest criteria also matched the less rigorous current IASP diagnostic criteria 
for CRPS.  
In this study, all included patients were referred to the Pain Treatment Unit because of limited or no 
response to non-invasive treatment (physical therapy, NSAIDs and acetaminophen). All patients were 
referred to the Pain Treatment Unit by the services of Traumatology and Pediatric Rheumatology, with a 
median time for the referral of 18 weeks. The medical and clinical documentation of the patients who were 
referred to our pain unit and who accomplished the diagnosis of CRPS were reviewed since the 
presumptive diagnosis of CRPS commenced at the referring service. These patients were followed for at 
least 12 months after the diagnosis was made at the pain unit. The length of time taken to make the 
diagnosis was calculated from the onset of symptoms. Once diagnosis was made the length of time to 
recovery was calculated. Full recovery was defined as recovery with no recurrence of symptoms within the 
initial 5 months following resolution. Recurrences after this time were considered new episodes.  
 
Treatment approach.  
In this study, the same treatment protocol was followed for every patient after exhaustive clinical 
investigations (Figure 1a). After the initial consultation and diagnosis, the first option was always 
pharmacological treatment for neuropathic pain, together with physiotherapeutic management and 
psychological therapy where needed. The physiotherapy treatment prescribed was exercise to facilitate 
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motion, strength, and proprioception among other qualities, together with sensory desensitization. 
Psychological treatment entailed daily individual and group-based cognitive behavioural therapy (CBT). 
Pharmacological treatments included gabapentin, pregabalin or antidepressants such as amitriptyline, 
prescribed alone or in combination with other analgesic drugs such as tramadol. Additionally, if the patient 
presented intense allodynia and/or severe hyperalgesia, the capsaicin 8% patch was offered as an option 
to support pharmacological treatment. For those children who did not respond to this type of treatment 
after a period of 3 to 5 weeks, a more invasive treatment was chosen. Treatment responsiveness was 
determined by a decrease of at least 33% on the Visual Analogue Scale (VAS) and functional 
improvement determined independently by the patient, the physiotherapist and one of the consultants at 
the pain unit.  At this point, the first step was neuraxial analgesia. Under general anaesthesia, we placed a 
lumbar epidural catheter for bupivacaine infusion of two weeks (Figure 1b). After this time, the catheter 
was removed and the subject was evaluated. The VAS scale and motor dysfunction were assessed and 
compared with previous records, and possible side effects were also recorded. If pain persisted, our next 
step was to surgically place a spinal cord stimulator under general anaesthesia. Correct positioning of the 
electrode and stimulation parameters were set once the patient was awake and fully recovered from the 
anaesthesia. A trial stimulation with a temporary percutaneous extension was performed for about two 
weeks before permanent implantation of the pulse generator. 
 
Outcome measures included spontaneous and evoked pain (VAS), the presence of dysaesthesia, 
allodynia, hyperalgesia, sensitivity to cold, dysautonomic signs, motor dysfunction (Functional Disability 
Inventory (FDI)) (Kashikar-Zuck et al. 2011) , ability to weight-bear, analgesic consumption, and school 
attendance. All of these items were assessed at periodic appointments every 2 weeks except for motor 
dysfunction, measured at the first visit, at month 6 and at the end of the follow-up, i.e. month 12. FDI 
classifies the physical disability as minimal, moderate or severe. The appointments were made between 
the diagnosis and the resolution of symptoms in order to follow the evolution closely, modify the treatment 
if needed and to detect any possible side effects. 
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Spinal Cord Stimulation 
Neuraxial Bupivacaine Infusion * (Fig 1b) 
1st month follow up: Oral drugs readjustment and aplication of the Capsaicin patch 8% (if 
intense allodynia is present) 
1st visit: CRPS Diagnois  
Physiotherapy, Psychological management and Oral Drugs 
Figure 1b: Epidural local analgesic infusion. All patients who were going to receive this treatment were 
hospitalized the day before. The epidural catheter was inserted via the L3–L4 inter-space and advanced into 
the epidural space using an 18G Thuoy needle under fluoroscopy guidance. This technique was performed 
under general anesthesia and with the patient in lateral decubitus position. The catheter was then tunneled 
subcutaneously and connected to the pump. Pump-catheter system integrity was verified post-operatively. 
Treatment was started after the patient got recovered from the anesthesia, Bupivacaine 0.25% at 2ml/hour. 
This dose was titrated until reach the 4ml/hour over 72hours. All patients continued at the hospital for 24 
hours after the intervention prior discharge. This treatment continued for 14 days. After this time the epidural 
catheter got carefully removed.  
 
Figure 1: Treatment approach. At the first visit CRPS diagnosed is made and a new treatment plan is 
recommended. This gathers oral medication as gabapentinoids, antidepressants and analgesics. Weekly 
follows up allow us to readjust the medication and add topical capsaicin if allodynia is intense. 40 to 50 days 
after conservative treatment has been started, if this has not been effective Neuraxial bupivacaine is tested 
over 2 weeks (Figure 1b). If neuraxial analgesics are not effective either, SCS is tested and finally implanted 
if the treatment is successful. 
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Case Reports: 
 
Case 2 
Female, 13 years old. Without any trauma or other reasonable cause, she started to have pain in both feet 
16 weeks before she was referred to the pain unit. CRPS was diagnosed and we rapidly started extensive 
psychiatric treatment and physiotherapy (VAS 8/10). At that time, she had developed contractures and 
was confined to a wheelchair (FDI 41). Pharmacological treatment was started as well, using the capsaicin 
8% patch to minimize allodynia. A few weeks later, she reported progressive relief of her pain and motor 
disturbances. At follow-up 12 weeks later, she had no pain or dysautonomy and was contracture free (VAS 
0/10, FDI 5). Neither mechanical nor dynamic allodynia were evoked after 2 weeks of the initial treatment 
with the capsaicin patch; this was maintained until CRPS resolution.  
 
Case 5 
Female, 8 years old. The patient was diagnosed with CRPS after suffering a minor trauma to her left foot 
while playing at school. CRPS was resolved successfully with pharmacological treatment in a few days. 
However, 4 weeks later, without any new trauma or other reasonable cause, she started to have pain on 
the contralateral limb. Oedema, redness, dysaesthesia, paraesthesia, allodynia and motor problems were 
also present at the time of the diagnosis. First line therapies of the management plan were implemented; 
however, the reduction of symptoms was modest, and the VAS score decreased by only by two points 
while the FDI score remained over 40 (severe). Therefore, we implanted an epidural catheter under 
general anaesthesia for continuous epidural infusion of bupivacaine (Figure 1b). After 2 weeks, the pain, 
dysautonomic and motor symptoms were significantly reduced. At this time, the infusion was stopped and 
the catheter was removed. She reported a reduction in spontaneous pain from VAS 9/10 to 1/10. She 
continued with oral medication and further physiotherapy, leading to the complete cessation of pain for 12 
more months. She is still pain-free in both feet 18 months later. Motor dysfunction is minimal and both 
autonomic and sensory abnormalities disappeared altogether in both feet. 
 
Case 7 
Male, 9 years old. After a minor ankle sprain while playing soccer, the patient developed persistent pain 
(VAS 7/10), severe allodynia and dysautonomic signs in the affected foot and lower leg. With our first line 
management therapies, including the 8% capsaicin patch, he reported a significant reduction in allodynia 
but insufficient relief of pain (VAS 5-6/10) and motor disability (FDI severe dysfunction). Neuraxial 
analgesia with a 2-week infusion of bupivacaine successfully diminished his pain and allowed him to 
recover full mobility of the limb once again (FDI 10). Reductions were achieved in the VAS score and 
functional disability, i.e. from 7 and 9 for evoked pain down to 0 and from severe to minimal, respectively, 
with this treatment protocol.  After the epidural catheter was removed and the infusion was stopped, the 
subject continued to be pain-free until the last follow up, 24 months later (VAS 0/10, FDI 3). 
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Case 9 
Female, 13 years old. CRPS in the lower right limb developed a few days after an ankle fracture. The 
patient did not respond adequately to physical and pharmacological treatment during the first 30 weeks. 
She presented a pain VAS score of 8/10 and severe motor impairment. She was thus referred to our pain 
unit where an epidural bupivacaine infusion was used to treat her pain. The pump was stopped and the 
catheter was removed 2 weeks after, obtaining excellent results. The girl reported pain relief with a VAS 
for evoked pain from 9/10 down to 2/10. However, the symptoms reappeared after the infusion was 
stopped. Following this, an SCS trial device was implanted with excellent results for 2 weeks (VAS 1/10), 
allowing the patient to resume school and physical therapy; the impact of this treatment allowed for the 
patient to minimize her motor impairment. Two weeks after that improvement, we disconnected the 
stimulator device and continued with the physical and psychological therapies. Four weeks later, we 
achieved complete remission of the pain and additional symptoms, so we decided to remove the 
percutaneous electrode. Twelve months later, the patient remains pain-free and with minimal functional 
disabilities.  
 
Case 10 
Female, 8 years old. She suffered a minor trauma to her left foot 17 weeks before she was referred to the 
pain unit with severe pain (VAS 10/10), allodynia, dysaesthesia and dysautonomic symptoms. Before her 
referral, she was treated with transdermic opioids and gabapentin among other analgesics, with poor 
results. At the pain unit, pharmacological treatment including topical capsaicin patches relieved her 
allodynia significantly but only modestly reduced her pain by two points on the VAS scale. Continuous 
epidural infusion of bupivacaine caused a temporary suppression of her spontaneous pain, but it came 
back when the infusion was stopped. SCS was decided on and about 7 months after the start of the pain, 
an octopolar paddle electrode was implanted. Three weeks after the stimulation started, the symptoms 
were minimal and the patient regained complete limb functionality, returned to school and also started 
taking part in extra-curricular activities (VAS 0/10, FDI 6). 
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3. Results 
 
 Following the management pathway described above, the outcomes were noteworthy. This clinical series 
shows that 9 out of 10 patients had suffered a minor trauma or ankle sprain months before they were 
referred to the clinic, and presented with high intensity, neuropathic-type pain, along with significant motor 
and autonomic disturbances since the onset of injury (Table 1). Strikingly, one patient suffered trauma to 
the limb contralateral to where the symptoms were reported. The treated children had significantly reduced 
pain and improvement in other symptoms such as allodynia, dysaesthesia, hyperalgesia, sensitivity to cold 
and dysautonomic signs. CRPS even disappeared in the majority of cases. Although the children were all 
instructed to assess their pain using a VAS, it was not feasible to achieve this on a regular basis. The 
patients in our study primarily remained at home and only came to the pain unit for appointments. The 
children failed to do regular evaluations at home, so data were usually collected only at appointment times. 
Pain scores (VAS) decreased substantially during the study. The mean VAS for ongoing pain at the first 
visit was 7.7 (SD 0.9) and for evoked pain was 9.1 (SD 0.93), while 12 months after the first appointment, 
the mean VAS for the whole group was 0.3 (SD 0.4).  
Physical functional disability was also reduced. Our patients showed severe disability at their first visit 
(mean FDI: 32.4, SD 7.3); however, at the end of the study, they presented minimal disability (mean FDI: 
4.8, SD 3.1). These data parallel school absences, which declined from 60% to 0% throughout the study.  
Within this series of patients, CRPS disappeared with oral medication and physical management in one 
patient. Three other children alleviated their symptoms by adding the capsaicin 8% patch to their 
pharmacological and physical management. Capsaicin treatment diminished mechanical and dynamic 
allodynia in all nine patients in whom it was used. Allodynia that was originally stated as “extremely 
unpleasant” at the beginning of the treatment in seven out of ten children either disappeared completely or 
was just mildly unpleasant at the last appointment for all patients.  
A second group of children needed further efforts to treat CRPS. Non-invasive management was 
unsuccessful in alleviating pain in these patients after a few weeks of treatment. Three of these children 
reduced their pain with two weeks of epidural bupivacaine by continuous infusion. None of these patients 
experienced a recurrence of symptoms after the epidural catheter was removed. 
Finally, three patients who did not respond to systemic medication or to neuraxial analgesia needed the 
surgical placement of an octopolar paddle spinal cord stimulator to relieve their pain. This last group of 
patients improved their clinical situation significantly with this treatment, making better physiotherapeutic 
management possible and reducing and/or abolishing the need for any oral medication (Table 2).  
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Table 1.   
 
 
Case 1 2 3 4 5 6 7 8 9 10 
Age (years) 13 13 10 11 8 10 9 11 13 8 
Gender Male Femal
e 
Male Male Femal
e 
Female Male Female Femal
e 
Femal
e 
Area affected RLL Bilater
al 
RLL LLL RLL RLL LLL LLL RLL LLL 
Trauma Mild No Mild Mild Minor* Mild Minor Mild Mild Minor 
Time diagnosis-
referral (weeks) 
28 16 19 17 4 150 95 36 30 17 
Ongoing Pain 
(VAS) 
6 8 7 8 8 7 7 9 8 9 
Evoked Pain (VAS) 9 10 8 9 10 7 9 10 9 10 
Allodynia 
 
+ ++ ++ +++ +++ ++ + +++ ++ ++ 
Motor dysfunction 
(FDI) 
Minimal- 
Moder
ate 
Severe Minim
al 
Moderat
e 
Sever
e 
Moderat
e-
Severe 
Sever
e 
Moderat
e-
Severe 
Sever
e 
Severe 
Dysautonomic 
symptoms 
+ + + ++ ++ ++ + ++ +++ + 
Other sensory 
disturbances 
+ + + +++ ++ ++ ++ + +++ + 
 
 
Table 1.  Demographics and clinical data of ten cases of children with CRPS 
 
None of our patients reported mild or important secondary effects due to any of the therapies used during 
the study. Some minor side effects such as transient dizziness, dry mouth or minor pain after surgery were 
reported in 30% of cases. 
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Table 2.  
 
 
Case 1 2 3 4 5 6 7 8 9 10 
Time diagnosis- referral (weeks) 28 16 19 17 4 150 95 36 30 17 
Physical Therapy Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Psychological Therapy Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Pharacological Th. Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Capsaicin 8% Patch - Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Neuroaxial Bupivacaine infusion - - - - Yes Yes Yes Yes Yes Yes 
SCS - - - - - - - Yes Yes Yes 
Follow up 12 months after the 
first visit at the Pain Unit. 
Time referral – “CRPS free” 
(weeks) 
22 12 19 8 30 32 24 48 21 39 
Ongoing Pain (VAS) 0 0 1 0 0 0 0 1 0 0 
Allodynia No No No No No No No No No No 
Motor dysfunction (FDI) 
Mino
r 
Mino
r 
Mino
r 
Mino
r 
Mino
r 
Mino
r 
Mino
r 
Mino
r 
Mino
r 
Mino
r 
Taking Drugs No Yes No Yes Yes No No Yes No Yes 
School absence No No No No No No No No No No 
 
 
Table 2. - Therapies prescribed and clinical evaluations after a 12 moths follow up. 
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4. Discussion 
 
Complex regional pain syndrome is usually represented by a complex clinical presentation and (Merskey 
1994a, 1994b, Meier et al. 2006, Marinus et al. 2011, Gierthmühlen et al. 2014) a pathophysiology that 
seems to be multifactorial in nature, characterized by an aberrant host response to tissue damage. Most of 
the clinical features of this condition are apparent in the confluence of three major pathophysiological 
pathways: vasomotor dysfunction, aberrant inflammatory mechanisms and maladaptive neuroplasticity. 
The clinical heterogeneity of the disorder is indicative of the inter-individual variability in the activation of 
these pathways after tissue injury (Jänig 2009, Coderre and Bennett 2010, Marinus et al. 2011) . 
Several authors have highlighted differences in the picture presentation compared to that of adults with 
CRPS (Tan et al. 2008)  (Table 3). Abnormal intensity and burning pain, in addition to mechanical 
allodynia, dysaesthesia and paraesthesia are present in nearly 100% of the cases reported in the 
literature. Signs of autonomous dysfunction such as oedema and discoloration are present along with a 
significant reduction in movement range of the affected limb (Berde and Lebel 2005, Finniss et al. 2006, 
Meier et al. 2006, Fitze 2011, Logan et al. 2013) . The symptoms displayed in our patients were in most 
cases the majority of those described above. The complexity of CRPS shown in this group of children was 
outstanding as the majority took a long time to be diagnosed and treated appropriately for their condition.  
In our experience, the prognosis of the disorder substantially depends on an early diagnosis. Most studies 
agree with this finding (Murray et al. 2000, Lee et al. 2002, Berde and Lebel 2005, Finniss et al. 2006). 
Low et al. showed that children who get a prompt diagnosis (less than 12 weeks) and therefore rapid 
treatment achieved a quicker and more successful remission of CRPS when compared to those whose 
diagnosis was delayed (10.6 and 21.5 weeks) (Low, Ward, and Wines 2007a) . In spite of this, Murray et 
al. could not corroborate the relationship between early onset of treatment and early recovery (Murray et 
al. 2000) . Still, we support that early detection and diagnosis, using standards such as the Budapest 
criteria to ensure this, can attenuate the possibility of permanent suffering, since delayed diagnosis may 
result in lifelong pain, functional deficiency and psychological complications (Harden et al. 2007, Fitze 
2011) . Unfortunately, children are often diagnosed in a delayed fashion because CRPS is still a rare and 
unknown condition in this population. Frequently, children will have seen multiple health care providers 
before a formal diagnosis is made, eventually leading to the symptoms described above (Kachko et al. 
2008).  
Several characteristics have been identified that differentiate CRPS in children and adults (Table 3) (Tan 
et al. 2009, Logan et al. 2013) ; however, these are not only clinical. During childhood, CRPS usually 
appears in the lower extremities, whereas the upper limb is most commonly affected in adults (Berde and 
Lebel 2005, Harden et al. 2007) . To further this point, Tan et al. demonstrated in a retrospective study of 
young patients that the upper limb was affected in only 23.3% of these patients versus the 72.6% who had 
an affected lower limb (Tan et al. 2008). In our study, the difference was even more notable as all patients 
presented CRPS in the lower extremities. Another difference identified in the literature between adults and 
children is that females are more often affected than males (7:1) (Harden et al. 2007, Low, Ward, and 
Wines 2007a) . However, we did not find this ratio, as our study had an equal proportion of male to female 
patients. Finally, another interesting detail found in this study is that children show complete recovery of 
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any lost functionality after correct management, whereas adults retain some disability after the symptoms 
are resolved (Stanton-Hicks et al. 1998, Sherry et al. 1999, Berde and Lebel 2005, Bruehl 2010) . 
 
 
Table 3.  
 
Characteristic Adult Paediatric 
Age* 45 12 
Gender ratio Male predominance Female predominance 
Extremity affected Upper Lower 
Trauma Mild- Severe Minor- Mild 
Limb temperature 30% cooler 70% cooler  
Oedema 40% 75% 
Prognosis Variable, long term disability Excellent recovery in most cases 
Relapse rate 10% 30% 
 
Table 3. Adult vs. Paediatric CRPS characteristics. 
* Mean age at presentation of the symptoms  
 
 
 
Most clinicians agree that the best possible prognosis is achieved with an diagnosis and treatment (Murray 
et al. 2000, Lee et al. 2002, Finniss et al. 2006) . Additionally, the medical community agrees that the 
cornerstone outcome should be the restoration of function. Acknowledged therapies include a combination 
of pharmacotherapy, physical therapy and psychotherapy where appropriate (Lee et al. 2002, Wilder 2006, 
Zernikow et al. 2012, Chopra and Cooper 2013, Borchers and Gershwin 2014) . Several studies have 
shown that early mobilization of the affected limb assisted with cognitive behavioural techniques is the 
most important part of the management process in childhood (Sherry et al. 1999, Lee et al. 2002, Wilder 
2006) . In our experience, this has remarkable importance, but so does the use of medication as it was 
shown to be indispensable in pain reduction. This is why we provide multidisciplinary management, 
including physiotherapy, psychotherapy and pharmacological treatment as soon as patients arrive at the 
pain clinic. 
Among the drugs used to treat CRPS, NSAIDs, acetaminophen, tramadol, tricyclic antidepressants and 
gabapentinoid anticonvulsants are frequently recommended (Low, Ward, and Wines 2007a, Chopra and 
Cooper 2013) . However, despite different combinations and dose escalation of these drugs, some patients 
do not improve in terms of sensations such as allodynia in severe cases. With the aim of reducing this, we 
began treatment with a capsaicin 8% patch in those who presented severe allodynia. The capsaicin 8% 
patch is not currently FDA or EMA approved for use in children. We meticulously explained to the children 
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and their families the mechanism of action of the patch in adults, the risks associated with its use, 
secondary effects, different therapeutic options and, more importantly, our aims and hypothesis. After this, 
the parents of seven children signed the consent form approving the use of the patch. The capsaicin patch 
was applied in the seven children, providing significant relief for allodynia, hyperalgesia and dysaesthesia 
in five of them. In three patients, the capsaicin 8% patch together with oral medication and physical and 
psychological treatment eradicated all symptoms. Here, the application of the patch was the final and 
decisive step in their treatment. Notably, none of the children treated suffered any side effects. This new 
and improved topical formulation has emerged as an effective tool to treat chronic refractory pain in adults; 
however, to our knowledge, it has not yet been documented for use in CRPS during childhood. This is an 
important tool that should be incorporated as part of a complex analgesic regimen for improving pain 
management plans in the paediatric CRPS population. 
Only those patients who did not improve successfully after being treated with the three-pillar pain 
management plan described above were candidates for invasive pain therapies. The implications of 
invasive managements in children who do not respond to conventional treatments are not established and 
a positive publication bias must be assumed. Nevertheless, there are numerous reports of treatment 
success using invasive techniques (Kemler et al. 2000, Kemler, de Vet, et al. 2008, Kato et al. 2011, 
Olsson et al. 2012, Martin et al. 2013) , providing doctors new alternatives when non-invasive options are 
not enough.  
In this study, six patients (60%) required these techniques after exhausting all other possibilities. Pain and 
motor incapability continued progressing despite non-invasive treatment for more than four weeks at the 
pain unit. In the operating room and under inhalation anesthesia, we placed a lumbar epidural catheter for 
bupivacaine infusion, as described in Figure 1. Doctors at the Pain Treatment Unit managed the local 
anaesthetic infusion externally, which was titrated carefully until there was a decrease in pain without side 
effects. The infusion continued for two weeks, after which the catheter was removed and the subject was 
evaluated. In three of our patients, pain and other symptoms decreased permanently, co-medication was 
reduced and physical therapy management helped significantly. On the other hand, in the other three 
patients, symptoms reappeared after an initial period of improvement. 
In the unsuccessful cases, SCS was the next option for treatment. After obtaining consent, we surgically 
placed an octopolar paddle spinal cord stimulator. This last group of patients improved their clinical 
situation significantly with this treatment, making better physiotherapeutic management possible and 
reducing and/or abolishing any oral medication. In the line of this study, we have found several reports on 
the use of SCS in children (Olsson et al. 2012) . However, no curative effect of SCS has been reported, not 
even in adults. The mechanism behind the beneficial effects of SCS is basically unknown, but reviews of 
the present knowledge and some hypotheses relating to CRPS have started to come to light (Linderoth 
and Meyerson 2010). From our point of view, SCS is a minimally invasive and reversible treatment method 
that can be useful in the management of otherwise therapy-resistant CRPS presentations in children. 
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4. Conclusion 
 
This study offers a multidisciplinary management approach to the treatment of CRPS in children for whom 
the standard treatment was not successful. Because of the severity and rapid progression of symptoms in 
CRPS, we consider that early diagnosis of the condition together with comprehensive and individualized 
multidisciplinary treatment offers children with CRPS the best opportunity for complete recovery. Within 
this management plan, novel drugs should be included, such as the capsaicin 8% patch, in addition to 
invasive techniques for patients who otherwise do not respond to non-invasive therapies. Thus, a more 
aggressive approach needs to be attempted. We conclude that further research into CRPS in children is 
needed and new treatment guidelines are required for those children who do not respond to established 
management modalities. 
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II. Invasive Management for Paediatric Complex Regional Pain 
Syndrome: literature review and personal experience. 
 
1. Introduction 
Complex regional pain syndrome (CRPS) is a term defined by the International Association for the Study 
of Pain (IASP) to describe disorders primarily characterized by spontaneous or stimulus-induced pain that 
is disproportionate to the inciting event.  CRPS has been suggested to be a multifactorial disorder that is 
related to an aberrant host response to tissue damage (Swart et al. 2009, Marinus et al. 2011) . The 
disease often includes a wide variety of autonomic and motor disturbances in highly variable combinations 
(Merskey 1994a, 1994b). The symptoms can be categorized into two groups; positive noxious symptoms, 
such as hyperalgesia and allodynia and negative symptoms of sensory loss (Swart et al. 2009, 
Gierthmühlen et al. 2011, Marinus et al. 2011). Usually, patients with CRPS present following moderate or 
insignificant tissue damage. In the acute phase, the patient can exhibit an extremely painful, red, warm 
and swollen injured limb. Other potential accompanying features are changes in sweating, hair and nail 
growth, allodynia and hyperalgesia, and muscle weakness. As the disorder continues, pain spreads, 
voluntary motor control is reduced in most patients, and negative sensory signs, namely hypoalgesia and 
hypoesthesia, become more apparent (Bruehl 2010, Maier et al. 2010, Marinus et al. 2011).  
CRPS has been extensively studied in adults while studies in children are scarce (Marinus et al. 2011, van 
Eijs et al. 2011, Gierthmühlen et al. 2014). For a long time it was doubtful that this condition even existed 
in children, nonetheless within the last few years numerous articles have reported CRPS at young ages 
(Table 1). However, due to the lack of understanding regarding its precise pathophysiology, reliable 
diagnostic tests are not available. CRPS diagnosis entirely depends on observable signs and reported 
symptoms, which have been put together into various diagnostic criteria sets for adults (Stanton et al. 
1993, Merskey 1994a, Harden et al. 2007). Unfortunately these diagnostic criteria do not often agree, 
raising a high degree of uncertainty into CRPS diagnosis. To date specificity and sensitivity of the standard 
diagnostic criteria sets have not been evaluated for pediatric patients. 
As well as posing a significant diagnostic challenge, the timely diagnosis of CRPS can substantially 
influence the prognosis (Murray et al. 2000, Lee et al. 2002, Berde and Lebel 2005, Finniss et al. 2006). 
Additionally, prompt and accurate management is key, where the cornerstone is to restore function of the 
affected limb. Recognized therapies include a combination of pharmacotherapy, physical therapies and 
psychotherapy where appropriate (Lee et al. 2002, Wilder 2006, Zernikow et al. 2012, Chopra and Cooper 
2013, Borchers and Gershwin 2014). Only patients who fail to progress with physical therapy may require 
additional or more invasive pain therapy, such as spinal cord stimulation (SCS), intra-spinal analgesic 
infusion or sympathetic blocks (Hord and Oaklander 2003, Stanton-Hicks 2010, Taylor et al. 2012, Logan 
et al. 2013). Neurostimulation therapy and spinal cord drug infusion have been available since the 1970s 
and have grown in acceptance in recent years for the treatment of pain disorders of diverse etiology 
(Knight et al. 2007, Taylor et al. 2012). Today, CRPS in adults is the second-largest indication for the use 
of SCS in the United States, reaching success rates of up to 70% in pain reduction in CRPS sufferers 
treated with spinal cord stimulation when properly selected (Stanton-Hicks et al. 1998, Barolat and Sharan 
2000). However, the significance of invasive procedures during childhood and adolescence for the 
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treatment of CRPS patients who do not respond to conventional treatments or medications continues to be 
unestablished (Zernikow et al. 2015). Several reports in the literature demonstrate success with these 
procedures, providing physicians (or clinicians) with more alternatives after conventional options fail (Table 
3). 
The focus of this article is to review the evidence for invasive pain procedures along with presenting a 
management algorithm for pediatric CRPS, including invasive procedures for patients who do not respond 
to the conventional first-line treatment. 
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Intervention n studies (%) 
N=31 
n 
patients 
1980-   
2000 
2000- 
2015 
Reference 
Sympathetic 
blockade (singular or 
continuous) 
15 (48%) 123 7 8 (Doolan and BROWN 1984, 
Dietz et al. 1990, Wilder et al. 
1992, Stanton et al. 1993, 
Lloyd-Thomas and Lauder 
1995, Honjyo et al. 1997, 
Maneksha et al. 2000, Matsui et 
al. 2000, Tong and Nelson 
2000, Agarwal and Joseph 
2006, Meier et al. 2006, 
Nordmann et al. 2006, Dangel 
2008, Kachko et al. 2008, 
Franklin and Austin 2012) 
Spinal drug infusion 
or epidural catheter 
11 (35.5%) 25 0 11  
(100%) 
(Maneksha et al. 2000, Matsui 
et al. 2000, Tong and Nelson 
2000, Ingelmo et al. 2005, Meier 
et al. 2006, Stanton-Hicks and 
Kapural 2006, Farid and Heiner 
2007, Rodríguez et al. 2007, 
Kachko et al. 2008, Rand 2009, 
Kato et al. 2011) 
Regional anesthesia 10 (32%) 36 1 8     
(91%) 
(Stanton et al. 1993, Maneksha 
et al. 2000, Matsui et al. 2000, 
Suresh et al. 2003, Dadure and 
Capdevila 2005, Kachko et al. 
2008, Carayannopoulos et al. 
2009, Kato et al. 2011, Martin et 
al. 2013) 
Intravenous lidocaine 7 (22.4%) 28 4 3 (Buchta 1983, Doolan and 
BROWN 1984, Honjyo et al. 
1997, Di Vadi et al. 2006, Meier 
et al. 2006, Nordmann et al. 
2006, Dangel 2008) 
Spinal Cord 
Stimulation 
3 (9.6%) 11 0 3     
(100%) 
(Stanton-Hicks and Kapural 
2006, Rodríguez et al. 2007, 
Olsson et al. 2012) 
Surgery 3 (9.6%) 5 3 0     
(0%) 
(Buchta 1983, Ashwal et al. 
1988, Parano et al. 1998) 
Sympathectomy 2 (6.4%) 28 2 0     
(0%) 
(Buchta 1983, Greipp et al. 
1988) 
 31(100%) 171 
 
Table 1. Invasive Interventions for Complex Regional Pain Syndrome 
  
Chapter 3 
 118 
2. Material and Methods 
Literature selection 
A literature search identified studies relevant to invasive treatments for CRPS in children. Databases used 
included PubMed, Medline, Web of Science, Embase and Cochrane. Because of the small volume of 
literature on the pediatric population, database-specific controlled vocabulary (subject headings or index 
terms) was not used, and keyword searching produced a comprehensive and manageable yield. The 
following search strategy was used: ((complex regional pain syndrome) OR (CRPS) OR (reflex dystrophy) 
OR (algodystrophy) OR (causalgia) OR (Sudeck´s atrophy) AND (sympathetic OR neurovascular)) OR 
((amplified OR complex OR chronic) AND (neuralgia OR pain) AND musculoskeletal)) AND (therapy OR 
therapies OR therapeutic)) OR (transcranial AND magnetic AND stimulation) (OR spinal cord stimulation 
OR neurostimulation OR spinal drug infusion OR intra-spinal therapy OR epidural infusion OR epidural 
catheters OR sympathetic block OR sympathetic blockade OR peripheral blocks OR surgery) AND (child 
OR adolescent OR pediatric). Initial search results were limited to English and Spanish language articles. 
The references in the selected articles were used to identify additional relevant sources. In addition, the 
authors identified a limited number of articles or chapters from personal readings. 
31 studies met the criteria to be included in this review (Table 1). Their full texts were analyzed for 
retrieving information as: the invasive treatment used - including prior and concurrent conservative 
interventions-, outcomes measured, type of study, patient characteristics, quality of the study, design and 
methodology. 
 
3. Review of the evidence 
Conservative management: 
Although reviewing CRPS non-invasive therapy is not the goal of this article, we have considered it 
appropriate to briefly describe the most accepted model of management for this condition. CRPS in 
childhood and adolescents seems to respond favorably to conservative multimodal inpatient therapy 
(Maillard et al. 2004, Katholi et al. 2014). In the largest pediatric trial reported to date, 92% of children and 
adolescents were free of symptoms after an intensive physical therapy program (Sherry et al. 1999). Other 
smaller series identified in the literature have presented recovery rates of 70% as well after applying 
conservative management (Stanton-Hicks et al. 1998, Low, Ward, and Wines 2007b, Kachko et al. 2008), 
however recovery or resolution is not always well-defined.  
Nonetheless the long-term prognosis is unclear and between 28% and 48% of patients with pediatric 
CRPS experience a relapse (Stanton-Hicks et al. 1998, Sherry et al. 1999, Wilder 2006, Low, Ward, and 
Wines 2007b, Tan et al. 2008). Consolidation of the evidence suggests that conservative treatment of 
pediatric CRPS should form the basis of first-line treatment. Being the medication, the psychological and 
the physical therapies clearly the core of the initial treatment. However, further interventions are needed 
when the condition does not resolve or a relapse occurs.  
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Invasive Pain Therapy 
The relevance of invasive therapies in children who otherwise do not respond to conservative 
management or medications after a few weeks of treatment has not been established in pediatric patients 
(Nordmann et al. 2006, Rodríguez et al. 2007, Olsson et al. 2012, Zernikow et al. 2015).  There is not a 
single randomized control trial to date comparing the conservative and the invasive management of this 
particular group of patients. The largest series of pediatric cases showed that between 29% to 35% of 
children with CRPS needed interventional measures to manage this condition successfully (Kesler et al. 
1988, Lee et al. 2002, Kachko et al. 2008).  
Within this review we have identified 31 publications published between 1980 and 2015. Most studies were 
case series and case reports (n=28), including a total of 108 patients. One randomized control trial of 23 
patients and two controlled studies of 40 patients in total complete the collection of studies of this review 
(Table 1). The entire collection of publications contained data of 171 patients. The characteristic of the 
population who received invasive procedures correlates with the characteristic of the children showed by 
other publications affected by this syndrome who do not receive this sort of treatments (Table 2) (Tan et al. 
2008, Logan et al. 2013). Spontaneous pain and functional disability were the two outcomes measured 
with more assiduity. The overall improvement for spontaneous pain was documented in 79% of cases, 
16% of patients showed no change. Functional disability was reported in 25 publications, 24 of them 
showed improvement after treatment. 
This study reveals that the most used procedure was the sympathetic blockade (Table 1). Singular or 
continuous sympathetic blocks were used in 15 studies, 123 patients. Within this group of studies we 
found the only randomized control trial (Meier et al. 2009) and two controlled studies (Greipp et al. 1988, 
Dadure and Capdevila 2005). Numerous types of blocks are included in this group, for example: the 
sympathetic blocks of the ganglion stellatum for CRPS in the arm, the block of the lumbar truncus 
sympathicus for CRPS in the leg or the thoracic block of the Kuntz´s nerve. Local anesthetic blockade of 
the sympathetic chain has been widely used to treat CRPS in adults, however the empirical data is 
confusing yet (Ramsaroop et al. 2001, de Oliveira Rocha et al. 2014). A systematic review revealed the 
paucity of published evidence to support the use of local anesthetic sympathetic blockade as the 'gold 
standard' treatment for CRPS (Cepeda et al. 2005, Martin et al. 2013, Stanton et al. 2013). Likewise, we 
can concl that its efficacy has not been proven for the treatment of CRPS in adults. The data in children is 
far scarcer and uncertain, that is why this treatment has been relegated to a more tentative choice in 
pediatric CRPS. Additionally, most of the publications analyzed revealed that multiple invasive procedures 
were needed during the period of treatment with this technique, increasing the risks of side effects 
(Stanton et al. 1993, Kachko et al. 2008). 
 The spinal drug infusion of local anesthetics was used in 11 studies, all of them in the last 15 years. 
Spinal drug infusion through epidural catheter has been largely used in this group of patients when the 
physiotherapy program needs to be supported or when the symptoms do not decrease with conservative 
management. Epidural drug infusion with local analgesics is a viable alternative when conventional 
treatment do not achieve acceptable results, it also has the advantage of the supplementation with opiates 
to the local anesthetics to offer better analgesia. The complications and risks of this technique (eg. 
respiratory depression, motor block, sympathetic block resulting in hypotension and urinary retention) can 
be avoided by careful titration of the infused medications and adequate patient and family education. To 
date there is no randomized trial for spinal drug infusion in CRPS, however there are numerous reports 
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supporting this technique. Of 37 adult CRPS patients treated with continuous epidural infusion of 
bupivacaine and fentanyl, nearly 90% had a reduction in their symptoms when treated within 12 months 
after onset. However, the success rate diminished considerably when treatment was began more than a 
year after onset (Moufawad et al. 2002). In the pediatric literature reports are fewer yet analogous to those 
found in adults which would suggest a favorable outcome (Farid and Heiner 2007, Rodríguez et al. 2007, 
Kachko et al. 2008, Saito et al. 2015).  Some authors highlight the importance of avoiding delay for treating 
CRPS invasively(Rodríguez et al. 2007, Saito et al. 2015). Therefore, we conclude that early treatment 
with continuous epidural anesthesia may be promising when initial non-invasive management is 
ineffective.  
SCS has demonstrated efficacy in CRPS type 1 in adults (Grabow et al. 2003, Tracy Cameron 2004, 
Kemler, de Vet, et al. 2008). SCS in adults, same as in pediatrics, an electrode is placed in the epidural 
space on the dorsal aspect of the spinal cord at the level of the nerve roots innervating the painful area. 
Electrical current from the electrode brings about paresthesia, a sensation that suppresses the pain. This 
technique has become more popular during the last decade for the management of CRPS in adults, 
obtaining successful results in most cases (Tracy Cameron 2004, Turner et al. 2004, Kemler, De Vet, et al. 
2008, Taylor et al. 2012). In the pediatric population it has been suggested as a possible option when the 
subject is resistant to all conventional treatments (Turner et al. 2004, Bennett and Brookoff 2006, Grabow 
et al. 2006, Kemler, de Vet, et al. 2008), but only a few examples of successfully treated CRPS in children 
have been presented to date, 3 case series with 11 people in total (Wilder 2006, Rodríguez et al. 2007, 
Olsson et al. 2012). Therefore, to the best of our knowledge SCS can be a useful and promising treatment 
for CRPS in pediatric patients who do not respond to conventional treatment. Nevertheless, due to the 
small and non-controlled design of these case series, further studies are needed to verify that SCS can be 
recommended for its use in this group of patients.  
There are others invasive techniques that have been considered when conventional therapy has failed in 
pediatric CRPS. Regional anesthesia has been tried in 36 patients during the last years, mostly during the 
last 10 years, however the results do not appear to be as good as with some of the techniques mentioned 
previously. Similarly, intravenous regional blocks with lidocaine counts with unsatisfactory or unclear 
reports in general, being the decrease in spontaneous pain and functional disability improvement less than 
with any other procedure, 55% and 50% respectively.  
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Table 2. 
 
Characteristic Adult 1 Paediatric 2 
Age* 45 12.8 
Gender ratio Male predominance Female predominance (85%) 
Extremity affected Upper Lower (80%) 
Trauma Mild- Severe Minor- Mild  
Limb temperature 30% cooler 70% cooler  
Edema 40% 75%  
Prognosis Variable, long term disability Excellent recovery in most cases 
Relapse rate 10% 30% 
 
Table 2.- Adult vs. Paediatric CRPS characteristics. 
 
* mean age at presentation of the symptoms. 1Data extracted from CRPS adult literature. 2 Description of 
patients comprised in this review. 
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Table 3.   
Referenc
e 
Year Interve
ntion 
n Outco
me 
meas
ure.1 
Lengt
h2 
Previous 
medication 3 
Adver
se 
effect
s 
Improveme
nt (% 
patients) 
Comments 
Rodrigue
z et al. 
(33) 
2015 LA 
Spinal 
inf. 
 
SCS 
10 
(6)
* 
Yes 52 w. Opioids 
(67%) 
NSAIDs 
(83%) 
Anticonvul 
(100%) 
Antidepress 
(67%) 
Capsaicin 
(100%) 
 
No 100% This study 
showed 
successful 
results after 
applying a 
multimodal and 
progressive 
approach 
including 
invasive 
measures as 
well as physical 
management 
and novel 
medication as 
the capsaicin 
8%patch. 
Olsson 
et al. 
(Olsson 
et al. 
2012) 
2012 SCS 7 Yes 52/25
0w 
Opioids 
NSAIDs 
Anticonvul 
Antidepress 
Ketamine 
(14%) 
Epidural L.A 
(28%) 
Yes, 
Local 
infecti
on 
Full 
recovery 
(72%) 
 
Minor 
symptoms 
or 
recurrences 
(28%) 
Olsson´s study 
comprised 
seven girls, 
presenting with 
severe, 
incapacitating 
and therapy-
resistant 
CRPS-I, who 
were subjected 
to SCS. Good 
technique 
description but 
poor 
methodology. 
Meier et 
al. 
(Meier et 
al. 2009) 
2009 Cont 
Lumba
r 
sympat
h block 
 
Lidocai
ne iv 
23 Yes - ”6-week trial 
of aggressive 
physical, bio-
behavioral, 
and 
pharmacologi
cal 
therapies,” 
Minor LSB: 
Complete 
(29%). 
Adequate 
(41%) 
Minimal  
(32%) 
Lido iv: 
Minimal  
(84%) 
Adequate 
The purpose of 
this study is to 
compare the 
efficacy of 
lidocaine 
administered 
by lumbar 
sympathetic to 
IV route. 
Excellent 
methodology 
and clear 
results. No 
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Table 3.  Relevant publications, selection by the authors. 
 (1) Outcome measure carefully described. (2) Length of the follow up -weeks-. (3) Medication prior 
invasive treatment. * Number of patients treated with invasive measures within the total of patients. 
 
 
 
 
(16%) follow up 
period. 
 
Kachko 
et al. 
(Kachko 
et al. 
2008) 
2008 Epid 
cath 
(1) 
Stellat
e gang 
block 
(1) 
Region
al 
anesth
.(2) 
14 
(4)
* 
Poorly 8w. NSAIDs 
Anticonvulsiv
e 
Antidepressa
nt 
. Full  (78%) 
Partial 
(15%) 
 
Recurrence 
(29%) 
Retrospective 
study that 
aimed to 
assess the 
efficiency of the 
multimodal 
management of 
CRPS. Limited 
but illustrative 
of the actual 
clinical set up 
of many Pain 
Treatment 
Units. 
Stanton 
et al. 
(Stanton 
et al. 
1993) 
1993 Sympa
th 
block 
 
Region
al 
anesth 
36 
(x)
* 
Poor - NSAIDs 
Anticonvulsiv
e 
Antidepressa
nt 
Opioids 
- Moderate 
or poor 
Review of the 
experience at 
this center.  
They aimed to 
present 
diagnostic 
criteria for 
pediatric 
CRPS.  
Management 
and outcomes 
poorly 
described. 
Wilder et 
al. 
(Wilder 
et al. 
1992)  
1992 Sympa
th 
block 
70 
(3
7) 
Yes 20w NSAIDs 
Antidepressa
nt 
- Full (71%) 
 
Moderate 
(13%) 
Wilder 
retrospective 
study reported 
his experience 
with a 
multimodal 
treatment, 
using in more 
than 50% 
invasive 
techniques. 
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3. Discussion 
 
Complex Regional Pain Syndrome is characterized by complex clinical presentations and a 
pathophysiology that seems to be multifactorial in nature, characterized by an aberrant host response to 
tissue damage (Meier et al. 2006, Gierthmühlen et al. 2011, Marinus et al. 2011). Most of the clinical 
features of this condition can be explained by the confluence of three major pathophysiological pathways: 
vasomotor dysfunction, aberrant inflammatory mechanisms, and maladaptive neuroplasticity.  The clinical 
heterogeneity of the disorder is indicative of the inter-individual variability in the activation of these 
pathways after tissue injury (Jänig 2009, Coderre and Bennett 2010, Marinus et al. 2011).  
The recommendations of the Special interest group in Neuropathic Pain (NeupSIG) of the IASP for the 
pharmacological management of neuropathic pain (NP) only considered treatments with at least 2 high-
quality randomized clinical trials (RCTs) (Dworkin et al. 2010). Nonetheless, there is limited evidence 
evaluating interventional treatments for NP, and many interventions used in clinical practice to manage NP 
in refractory patients are supported by weak, if any, evidence (Dworkin et al. 2013). This evidence is even 
more fragile when talking about the management of CRPS, and completely exiguous when referring to the 
management of pediatric CRPS.  
Nonetheless, the scientific consensus is that the cornerstone of the CRPS management should be the 
restoration of function. Acknowledged therapies include a combination of pharmacotherapy, physical 
therapies and psychotherapy where appropriate (Lee et al. 2002, Zernikow et al. 2012, Chopra and 
Cooper 2013, Borchers and Gershwin 2014). Several studies highlight that early mobilization of the 
affected limb assisted with cognitive behavioral techniques is the most important part of the management 
process in children (Lee et al. 2002, Wilder 2006). In our experience this is highly important but so is the 
use of medication and the early diagnosis of the disorder, which substantially influence the prognosis of 
the condition (Murray et al. 2000, Lee et al. 2002, Berde and Lebel 2005, Finniss et al. 2006). Low et al. 
showed that children who received a prompt diagnosis (less than 12 weeks), and therefore were offered 
treatment more rapidly achieved a quicker and more successful remission of CRPS when compared to 
those whose diagnosis was delayed (10.6 and 21.5 weeks)(Low, Ward, and Wines 2007b).  
Unfortunately a significant percentage of children who suffered CRPS do not respond to conservative 
treatments. Only those patients who do not improve successfully after being treated with a complete pain 
management plan during a reasonable time are candidates for invasive pain therapies (Rodríguez et al. 
2007). Unfortunately the evidence supporting the use of these procedures is weak. This review shows that 
the methodological quality of the existing data is low as most of the publications found are case series or 
case reports representing level IV evidence. On top of that a very low percentage of publications used the 
established diagnostic criteria for CRPS of the IASP. Additional negatives aspects of this group of 
publications are that validated outcomes tools were not used in most cases and that the follow up period 
were usually not reported or rather too short.  
Within the invasive techniques described in these publications, we must highlight the continuous epidural 
infusion and the SCS. They seems to have an important effectiveness and to be minimally invasive and 
reversible, besides in adults they have been shown to be very effective for certain forms of NP (Moufawad 
et al. 2002, Linderoth and Meyerson 2010, Dworkin et al. 2013). Olsson et al. concluded that the SCS was 
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successful for treating CRPS in all their pediatric patients (Olsson et al. 2012), however this conclusion 
can be questionable from our point of view as in one of the patients the symptoms ceased after the patient 
had not responded well to any stimulus of the SCS and other patient of the same series developed an 
infection which seriously compromised the treatment. Rodriguez et al. had a great experience with the 
SCS, abolishing the symptoms in 3 children with a well-defined history of uncontrollable CRPS (Rodríguez 
et al. 2007). This study together with the positive experience of Wilder et al. (Wilder 2006) encourage the 
need for a better understanding and use of SCS in CRPS. Likewise, the use of epidural catheter for the 
infusion of local anesthetics has been implemented deeply in the last years. The majority of publications 
agreed that the treatment importantly diminish the pain and improve functionality of the limb affected. 
Regrettably, very few of these publications described the process (the space where the catheter was 
implanted, the concentration, the dose, etc.), the outcome or the side effects if any.  
Side effects were infrequently reported. Infections only occurred in two patients and minor side effects 
were reported only in 10 studies. 16 of 83 reported cases experienced a relapse. From our perspective, 
based in our experience and the literature behind these procedures, we believe that the side effects in this 
collection are underreported.  
 
4. Recommendation 
Based upon the available evidence with regard to effect and complications, we recommend the following 
algorithm for the management of pediatric CRPS (Figure 1).  
A crucial first step for the management of this condition appropriately consists in making an accurate and 
early diagnosis. We strongly encourage basing the diagnosis in the CRPS criteria of the IASP (Harden et 
al. 2007), despite this set of criteria has been made for adults. The real goal of the physician must be the 
restoration of the normal function of the affected limb, using every possible management tool to achieve 
this. Initially, physical therapy, psychological support and adequate pharmacological treatment should be 
used together, complementing one another and aiming to make the condition resolve within a few weeks. 
Pharmacological measures are prescribed on a symptom-oriented basis. However, new approaches 
should be adopted when fitting within a mechanism-based management (Gierthmühlen et al. 2014). 
Analgesics, anti-inflammatory therapy, antidepressant and antiepileptic drugs have been used to date. 
However, new topical drugs such as the high-concentration capsaicin patch have been tried within the past 
few years with excellent results (Rodríguez et al. 2007).  
Based on our experience (Rodríguez et al. 2007), the heterogeneity found at the literature regarding the 
duration of the conservative management for treating CRPS together with the lack of knowledge of its 
precise pathophysiology, we recommend that after a reasonable time of 4 to 5 weeks under intensive 
multimodal therapy without successful results, more invasive options should be considered. Before failure 
of conservative management is taken as a reason to contemplate invasive measures as the following step, 
only high-quality conservative treatment should be implemented. Therefore, knowledge concerning such 
treatment needs to be increased. Patients with CRPS with severe pain, allodynia, or with a measurable 
skin temperature difference compared to the non-affected limb that do not respond to the multi-modal 
conservative management should be put forward for therapies such as spinal infusion of drugs, 
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Complex Regional Pain 
Syndrome 
3.- Pharmacological  Therapy 
Prominent Mechanism? 
3a.- Inflamation  
3b.-Pain / Sensory abnormalities 
3c.-Vasomotor Disorder 
3d.-Motor Disorder 
Start with:  
1.- Active Physical Therapy 
2.- Psychological Therapy 
Conservative management (1, 2 & 3) is adequately carried out 
without improvement (25 - 40 days) 
4.- Continuous spinal infusion 
(local anaesthetics) - 2w. 
5.- Spinal Cord Stimulation 
sympathetic blockades or SCS. In our opinion, after reviewing the literature on the topic, the initial option 
for children who do not respond successfully to conservative management is the continuous epidural  
 
Figure 1. Clinical algorithm for the management of pediatric CRPS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. The first crucial step is the correct and early diagnosis. Immediately after, a multimodal approach 
must be taken. Active physical therapy, psychological support and the correct pharmacological approach 
must be planned. Initially a sign and symptom oriented pharmacological treatment is engaged.  Patients 
who do not respond succesfully to the conservative management carried out during a period of 25 to 40 
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days will attempt with invasive techniques. First LA continuous epidural infusion for 2 weeks and then SCS 
can be recommended after multidisciplinary evaluation.  
 
infusion of local anesthetics (Rodríguez et al. 2007). This technique provides analgesia and sympathetic 
blockade throughout the time the catheter is attached. This is usually enough to control the condition and 
prevent the reappearance of symptoms (Rodríguez et al. 2007). We recommend its use for 10 to 14 days. 
Having the catheter more time could increase the risk of infection (Sethna et al. 2010) or further side 
effects secondary to the drug infusion or the catheter itself. However, this technique can fail or the 
symptoms can reemerge after the catheter is removed. In this case, SCS can be recommended after 
multidisciplinary evaluation and a successful trial stimulation. SCS is a minimally invasive and reversible 
technique that facilitates physical therapy and helps decrease medication (Olsson et al. 2012). 
 
 
6. Conclusion 
 
This article proposes a multidisciplinary management approach to the treatment of CRPS in children for 
whom the standard treatment has not been successful. Because of the severity and rapid progression of 
the symptoms in CRPS we consider that an early diagnosis of the condition together with comprehensive, 
and individualized multidisciplinary treatment offers children with CRPS the best opportunity for a complete 
recovery. Within this approach we encourage clinicians to consider invasive procedures as a reliable 
option of treatment. Unfortunately the type of technique that should be applied when high quality 
multimodal conservative treatment fails cannot yet be based on empirical data. Therefore, since the 
significant limitations of the evidence, interventional treatments for the management of CRPS in children 
should ideally be offered in clinical and research settings with experience and ability to understand and 
report the outcomes. This will make it possible to substantially improve the evidence on which forthcoming 
recommendations are established. 
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THESIS CONCLUSIONS 
 
Analysis in detail of the results obtained, we have drawn up the following conclusions: 
 
This work travel among different areas within one of the most disabling forms of chronic pain, Neuropathic 
Pain. NP following peripheral nerve injury is associated with hyperexcitability in damaged myelinated 
sensory axons. NP continues being fairly difficult to diagnose and treat nowadays as we do not fully 
understand the molecular mechanisms that cause it. 
 
After a sensory nerve is cut or otherwise damaged it becomes hyperactive and produces spontaneous 
electrical activity that the brain interprets as nociceptive signals. However, it is not fully understood how 
cutting a nerve affects the ion channels in a way that generates this hyperactivity. Different types of ion 
channel are found in different regions of the nerve cell. At the first part of this work we have investigated 
the composition and distribution of shaker-type-potassium channels (Kv1 channels) within the nodal 
complex of myelinated axons following injury. Soon after nerve damage occurred, at the neuroma that 
forms after damage, expression of Kv1.1 and 1.2 was markedly decreased. In contrast Kv1.4 and 1.6, 
which were hardly detectable in the naive state, showed increased expression within juxtaparanodes and 
paranodes following injury, both in rats and humans. At the same time, electrical activity in the cut nerve 
increased, and the recovering animals responded in ways that suggested they were hypersensitive to the 
nerve being touched. 
 
Three weeks after the injury, most rats lost their hypersensitivity and the electrical activity in the cut nerve 
returned to near-normal levels. It was also found that the recovering nerves contained new subtypes of 
type 1 potassium channels. These potassium channels did not just appear in the juxtaparanode: they also 
invaded the ‘fence’ region that normally separates potassium channels from sodium channels. The same 
was observed to happen in the nerves of patients that suffer from NP due to a nerve injury. 
 
At this late time point after nerve injury, blocking the activity of potassium channels produced the same 
abnormal increase in the nerve’s electrical activity as seen immediately after the nerve had been cut. The 
rats’ hypersensitivity to touch also returned. This suggests that changes in the molecular composition and 
distribution of axonal Kv1 channels, therefore represents a protective mechanism to suppress the 
hyperexcitability of myelinated sensory axons that follows nerve injury.  
 
At the second stage of this thesis we moved to the diagnostic area of NP. Here we investigated how in 
human studies the screening tools for diagnosing NP are able allocates patients into sensory profiles. 
More precisely, we analyse if the overall PDQ score or its items reflect phenotypes of sensory loss in NP 
as determined by QST.  
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The results obtained shows that the PDQ score is not sensitive enough to distinguish different types of 
sensory loss in patients with NP. While our results demonstrate that there is variability in the responses to 
four items between groups of people with various kind of QST-detected loss of sensation, they do not 
provide clear information on an individual patient basis. Therefore, we can conclude that PDQ is unable to 
clearly separate between patients with varying types of loss of sensation while loss of function can be 
detected for all sensory qualities in QST. Nevertheless, more complex analysis, identifying items that 
differentiate between types of sensory loss in a new battery of questions would be an interesting approach 
for a future study. Besides, enquiring about autonomic disorders, which commonly appear in patients with 
small fibre neuropathy would be helpful for the development of this and other specialized questionnaires in 
the detection of NP phenotypes. This may improve clinical practice in the treatment of NP outside 
specialized centres, as, at present, none of such screening tools are sensitive enough to document 
sensory loss. 
 
Finally, the third, and last part of this work focused its attention in the management of NP. Because NP 
does not only appear during adulthood, I decided to dedicate part of this study to NP in children, 
particularly to the invasive management of CRPS during childhood. Within this section we examined and 
analysed the data data currently existing in this issue. Furthermore, we suggest a management algorithm 
based in the evidence reviewed and our team experience, which has been also described and analyse as 
part of this thesis.  
The conclusion of our review is that invasive techniques have been used to treat CRPS over the last few 
decades; however, the evidence for their use is still very weak. Therefore, invasive management should be 
contemplated only when high standard conservative management has failed to work.  
 
Based on the existing literature and in our experience, described in chapter 3, we propose a 
multidisciplinary management approach to the treatment of CRPS in children for whom the standard 
treatment has not been successful. Because of the severity and rapid progression of the symptoms in 
CRPS, we recommend that an early diagnosis of the condition together with comprehensive and 
individualized multidisciplinary treatment offers children with CRPS the best opportunity for a complete 
recovery.  
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RESUMEN EN ESPAÑOL 
 
 
El dolor crónico (CHP) es uno de los problemas de salud más onerosos que enfrenta la sociedad actual; 
Su costo para los países occidentales es casi el mismo que para el costo del cáncer y la diabetes mellitus 
combinados (Vos et al., 2012). La investigación epidemiológica confiable sobre la PP proporciona 
información clave sobre la prevalencia y los factores relacionados con su génesis y perpetuación. Mejorar 
nuestra comprensión de los detalles que rodean la enfermedad mejorará el manejo clínico, limitando la 
gravedad y minimizando la discapacidad. Existen hipótesis fundadas de que las estimaciones recientes de 
la carga global de la enfermedad han subestimado la contribución de ChP (Smith et al., 2007, Shmagel et 
al., 2016). La Organización Mundial de la Salud (OMS) y otros investigadores pronostican que para el 
2030 los cuatro principales responsables de la carga global de la enfermedad serán las enfermedades 
coronarias, los accidentes de tráfico, la depresión y las enfermedades cerebrovasculares (Vos et al 2015). 
Como era de esperar, el ChP es una comorbilidad importante vinculada a todos ellos; Sin embargo, ChP 
es mucho más que una simple comorbilidad de otra lesión o enfermedad. ChP se reconoce hasta la fecha 
como una condición por derecho propio (Merskey 1994, Tracey y Bushnell 2009, Treede et al., 2015). 
Aproximadamente una quinta parte de la población europea adulta sufre de ChP (Breivik et al., 2006) y, 
además de la carga física y emocional que esto trae, el costo monetario para la sociedad es enorme, 
estimado actualmente más de 200.000 millones de euros por año en Europa y mas de 150 millones por 
año en los Estados Unidos (Tracey and Bushnell 2009). 
Nuestra comprensión de la fisiopatología de ChP ha aumentado sustancialmente en los últimos 20 años, 
incluyendo de la periferia al cerebro (Dubin y Patapoutian 2010, Baron et al., 2012). No obstante, todavía 
no entendemos por qué el CHP se desarrolla en algunas personas y no en otras, pero sabemos que la 
magnitud o el tipo de lesión, las características psicosociales, las creencias religiosas, la ocupación, el 
nivel educativo, la raza o el código postal no son predictores confiables. 2010). La investigación extensa 
en la genética de ChP también no ha podido predecir el inicio de la enfermedad, posiblemente debido a la 
gran cantidad de genes implicados ya los resultados contradictorios de la investigación (Diatchenko y 
otros 2007, Møller y Jensen 2010). El tratamiento de ChP es generalmente una tarea tediosa y compleja, 
donde el especialista del dolor y el paciente deben crear una relación fuerte y genuina. Parece que, a 
pesar del gran progreso en múltiples campos, poco se ha hecho (White et al., 2011, Rajapakse et al., 
2014, Moulin et al., 2015). 
Dentro de la imagen evolutiva la activación de cualquier tipo de nociceptor especializados como el alto 
umbral mecanorreceptores tienen un papel protector, actuando como un sistema de advertencia para las 
señales amenazantes. Sin embargo, mientras que el dolor inflamatorio es adaptativo, la evolución no ha 
tenido éxito en explicar nuestra mayor capacidad para sobrevivir a enfermedades, traumatismos o 
agresiones iatrogénicas destinadas a extender o mejorar la calidad de vida. En tales ambientes, el dolor 
ya no es una característica útil, sino que se convierte en la enfermedad misma. Sin embargo, es natural 
pensar en el dolor como una entidad homogénea, esto es demasiado simplista. De hecho, existen 
diferentes tipos de dolor, cada uno con diversos mecanismos fisiopatológicos y neurobiológicos. La 
clasificación más reconocida divide el dolor en dos tipos principales: dolor nociceptivo y neuropático; Sin 
embargo esta clasificación es otra vez más simplista. Por lo tanto, recientemente la nueva categoría de 
DCI para "Dolor crónico" trató de incluir y dividir los trastornos clínicamente más relevantes, los cuales se 
dividieron en 7 grupos: dolor crónico primario, dolor crónico de cáncer, crónica crónica (5) dolor de cabeza 
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crónico y dolor orofacial, (6) dolor visceral crónico y (7) dolor crónico osteomuscular, esta división es 
importante porque no sólo indica la etología y la neurobiología Sino también el tratamiento puntual El 
dolor nociceptivo puede clasificarse como visceral o somático (Treede et al., 2015). 
El dolor neuropático se define como el dolor resultante de una lesión o disfunción del sistema 
somatosensorial (Treede et al., 2008), por lo que el daño tisular afecta directamente al sistema nervioso, 
dando lugar a la generación de descargas ectópicas que puentean la transducción Et al., 2010). NP es 
ampliamente identificado como uno de los síndromes de dolor más complicados de manejar, y los 
resultados son a menudo decepcionantes. Esto se debe en parte a que la contribución de la neuropatía al 
dolor que se presenta en la atención primaria puede no ser reconocida (Rodríguez et al., 2007, Leadley et 
al., 2012) y hay evidencia de un uso de fármacos subóptimo en el tratamiento de NP (Smith et al., 2007, 
Jongen et al., 2013, Helfert et al., 2014). La investigación epidemiológica en el campo de NP es 
problemática y las razones son diversas: la falta de una definición de caso legítimo que realmente indique 
la (s) condición (es) bajo consideración y que sea factible utilizar en estudios poblacionales; La calidad 
heterogénea de los estudios, el uso de medios inconsistentes de verificación de casos y los criterios de 
inclusión o exclusión en los que el dolor no es la principal queja (Torrance et al. 2006, Smith, Macfarlane, 
et al. 2007, Smith et al. 2012, van Hecke et al. 2013). Los cálculos existentes de la prevalencia general de 
la población difieren ampliamente, y es plausible que la gente experimente síntomas neuropáticos en 
mayor medida de lo que se ha diagnosticado con una afección neuropática relacionada con el dolor 
(Torrance et al 2006, Freynhagen y Baron 2009). Los estudios epidemiológicos de NP son de gran valor 
para decidir las necesidades de recursos (educativas, económicas y clínicas) en la atención primaria y en 
los centros hospitalarios, e informar sobre las estrategias de prevención y la orientación de la gestión. A 
medida que las herramientas de cribado validadas para identificar NP se han desarrollado (Torrance et 
al., 2006, Bennett et al., 2007, Haanpää et al., 2011, Mick y otros, 2014), estos han permitido estudios 
epidemiológicos basados en cuestionarios y hay una creciente Cuerpo de literatura que investiga la 
epidemiología de NP síntomas y condiciones en la sociedad. Hasta la fecha, la estimación más fina de la 
prevalencia de la población de dolor con características neuropáticas es probable que se sitúe entre 7% y 
10% (van Hecke et al., 2014). 
NP se caracteriza por síntomas positivos y negativos que abarcan dolor, hipoestesia al tacto, hormigueo, 
descargas eléctricas y pasadores y agujas (Woolf y Mannion 1999). Varios estímulos nerviosos 
perjudiciales en el sistema nervioso central o periférico pueden conducir a NP, aunque las características 
clínicas del dolor pueden ser similares a través de los diferentes síndromes neuropáticos y etiologías 
(Freeman et al., 2013). Aunque muchas formas de dolor nociceptivo, y algunas formas de dolor 
neuropático, pueden conferir beneficios evolutivos, NP crónica es en todo momento maladaptativa. Los 
enfermos de NP manifiestan regularmente percepciones sensoriales paradójicas acompañadas de dolor 
como un síntoma primordial positivo combinado con sensaciones degradadas inducidas y degradadas. 
Estas sensaciones son típicamente muy únicas y no se han sentido previamente por los pacientes. Esta 
combinación de signos de hiposensibilidad e hipersensibilidad no es inusual en trastornos neurológicos; 
Por ejemplo, cuando aparece espasticidad después de la lesión de la médula espinal o cuando se 
desarrolla temblor parkinsoniano después de la degradación de la sustancia negra. Sin embargo, 
comparado con estas interrupciones motrices, el dolor como síntoma sensorial subjetivo es difícil de medir 
y abarca no sólo características físicas, sino también atributos psicológicos y emocionales (Gustin et al. 
2015, Thacker 2015). Las anomalías sensoriales distintivas son hallazgos clave para diagnosticar y 
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clasificar NP apropiadamente, y para diferenciar esto de otros patrones de dolor. Los principales retos en 
el desarrollo de un enfoque holístico orientado a la gestión de PN abarcan un diagnóstico adecuado de la 
etiología y los mecanismos por debajo, el reconocimiento del tipo de dolor y la evaluación de su patrón y 
su perfil sensorial y la determinación del tratamiento adecuado. 
Dolor Neuropático (DN) abarca, o acompaña, a una amplia variedad de patologías ligadas con 
enfermedad o lesión del sistema somatosensorial a nivel central o periférico, oscilando su prevalecía en la 
población general en torno al 7-10%.  En la actualidad la mayor parte del conocimiento que tenemos de 
los mecanismos subyacentes al origen y desarrollo del DN han sido obtenidos de estudios en ciencias 
básicas. Los obvios problemas que surgen de la traslación en investigación médica revelan las 
importantes limitaciones de ciertos modelos experimentales, y desde esa línea se originan esenciales 
limitaciones para la investigación clínica. A pesar de estas dificultades, la comunidad científica escruta sin 
cesar nuevas y mejores ideas que nos ayuden a entender mejor la patofisiología del dolor basándose 
fundamentalmente en nuevos descubrimientos en el campo de las ciencias básicas. 
Hasta la fecha, tanto los datos básicos como los humanos sugieren que una lesión de vías aferentes es 
necesaria para el desarrollo de NP. Además, numerosos estudios demuestran que no uno sino varios 
mecanismos pueden inducir a NP. Significativamente, un gran número de estos mecanismos no se basan 
en la causa de la enfermedad, el mismo mecanismo puede ser detectado en diferentes condiciones. En 
un solo paciente, varios mecanismos pueden estar implicados y diversos mecanismos podrían ser el 
origen del mismo síntoma. Esto no sólo evidencia la complejidad de NP, sino que también subraya la 
importancia clínica de identificar mecanismos de dolor subyacentes en cada paciente. Debido a que se 
requieren diferentes planes de manejo para diferentes mecanismos de dolor, un enfoque de tratamiento 
basado en mecanismos puede guiar a los médicos para obtener mejores resultados. 
Uno de los principales problemas en el manejo de estos síndromes es el hecho de que los tratamientos se 
aplican de manera uniforme cualquiera que sea el cuadro clínico, mientras que estos estados 
neuropáticos son de hecho muy heterogéneos. En los últimos años se han realizado importantes avances 
clínicos en este campo, tras la validación de nuevas herramientas clínicas y la estandarización de 
paradigmas de perfil sensorial, permiten mejorar la caracterización clínica de estas condiciones. 
Numerosos estudios han demostrado que la NP es una entidad clínica consistente, pero es 
multidimensional en cuanto a su expresión clínica, con perfiles sensoriales disímiles, potencialmente 
indicativos de mecanismos fisiopatológicos particulares. Este nuevo concepto de NP debe perfeccionar la 
caracterización de los perfiles de los pacientes en los ensayos clínicos y poner a disposición los datos 
esenciales para el desarrollo de nuevos y clínicamente más sólidos enfoques traslacionales. 
Una ruta para avanzar en esta etapa en los contextos clínicos de investigación es la hipótesis de que los 
mecanismos del dolor se pueden deducir mediante el estudio de los síntomas individuales y patrones de 
signos con los métodos mencionados anteriormente. Al estudiar el efecto del tratamiento que se dirige a 
estos mecanismos propuestos, el concepto de tratamiento basado en mecanismos puede ser validado. 
Este enfoque permitirá diseñar estudios clínicos más centrados en un mecanismo de síntomas 
relacionados y el tratamiento de los signos en lugar de los ensayos basados en la etiología. Hasta el 
momento, los datos actuales contribuyen a comprender los vínculos entre al menos algunos síntomas 
clínicos y los mecanismos subyacentes sugeridos, sin embargo, todavía hay un largo camino para 
caminar en este campo. La segunda parte de esta tesis pretende establecer o aclarar algunos vínculos 
entre la TVQ y los síntomas clínicos manifestados por los pacientes con NP. 
Spanish Summary / Resumen en español 
 144 
NP es también un tema importante durante la infancia y durante la adolescencia, sin embargo, muchas de 
las etiologías subyacentes en las que ocurre son infrecuentes o nunca se encuentran en niños. Sin 
embargo, se han descrito hasta la fecha varias causas de NP, incluyendo lesión traumática, enfermedad 
neurológica y metabólica, disfunción hereditaria del nervio sensorial y CRPS. La evidencia en estudios 
básicos y clínicos de NP ha revelado diferencias significativas relacionadas con la edad en la 
presentación clínica y el pronóstico. Clínicamente, el diagnóstico, la evaluación y el tratamiento de NP en 
niños se basan en métodos, experiencia y evidencia adquirida a partir de datos en adultos. Por lo tanto, y 
debido a la complejidad cuando se establecen ensayos clínicos con niños, es especialmente importante 
aumentar los datos disponibles en los niños compartiendo todas las experiencias que pueden ayudar a los 
médicos a mejorar el conocimiento cuando manejan estados neuropáticos durante la infancia. La tercera y 
última parte de este trabajo, centra su atención en la gestión de NP en los niños; Particularmente en el 
manejo invasivo de la CRPS. 
El tratamiento de la NP sigue siendo un gran desafío, porque un gran número de pacientes no 
experimentan suficiente alivio del dolor, como se deduce de los resultados de los ensayos clínicos y de la 
experiencia clínica. Esta complejidad en el tratamiento podría ser consecuencia de la heterogeneidad de 
los mecanismos fisiopatológicos de NP y las facetas emocional y psicológica comúnmente coexistentes 
de ChP. En primer lugar, un diagnóstico riguroso puede revelar la fuente del dolor. Por lo tanto, un 
adecuado manejo del  mismo puede resultar en alivio parcial o total del dolor. Cuando se comienza el 
tratamiento sintomático, la educación de los pacientes, la inclusión de información sobre NP, el plan de 
manejo y los efectos secundarios factibles de cualquier tratamiento -farmacológico o no farmacológico- 
son indispensables para aumentar el cumplimiento por parte del paciente. Para evitar las expectativas 
poco realistas de los enfermos de NP sobre la tolerabilidad y la eficacia, los objetivos de gestión realistas 
deben ser determinados. El agotamiento del dolor de por lo menos el 25% es generalmente bienvenido 
para ser un resultado clínicamente significativo (Attal 2011). Además del dolor, tanto la calidad de vida 
relacionada con la salud como la alteración del sueño deben evaluarse al evaluar la eficacia analgésica 
(Smith et al., 2007, Gustorff et al., 2008). 
Además, la ansiedad y la depresión coexistentes pueden obstaculizar el manejo exitoso del dolor y deben 
ser reconocidas y dirigidas para un tratamiento específico (Maletic y Raison 2009, Brod et al., 2014). En 
contextos clínicos, esta complejidad se tiene en cuenta mediante un enfoque terapéutico multimodal, que 
incluye opciones de manejo farmacológico y no farmacológico, tales como terapia física, intervenciones 
psicológicas como conducta cognitiva y terapia ocupacional (Kerns et al., 2010, Kozma et al 2014, 
Casanova-García et al., 2015). A pesar de que la eficacia de este punto de vista biopsicosocial multimodal 
se ha informado rutinariamente en condiciones de ChP distintas de NP, su fortaleza en pacientes con NP 
es bien aceptada (Garven et al., 2011). En aquellos que desarrollan dolor de miembro fantasma y CRPS, 
se ha demostrado que los tratamientos no farmacológicos como la terapia cognitivo-conductual y la 
terapia ocupacional, así como los nuevos métodos, como la imagen de motor graduada (incluida la terapia 
de espejo), reducen el dolor y mejoran la funcionalidad (Katholi Et al., 2014, Simons 2016). Del mismo 
modo, los tratamientos invasivos han sido reportados como métodos útiles en estados neuropáticos 
cuando se usan adecuadamente (Slavin 2008, Pereira y Aziz 2014). 
Terapia basada en el mecanismo. Las condiciones de ChP son estados heterogéneos con un gran 
número de características genéticas, fisiopatológicas y psicosociales, las cuales son caprichosamente 
expresadas en cada persona. Como resultado, los enfoques científicos y clínicos actuales deben estudiar 
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los diferentes elementos subyacentes lo más detallados posible, con el objetivo de adaptar la gestión al 
paciente único, una estrategia que se denomina medicamento para el dolor personalizado. NP se sugirió 
en el que los síndromes de dolor se agrupan sobre la base de los mecanismos fisiopatológicos 
subyacentes de la causación del dolor en lugar de en la causa de la enfermedad (Woolf et al., 1998). La 
idea que apoyaba esto era que podría ser factible y más apropiado conducir tratamientos específicos 
hacia condiciones específicas que miran su procesamiento nociceptivo particular.  
La comprensión actual sobre los mecanismos del dolor ha crecido excepcionalmente en los últimos años, 
quedando claro que numerosos mecanismos tanto en el sistema nervioso central o periférico actúan solos 
o en combinación en una sola persona. Como una condición necesaria para transferir la idea de 
tratamiento basado en mecanismos a la práctica clínica, es esencial desarrollar instrumentos de 
diagnóstico que contribuyan a determinar los mecanismos del dolor en los pacientes ya agrupar a los 
individuos en consecuencia. Hasta ahora, no hay biomarcadores de los mecanismos del dolor, por esa 
razón, los clínicos tienen que confiar en los marcadores de sustitución que se cree que son iguales a los 
mecanismos de generación de dolor. Una estrategia potencial para subgrupos de pacientes es emplear el 
perfil de los síntomas sensoriales y las características del dolor, el denominado fenotipo sensorial, como 
una medida de las anomalías en las vías de procesamiento del dolor. Tanto las pruebas científicas de 
animales como las humanas apoyan este enfoque en NP. Está claro ahora que la lesión nerviosa provoca 
multitud de cambios moleculares y funcionales en cada constituyente de la vía nociceptiva. Como 
resultado, las fibras nociceptivas desarrollan sensibilidad irregular y actividad espontánea. 
Presumiblemente, estos cambios en el sistema nervioso del paciente conducen a la percepción de 
sensaciones de dolor de disparo, dolor espontáneo, además de hiperalgesia térmica. Después de 
anomalías somatosensoriales adicionales, periféricas y centrales, puede ocurrir el desarrollo de un perfil 
somatosensorial único y distintivo para cada individuo. 
Con el fin de validar la idea de tratamiento basado en mecanismos, tiene que demostrarse que los grupos 
de personas con un fenotipo sensorial específico realmente responden de manera diferente a un 
tratamiento determinado. Hasta la fecha, los ensayos clínicos diseñados prospectivamente que se han 
llevado a cabo utilizando el método de fenotipificación sensorial como un criterio de estratificación y el 
análisis de respuesta retrospectiva utilizando el fenotipado sensorial de los pacientes con NP al inicio del 
ensayo son muy prometedores (Herrmann et al., 2006, Baron et al. 2012, Yarnitsky y otros, 2012, 
Martínez y otros, 2013, Cruz Almeida y Fillingim 2014, Höper et al., 2014, Mainka et al., 2016). Sin 
embargo, esta técnica debe ser implementada en los siguientes diseños de estudios para eventualmente 
validar el concepto de tratamiento basado en mecanismos. Además, se deben desarrollar técnicas de 
evaluación más sencillas para identificar con fiabilidad los subgrupos de pacientes con NP en la práctica 
clínica general. 
 
Tratamiento farmacológico para el dolor neuropático.  
Durante la última década, se han sugerido varias recomendaciones para la farmacoterapia de NP o 
ciertas condiciones NP, especialmente neuralgia post-herpética y neuropatías diabéticas dolorosas 
(Finnerup et al., 2015, Dworkin et al., 2007, Attal et al. 2010, Bril et al., 2011). Al mismo tiempo, se han 
desarrollado nuevas terapias farmacológicas y se han completado ensayos clínicos de alto nivel. Además, 
se ha reducido el riesgo de sesgo en los datos de recopilación, análisis y notificación debido al análisis del 
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sesgo de publicación, junto con la identificación más fácil en línea de los estudios farmacológicos no 
revelados o no publicados. Se ha demostrado que los diferentes tipos de medicamentos con efectos 
analgésicos funcionan mejor que el placebo en ensayos clínicos incluyendo pacientes con diversas 
condiciones de NP que cubren opiáceos, anestésicos locales, antagonistas de receptores NMDA, 
cannabinoides, antidepresivos, anticonvulsivos, toxina botulínica, capsaicina tópica y varios otros 
(Finnerup et al., 2015). 
Muchos de estos fármacos se desarrollaron inicialmente para otras indicaciones, como la epilepsia o la 
depresión, y posteriormente se evaluaron en NP. El metanálisis y las revisiones sistemáticas de los 
ensayos de NP y el desarrollo de guías de manejo por varias asociaciones y sociedades han llevado a las 
recomendaciones actuales para la gabapentina, la pregabalina, los antidepresivos tricíclicos y los 
antidepresivos de la recaptación de serotonina-norepinefrina (SNRI) como terapias de primera línea; 
Recomendaciones débiles para parches de lidocaína, parches de capsaicina de alta concentración, 
opioides, toxina botulínica A y combinaciones de agentes de primera línea seleccionados; Y 
recomendaciones débiles contra el uso de cannabinoides y valproato (Finnerup et al., 2015). Parece claro 
entonces que la matriz de medicamentos, y otras intervenciones de tratamiento, con eficacia demostrada 
en NP se está expandiendo. Por lo tanto, la investigación futura no sólo debe definir el mejor uso de los 
medicamentos existentes solo y en asociación, sino que también debe determinar los medicamentos que 
aumentan la magnitud del alivio del dolor o la probabilidad de una respuesta beneficiosa. 
 
Terapia Invasiva para el Dolor Neuropático.  
Los pacientes con NP con frecuencia no responden lo suficiente a la medicación usada sola o en 
combinación con tratamientos no farmacológicos y su dolor es usualmente como resultado refractario 
(Smith et al., 2012). En lugar de continuar la rotación farmacológica interminable que no ofrece la 
reducción del dolor deseada o los efectos secundarios indeseables de origen, los tratamientos 
intervencionistas pueden ser contemplados. Las técnicas de manejo del dolor intervencionistas abarcan el 
bloqueo neural, la estimulación de la médula espinal, la medicación intratecal y las intervenciones 
neuroquirúrgicas (Día 2008, Dworkin et al., 2013, Pereira y Aziz 2014). Una revisión sistemática 
actualizada analizó la eficacia de varias técnicas invasivas en varias condiciones de dolor neuropático, 
tales como neuralgia post-herpética, dolor neuropático de la lesión medular y dolor de postrada central, 
neuropatías diabéticas dolorosas y otras neuropatías periféricas, radiculopatía y síndrome de cirugía de 
espalda fallida, Neuralgia del trigémino y neuropatía trigeminal y CRPS (Dworkin et al., 2013). 
Este estudio concluyó que las pruebas para la efectividad de las técnicas intervencionistas en NP son 
limitadas. Se demostró que casi la mitad de los pacientes obtener alivio parcial duradera del dolor, incluso 
un número menor de aquellos cuyo alivio fue completa. Sin embargo, es importante resaltar que la 
evaluación cuidadosa de las opciones de dolor intervencionista y quirúrgico está plagada de numerosos 
riesgos de sesgo asociados al obstáculo ético y práctico al cegamiento del tratamiento y al empleo de una 
falsificación óptima u otras intervenciones de control; Estudiar los abandonos de los pacientes atribuibles 
a la intratable o severidad ya los individuos tratados; Y la logística y los costos de seguimiento y duración 
del estudio. Además, debe recordarse que el déficit relativo de evidencia de eficacia no obligatoria indica 
evidencia de falta de eficacia y por lo tanto, el manejo racional de la intervención de los estados NP debe 
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ser contemplado como un componente integral de un enfoque más amplio que abarca farmacológico y no 
farmacológico y no intervencionista. 
 
El enfoque multimodal y las terapias no farmacológicas.  
Ningún tratamiento farmacológico o de intervención suprime totalmente los síntomas de NP. Un enfoque 
de gestión completo implica preferentemente el uso de estrategias de tratamiento adicionales en un 
esfuerzo por mejorar la situación. Los objetivos de cualquier terapia de dolor incluyen no sólo mejorar los 
síntomas, sino también recuperar la función física, reducir la angustia psicológica, y mejorar la calidad de 
vida en general. Es necesario que los clínicos luego aclaren estos objetivos a los pacientes, establezcan 
las expectativas apropiadas para el alivio del dolor, e involucren a los individuos como actores activos en 
su manejo. Además, el médico debe comprender los beneficios de la gestión multidisciplinaria, facilitando 
la participación activa en este enfoque multifacético. Se ha demostrado que las personas tratadas en 
centros de dolor multidisciplinarios redujeron la intensidad del dolor más rápidamente, redujeron el uso de 
opioides y mejoraron la calidad de vida relacionada con la salud en comparación con los pacientes 
tratados por médicos generales incluso cuando se adhieren a un plan de control del dolor delineado por 
un especialista en dolor (Becker et al., 2000). Neurología, psicología, fisioterapia, terapia ocupacional y 
apoyo social contribuyen al resultado final de los pacientes con ChP. 
Asistir al componente psicológico del NP crónico es crucial para el éxito. Los clínicos pueden apoyar a los 
pacientes muy fácilmente, simplemente centrándose en la funcionalidad y el compromiso normal en las 
actividades. El catastrófico del dolor, es un predictor bien conocido de la mala respuesta a la 
farmacoterapia y una mayor probabilidad de interrupción del tratamiento; Catastrófica también predice 
duración más extensa del dolor, mayor grado de discapacidad y peor calidad de vida (Smeets et al., 2006, 
Toth et al., 2014). La terapia cognitivo-conductual aborda directamente este comportamiento 
desadaptativo, ayudando a los pacientes a refinar las emociones y los pensamientos a través de la 
educación y el entrenamiento en habilidades de afrontamiento y / o confrontación consciente de 
comportamientos y pensamientos dañinos (Turk 2003, Nijs y otros, 2014). Este tipo de enfoque 
psicológico ha demostrado proporcionar un beneficio en los pacientes NP no sólo la reducción de la 
intensidad del dolor, sino también proporcionar una mejora duradera en la funcionalidad, la afrontamiento, 
el dolor relacionado con el comportamiento, la ansiedad y la participación de los pacientes que sufren de 
dolor neuropático crónica Et al., 2003, Heutink et al., 2014). Además, la intervención psicológica está 
siendo mejorada por la presencia de un apoyo social adecuado. Por esa razón, las terapias de grupo de 
apoyo se han adoptado en el manejo del dolor, facilitando el compromiso del paciente en la estrategia de 
manejo, permitiendo a los pacientes compartir técnicas de afrontamiento y proporcionar un ambiente de 
apoyo para el refuerzo positivo. Otros programas de bienestar psicoeducativo que aumentan la conciencia 
de los factores sociales, intelectuales, emocionales y espirituales también son eficaces para mejorar la 
calidad de vida general y el bienestar de los individuos con dolor (Subramaniam et al., 1999, McGuire y 
otros, 2015). 
NP, como se mencionó anteriormente, por lo general conduce a reducir la actividad física y funcionalidad. 
El tratamiento eficaz debe dirigirse tanto a la mejora de los síntomas como a la restauración y 
movilización funcional. Un enfoque multidisciplinario de cualquier condición NP es importante; Por 
ejemplo, en la neuropatía diabética recuperar la movilidad y la funcionalidad es crucial para evitar las 
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úlceras, contracturas y pérdida de sensibilidad. Además, el entrenamiento físico en estos pacientes 
mejoró las limitaciones funcionales percibidas, la fuerza muscular y la regulación de la glucosa en la 
sangre (Otterman et al., 2011). Otras modalidades físicas como la estimulación nerviosa eléctrica 
transcutánea o el uso de técnicas osteopáticas pueden ser aplicadas para mejorar la NP crónica (Kumar y 
Marshall 1997, Kuchera 2007, Arienti et al., 2011). La fisioterapia para la restauración funcional también 
es comúnmente aceptada como uno de los pilares en el manejo de CRPS (Zernikow et al., 2012). 
 
Dolor neuropático en los niños 
El CHP afecta aproximadamente al 6% de los niños y adolescentes (van Dijk et al., 2006). El porcentaje 
de estos niños que desarrollan NP es desconocido. Algunas personas sugieren que la prevalencia de ChP 
con características neuropáticas en la edad adulta es similar a la encontrada en niños (5% -10%) 
(Torrance et al., 2006, van Hecke et al., 2014). Sin embargo, la evidencia actual indica que a pesar del 
hecho de que NP se ve en una parte notable de referencias a clínicas pediátricas de ChP, la prevalencia 
es mucho más baja (Martin et al., 2010, Borsook 2012) y las condiciones con las que está vinculada 
varían de aquellas Generalmente descrito en la edad adulta. 
Las causas aceptadas de NP durante la niñez abarcan desde situaciones en las que se han producido 
daños en los nervios, por ejemplo, dolor post-traumático, de miembro fantasma, post-quimioterapia y en 
algunos estados crónicos o infecciones como VIH / SIDA a condiciones genéticas que afectan la función 
nerviosa sensorial, Y la eritromelalgia (Ramaswami 2008, Fischer y Waxman 2010, Walco et al., 2010). 
CRPS es una condición idiopática importante que ocurre en niños y adultos que generalmente se cree 
que se caracteriza por NP. 
Así se ha detectado evidencia de NP en la infancia, siendo neuropatía y disfunción del nervio sensorial 
características principales de la mayoría de las afecciones neuropáticas. Sin embargo, es evidente a partir 
de nuestro conocimiento actual de la prevalencia y el pronóstico que hay diferencias significativas en la 
respuesta sensorial a la lesión nerviosa y los daños del SNC que parecen estar fuertemente relacionados 
con la edad de desarrollo. A modo de ilustración, varios ensayos clínicos en animales han estudiado los 
efectos de diversos tipos de lesión nerviosa en diferentes condiciones de NP y edades de desarrollo, 
mostrando cómo los mecanismos que operan en NP infantil pueden variar de aquellos en edad avanzada. 
Los modelos de laboratorio de lesión traumática del nervio periférico han confirmado una susceptibilidad 
disminuida a NP si el daño aparece en una edad más joven; Además, estos hallazgos se han utilizado 
para mejorar la comprensión de los cambios relacionados con la edad en la fisiopatología de NP (Howard 
et al., 2005, Walker et al., 2009). Del mismo modo, la literatura actual sugiere que los síntomas de NP en 
la infancia son generalmente menos frecuentes y su gravedad se relaciona con la causa subyacente, la 
edad de inicio o la duración de la enfermedad (Vogel y otros 2002, Atherton et al., 2008). 
Las recomendaciones actuales para la evaluación y diagnóstico de NP están configuradas para adultos, 
sin embargo, generalmente se extrapolan a niños o adolescentes. Como no hay pruebas definidas de 
biomarcadores para NP el diagnóstico se hace sobre la base de indicadores clínicos que es un tema bien 
conocido de la evaluación del dolor en niños pequeños. La historia clínica sigue siendo en la infancia la 
pieza central del diagnóstico; Sin embargo, los niños pueden emplear descriptores cualitativos que se 
consideran indicativos de NP, tales como disparos, radiación, ardor, pinchazos, hormigueo, 
electrochoque, apuñalamiento, pinchazos y pinzamiento (Krane y Heller, 1995, Walco Et al., 2010). 
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Obviamente, muchos niños pueden no ser capaces de describir su dolor usando estos términos, pero en 
cualquier caso el historial del dolor debe contener la evaluación de la intensidad, la calidad, los aspectos 
temporales del dolor y la respuesta al tratamiento (Haanpää et al. Preferiblemente, todas estas 
características -pero lo más importante, la intensidad del dolor- deben ser evaluadas usando una escala 
validada; Desafortunadamente, las escalas observacionales se han diseñado principalmente para 
aplicarse en los ajustes de dolor agudo en adultos y pueden no ser confiables. 
Al igual que en los adultos, la evaluación física debe apuntar a identificar, confirmar y localizar el daño del 
sistema somatosensorial e informar cualquier signo neurológico asociado. Las anomalías sensoriales son 
más complicadas de adquirir en los niños por muchas razones, como la comunicación o la falta de datos 
previos. Por ejemplo, métodos confiables como la QST evalúan los patrones de cambio en asociación con 
NP en adultos, además de que es muy importante establecer una buena comunicación entre el paciente y 
el investigador, ambos rasgos que usualmente disminuyen al evaluar a un niño. La micrononeurografía, la 
imagen cerebral funcional, la electroneuromiografía y la biopsia cutánea pueden estar indicadas, aunque 
nuevamente su uso se limita principalmente a la investigación (Lebel et al., 2008). Además, la evaluación 
de la discapacidad relacionada con el dolor, el sueño, la calidad de vida, el funcionamiento del papel y el 
estado de ánimo deben ser evaluaciones habituales para los niños que sufren de NP. 
Eltratamineto de la NP en las edades jóvenes es aún más difícil y refractario que en los adultos. Como se 
mencionó anteriormente, el NP crónico en raras ocasiones responde aceptablemente a una sola 
medicación analgésica o estrategia de manejo del dolor. La mayoría de los estados de dolor están 
altamente modulados por la actividad en el SNC-cerebro y médula espinal, que a su vez están afectados 
por factores cognitivos y emocionales y por lo tanto un abordaje multimodal basado en un modelo de dolor 
biopsicosocial siempre puede ser contratado. Por lo tanto, es probable que los avances en el manejo de 
PN sean consecuencia de una mejor comprensión de los mecanismos heterogéneos implicados en 
diferentes etapas de desarrollo, mejoras en la precisión del diagnóstico clínico y un enfoque documentado 
mucho más sistemático y cauteloso de la terapia. El manejo correcto debe abarcar ciertos fármacos 
analgésicos idealmente elegidos sobre la base de los mecanismos de dolor que se cree que están 
implicados y una gama de estrategias de manejo del dolor adecuadas para la evaluación clínica del dolor 
y cualquier deterioro funcional relacionado. La farmacoterapia en NP suele ser empírica y decepcionante, 
ya que el mecanismo subyacente particular rara vez se entiende completamente. Aun así, es razonable 
un enfoque general basado en una evaluación de los beneficios previsibles balanceada. 
 
Condiciones especiales. CRPS 
El síndrome de dolor regional complejo (CRPS) es un término acuñado por la Asociación Internacional 
para el Estudio del Dolor (IASP) para designar estados caracterizados por dolor espontáneo o inducido 
por estímulo que es desproporcionado con el evento incitante y asociado con una amplia variedad de 
Motora y autonómica en combinaciones muy variables (Harden et al., 2007). La evidencia apunta a que la 
etiología del CRPS es un trastorno multifactorial que está asociado con una respuesta aberrante del 
huésped a la lesión tisular. La variación en la susceptibilidad a la regulación perturbada de cualquiera de 
las vías biológicas subyacentes probablemente explica la heterogeneidad clínica del CRPS (Marinus et 
al., 2011). Existen muchos aspectos fisiopatológicos etiológicos que se han acusado en el desarrollo de la 
CRPS, sin embargo se han identificado tres vías fisiopatológicas principales: mecanismos inflamatorios 
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aberrantes, disfunción vasomotora y neuroplasticidad maladaptativa. Además, parece claro que las 
diferencias interindividuales en la medida en que estos mecanismos están afectados explican la 
heterogeneidad clínica del trastorno (Bruehl 2010). 
Este síndrome está lleno de incertidumbre y comúnmente inexacta. No existen pautas totalmente 
aceptadas que puedan utilizarse para el diagnóstico y llenarán las definiciones de la medicina basada en 
la evidencia. De hecho, hay casi tantos criterios de diagnóstico como hay denominaciones a esta 
condición. El término paraguas CRPS puede separarse actualmente en tipos I y II. CRPS I pretende 
abarcar la distrofia simpática anteriormente conocida y trastornos similares sin una lesión nerviosa; 
Mientras que CRPS II se produce después de un daño a un nervio periférico (Harden et al., 2007, 
Borchers y Gershwin 2014). Hasta la fecha, la cantidad de ensayos que han incluido controles apropiados 
y tienen un número suficiente de participantes para permitir el análisis estadístico con cálculos de 
potencia aceptables es menor.  
Esto tiene como resultado un diagnóstico excesivo y, a menudo, el uso de una farmacoterapia excesiva e 
incluso intervenciones quirúrgicas innecesarias (Maihöfner et al., 2010). 
En la última década también se ha convertido en una entidad bien establecida en niños y adolescentes, 
aunque con problemas similares a los adultos (Berde y Lebel 2005). CRPS sigue siendo probablemente 
diagnosticado y no distinguir CRPS lleva a retraso en el manejo, las pruebas diagnósticas innecesarias y 
el tratamiento inadecuado, lo que puede empeorar la situación y agravar el sufrimiento. El diagnóstico 
precoz, la derivación y el tratamiento adecuados son esenciales para disminuir el dolor y mejorar la 
función de los niños con SDRC (Stanton-Hicks 2010, Logan et al., 2013). 
Por estas razones hemos dividido el estudio en tres partes. 
La primera de las tres partes de las que se compone este trabajo tiene como objetivo el reconocimiento 
de cambios o hallazgos no descritos en el sistema somatosensorial en un modelo experimental de DN. 
 
Primer Estudio. La alteración de la distribución y composición de los canales de potasio en los 
axones mielinizados suprime la hiperexcitabilidad después de la lesión. 
El DN tras un daño nervioso periférico esta asociado con la hiperexcitabilidad de los axones sensoriales 
mielinizados afectos, la cual comienza a normalizarse con el tiempo. Este trabajo investiga la composición 
y distribución de los canales de potasio voltaje dependientes de la familia Shaker (Kv1) en el complejo 
nodal de los axones mielinizados tras la lesión nerviosa. En el neuroma que se forma tras el daño, la 
expresión de Kv1.1 y Kv1.2 estaba considerablemente reducida. Por el contrario Kv1.4 y Kv1.6, que eran 
casi imperceptibles en el estado naive, mostraron un importante aumento en su expresión tras el daño. En 
la raíz dorsal se pudo demostrar una redistribución de los canales Kv1 hacia el paranodo. El bloqueo de 
los canales Kv1 con a-DTX tras la inducción de la lesión reinstauró la hipersensibilidad de las fibras A y 
aumentó la sensibilidad mecánica. Los cambios observados en la composición molecular y distribución 
axonal de los canales Kv1, representan por tanto un mecanismo protector que disminuye la 
hiperexcitabilidad de los axones sensoriales mielinizados tras un daño nervioso.  
Actualmente, tanto la evidencia animal como la humana coinciden en que para el desarrollo del DN una 
lesión de las vías aferentes somatosensoriales es necesaria. Además, numerosos estudios demuestran 
que son varios los mecanismos que pueden inducir el desarrollo del DN. Esto no solo pone de manifiesto 
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la complejidad del DN, sino que también destaca la importancia clínica de identificación de los 
mecanismos subyacentes del dolor en cada uno los individuos que lo sufren. Ya que diferentes planes de 
tratamiento son necesarios para el manejo de los diferentes mecanismos, un abordaje terapéutico basado 
mecanismos podrá guiar a los profesionales de la salud hacia mejores resultados.  
Este trabajo muestra que dentro de un neuroma, los niveles de expresión de Kv1.1 y 1,2 están 
marcadamente reducido, pero con el tiempo Kv1.4 y 1,6 expresión aumenta dentro de yuxtaparanodos y 
paranodos. En sitios alejados de la lesión, también hay una redistribución gradual de canales Kv1 al 
paranodo. Los experimentos electrofisiológicos y de comportamiento sugieren que los cambios en la 
expresión de la subunidad y la redistribución de los canales Kv1 actúan como un "freno" sobre el estado 
hiperexcitable que surge en los axones mielinizados después de la lesión traumática del nervio. 
Hemos encontrado cambios importantes en la composición y distribución de la subunidad de los canales 
Kv1 dentro del axolemma de los axones mielinizados tras la lesión traumática del nervio. En contraste con 
el soma en el que se reduce la expresión de los canales Kv1, esta mayor disponibilidad de canales Kv1 
dentro de los paránodos y la composición de la subunidad alterada parece cumplir un papel adaptativo en 
la supresión de la excitabilidad excesiva en las aferencias mielinizadas. 
 
Segundo estudio. Perfiles de síntomas en el cuestionario de dolorDETECT en pacientes con dolor 
neuropático periférico estratificados según pérdida sensorial en pruebas sensoriales cuantitativas 
El dolorDETECT cuestionario (PDQ) se desarrolló y validado para apoyar la identificación de 
componentes de dolor neuropático en pacientes que sufren de dolor crónico de origen diferente 
(Freynhagen et al., 2006). Se ha demostrado previamente que los descriptores de dolor del PDQ se 
correlacionan con los ítems de QST que prueban umbrales de dolor relacionados en pacientes que sufren 
de radiculopatía, pero no en pacientes que padecen fibromialgia (Tampin et al., 2013). Se realizó este 
análisis exploratorio en un estudio prospectivo de muestra mayor debido a que el PDQ fue desarrollado 
antes de que se estableciera una definición clara de NP (Treede et al., 2008). Por lo tanto, nunca fue 
parte del proceso de validación del PDQ para investigar si diferentes tipos de pérdida sensorial (como se 
describió anteriormente) presentan con diferentes perfiles PDQ o si los elementos PDQ individuales son 
sensibles a los tipos de pérdida sensorial en un examen clínico. Esto sería útil para validar el PDQ no sólo 
como una herramienta de cribado para la NP misma, sino también para diferentes subtipos sensoriales de 
NP. El objetivo del estudio fue analizar si el puntaje total del PDQ o sus ítems reflejan los fenotipos de 
pérdida sensorial en NP según lo determinado por la QST. 
Dentro del consorcio europeo Europain y Neuropain, tanto los datos QST como los PDQ de los pacientes 
con dolor neuropático evaluados por unidades de investigación del dolor en toda Europa se recogieron en 
una base de datos central, permitiendo un análisis de la correlación entre la QST obtenida somato- 
Perfiles sensoriales de pérdida de función térmica y / o mecánica y perfiles PDQ. 
Nuestros resultados demuestran que la puntuación PDQ no es lo suficientemente sensible como para 
distinguir los diferentes tipos de pérdida sensorial en pacientes con NP. Si bien nuestros resultados 
indican que existen diferencias en las respuestas a cuatro ítems entre grupos de pacientes con uno u otro 
tipo de pérdida de sensibilidad detectada por la QST, no proporcionan información clara sobre la base de 
un paciente individual, ya que las diferencias de medias son comparables Pequeño (alrededor de un 
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punto en una escala de cero a cinco) y muestran una gran superposición. PDQ es incapaz de separar 
claramente entre los pacientes con diversos tipos de pérdida de sensación, porque sus preguntas para la 
pérdida de función se limitan a entumecimiento (y están completamente ausentes en otros cuestionarios 
de dolor), mientras que la pérdida de función puede ser detectada para todas las cualidades sensoriales 
en QST. Un análisis más complejo, que identifica elementos que diferencian los tipos de pérdida sensorial 
en una nueva batería de preguntas, sería un enfoque interesante para un estudio futuro. Algunos 
dominios pueden dar información más detallada si se dividen en dos elementos, por ejemplo, el tema de 
dolor frío o calor, uno para el dolor evocado por el frío y otro por el dolor evocado por el calor. Artículos 
separados para las diferentes formas de hiperalgesia o alodinia también podría ser de valor. Además, las 
preguntas sobre los trastornos autonómicos, que comúnmente aparecen en pacientes con neuropatía de 
fibra pequeña (Lacomis 2002), sería útil. Los resultados de nuestro estudio concluyen que los pacientes 
con perdida significativa de sensación térmica reportaban mas frecuentemente dolor evocado por tacto 
fino, y los pacientes con perdida significativa de sensibilidad mecánica reportaban mas frecuentemente 
adormecimiento, así como una menos frecuente sensación de quemazón y dolor evocado por tacto fino. A 
pesar de que el PDQ no fue diseñado para evaluar la perdida de sensibilidad, sus ítems individuales 
pueden reflejar la perdida de sensibilidad térmica y/o mecánica, pero debido a la importante variabilidad  
existente, el PDQ no nos permite la asignación de pacientes en perfiles sensoriales. La continuación de 
este paso en el desarrollo de una herramienta de cribado conveniente podría ayudar a identificar 
diferentes fenotipos involucrados en NP. 
 
Tercer estudio. Síndrome de dolor regional complejo en niños. 
I.Un enfoque multidisciplinario y técnicas invasivas para la gestión de los no respondedores 
Síndrome de dolor regional complejo (CRPS) es un término refinado por la Asociación Internacional para 
el Estudio del Dolor (IASP) para describir trastornos caracterizados por dolor espontáneo o inducido por 
estímulo que es desproporcionado con el evento incitante (Swart et al., 2009, Bruehl 2010 , Borchers y 
Gershwin 2014). CRPS ha sido ampliamente estudiado en adultos, pero los estudios en niños son 
escasos. El presente artículo informa sobre el curso y el manejo de 10 niños diagnosticados con SDRC 
que no respondieron con éxito a las terapias conservadoras del manejo del dolor que se presentan en 
nuestra Clínica del Dolor. 
Este estudio ofrece un enfoque de manejo multidisciplinario para el tratamiento de la SDRC en niños para 
quienes el tratamiento estándar no tuvo éxito. Debido a la gravedad y rápida progresión de los síntomas 
en la CRPS, consideramos que el diagnóstico temprano de la enfermedad junto con un tratamiento 
multidisciplinario integral e individualizado ofrece a los niños con CRPS la mejor oportunidad para una 
recuperación completa. Dentro de este plan de manejo, deben incluirse nuevos fármacos, como el parche 
de capsaicina al 8%, además de técnicas invasivas para pacientes que de otro modo no responden a 
terapias no invasivas. Por lo tanto, un enfoque más agresivo debe ser intentado. Llegamos a la conclusión 
de que se necesita más investigación sobre el SDRC en niños y se requieren nuevas pautas de 
tratamiento para aquellos niños que no responden a las modalidades de manejo establecidas. 
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